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Abstract 
 
A common feature of cancer cells is the loss of cell polarity. Scribble is a cell polarity 
protein with an unknown mechanism for its role in tumour suppression. Changes in the 
phosphorylation pattern of four serine sites at the C-terminal of scribble, implicate scribble 
in breast cancer invasion and metastasis. This was due to CD74 overexpression in lymph 
node metastatic triple negative breast cancers. Investigating how changes in serine 
phosphorylation status at these sites affect the regulation of invasion and metastasis in 
breast cancer was the focus of this study. These sites were mutated by site-directed 
mutagenesis to generate mutant scribble genes grouped into A-mutants and D-mutants, 
based on the amino acid change to the serine sites to mimic unphosphorylated and 
phosphorylated scribble, respectively. Widefield and confocal bioimaging of the 
expression and localization of these mutants in cell line HEK293T revealed good 
expression but varied localization to cytoskeletal elements, intercellular contact site, 
microtubules, centrosome and vesicles. Wound healing, MTT and flow cytometry assays 
were conducted on HEK293T transfected with these mutant genes to study how their 
expression affected cell migration, proliferation and the cell cycle, respectively. Notable 
differences emerged: 1.) A-mutants migrated more than D-mutants. 2.) D-mutants 
proliferated more than A-mutants and 3.) There were significantly more D-mutant 
expressing cells in the G2 phase of the cell cycle. Protein interaction study was also 
conducted. The binding partners of S[1306+1309]A and S[1306+1309]D mutants of 
scribble were captured and analysed by Co-IP and mass spectrometry. Bioinformatics 
analysis identified the pathways these binding proteins were significantly involved in: 
S[1306+1309]A binding partners were involved in cell migration via regulation of actin 
cytoskeleton pathway but contribute to intercellular adhesion via the tight junction pathway. 
S[1306+1309]D binding partners were involved in the TSH signalling and cell cycle 
pathways. The results show a significant possibility that unphosphorylated and 
phosphorylated hScrib support cell invasion and cell proliferation, respectively, and that 
these processes are antagonistic.      
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1. Introduction to Breast Cancer  
1.1 Breast cancer- definition and classification 
When the growth and division of cells in any part of the human body is unchecked by the 
body’s cell cycle regulatory mechanisms, it leads to formation of a tumour or neoplasm 
(Lodish et al., 2000:13.6; Chow, 2010). A tumour is an abnormal mass of tissue which 
could be benign or malignant (cancerous). Tumours can occur sporadically (acquired) or 
by hereditary (familial). An example is in cancer of the breast. Breast cancer is a disease 
defined by the American Cancer Society (ACS) as an abnormal growth and multiplication 
of cells that occurs in any part of the breast and forms tumour (or lump), with cells that can 
invade the surrounding tissues and other areas of the body (Cancer.org, 2016). In a 
broader classification of cancer types, NCI groups breast cancer as a carcinoma (National 
Cancer Institute, 2016). This is because it is initiated in epithelial cells that line the breasts. 
1.2 Breast cancer- incidence, mortality and treatments  
Out of more than 200 different types of cancer, breast cancer has become the most 
common cancer in the United Kingdom (UK) since 1997. Cancer research UK reported 
53,696 new cases (99% in woman and 1% in men) of breast cancer in the UK in 2013 
compared to 2010 (49,961 new cases). This is a 7.5% increase that contributes to the 4% 
increase in the incidence rate over the last 10 years, making UK the sixth highest in breast 
cancer incidence rate in Europe. Breast cancer deaths in the UK in 2014 were 11,433. 
However, comparing the last 10 years, this is a 20% decrease in mortality rate. This rise in 
incidence and fall in mortality rates has increased the survival rate of breast cancer in the 
UK to 78% i.e. 8 in 10 women would survive 10 years or more after diagnosis. It is a 
consequence of early detection (breast cancer screening) and improved treatments with 
surgery, adjuvant radiotherapy, chemotherapy and use of tamoxifen citrate in hormone 
sensitive breast cancer (Chew, 2001; Cancer Research UK, 2015). 
1.3 Breast cancer- risk factors 
The increased incidence rate is influenced by certain risk factors of which age is the most 
common. The probability of breast cancer occurrence increases as we age (National 
Cancer Institute, 2016). This increase, according to Cancer research UK, is linked with 
hormones, another risk factor (Cancer Research UK, 2015). Other risk factors include: 
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smoking, alcohol, obesity, radiation (ionizing, UV), infectious agents (viruses, bacteria, 
and parasites), chronic inflammation. The risk factors induce changes or events at cellular 
and molecular level of which this review will look into. 
Understanding breast cancer relies on the knowledge of the structure and the function of 
the breast. 
1.4 Anatomy of the human breast 
All humans have a pair of breasts: on the left and right sides of the upper ventral region of 
the torso. The breast tissue is measured from underneath the collarbone to the level of the 
sixth or seventh rib, and from the sternum to the axilla. The female breast tissue 
comprises of external and internal features. The external feature is the central nipple (or 
mammilla) surrounded by a spherical disk of darkened skin called the areola. As seen in 
Figure 1.1, the internal features consist mainly of three tissues. (1) The milk-producing 
glands made up of 15 to 20 lobes. Each lobe is subdivided into smaller lobules that further 
branch into many tiny bulbs or alveoli where milk is produced. (2) the tubular ducts which 
link the lobules to the nipple and (3) the stroma, made up of fibrous connective tissues 
and fatty tissues that encase the lobules, ducts, blood and lymphatic vessels to provide, 
together with the chest muscles, a supportive framework and give the breast its distinctive 
shape and size (Macea and Fregnani, 2006; Ellis and Mahadevan, 2013). 
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In addition, the breast is connected to the circulatory and lymphatic systems via blood and 
lymphatic vessels respectively. These connections are significant because blood delivers 
oxygen and nutrients to the breast tissue while removing waste material from the cells. 
The waste material and interstitial fluid are collected and transported via the lymphatic 
vessels in a clear fluid called lymph, which drains into the lymph nodes (Figure 1.2). 
These lymph nodes, which are significant in breast cancer diagnosis, are located in areas 
under the arm (axillary nodes), beside the sternum or inside the chest (internal mammary 
nodes) and above (supra) or below (infra) the clavicle (Suami et al, 2008; Ellis and 
Mahadevan, 2013). 
Figure 1.1 Internal anatomy of the female breast showing its distinctive shape provided by 
the stromal composition (connective and fatty tissues) and the organisation of epithelial 
cells of the ductal-lobular units that give the breast its milk-producing function. Image from 
Sarkar and Mandall (2011). 
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1.5 The cell cycle 
The appreciation of breast cancer, from initiation to histopathological and clinical 
outcomes, requires an understanding of the highly ordered and regulated complex 
sequence of events of the cell cycle. The cell cycle is the universal machinery by which 
cells in all organisms grow and divide. Triggered by external mitogenic stimuli, its 
processes, as seen in Figure 1.3, comprise four critical phases that can be grouped into 
two categories. The first group is the interphase which comprises 3 of the 4 critical phases: 
The G1, G2 and S phases. G1 and G2 are preparatory stages for cell progression into S 
and M phase, respectively. The fate of a cell to become quiescent or commit to further 
cycles of division is decided at the early stage of the G1-phase. Quiescent cells are 
metabolically active cells in a state of rest (G0) from the cell cycle. The S phase is the 
period of chromosomal duplication due to DNA replication. The second category, the 
mitotic or M-phase is subdivided into several distinctive phases which lead to nuclear 
division and cytokinesis. The M-phase is the final stage of the cell cycle that produces two 
genetically identical daughter cells from a parent cell (Shackelford et al., 1999; Pinheiro 
and Sunkel, 2012). 
Figure 1.2 The location of the lymph nodes around the breast. Lymph nodes are important 
in the body’s immunity but the presence of breast cancer cells in them is an indicator of the 
extent of metastasis around the body. Image from American Cancer Society. 
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A cells progression through the four phases of the cell cycle is via a sequence of transient 
phosphorylations setup by complexes of catalytic cyclin-dependent kinases (CDKs) and 
their corresponding regulatory cyclins i.e. cyclin:CDK complex. These major regulatory 
proteins of the cell cycle overlap due to their fluctuating concentrations at various points in 
the cell cycle, as seen in Figure 1.4. 
 
 
 
 
 
 
 
 
Figure 1.3 The four phases of the cell cycle. The cycle begins from interphase G1 
through to cytokinesis of the M phase. Intersections G1/S, G2/M and M/G1 (thick 
unbroken lines) indicate checkpoints with proteins that monitor and maintain genetic 
stability. Cells not committed to enter the cycle remain quiescent, G0. Image from 
Rausch and Kortleever (2011). 
I N T R O D U C T I O N  T O  B R E A S T  C A N C E R   | 21 
 
S
G1
M
G2
G0
Cyclin C:Cdk 3 
hypophosphorylation
of pRb
Cyclin D:
Cdk 4/6
Cyclin E:
Cdk 2
Cyclin A:
Cdk 2
Cyclin A:
Cdk 1
pRb E2F
E2FpRbp- +
Activation of genes 
required to enter S-phase 
Cyclin D: 
Cdk 4/6
p
Cyclin B:
Cdk 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The activation or inactivation of each complex depends on the addition or removal of 
phosphate from the two conserved phosphorylation sites of CDK (activating and inhibitory 
phosphate groups): addition of phosphate groups to CDKs inactivates cyclins:CDKs 
complexes while removal of inhibitory phosphate groups from CDKs by a Cdcs 
(phosphatases that belong to the Cdc25 family) activates cyclin:CDK. CDKs catalyze the 
covalent binding of ATP-derived phosphate to proteins that contribute to regulating the 
progression of the cell cycle. G0 to G1 transition is negatively regulated by 
unphosphorylated pRb. The re-entry of cells at G0 into the cell cycle at early G1, is 
dependent on the hypo-phosphorylation of pRb by cyclin C:CDK3 complex. Cell 
(Cdc2) 
Figure 1.4 The cell cycle showing the order of Cyclin/CDK complexes in the phosphorylation cascade. 
The phosphorylation cascade helps to relay and regulate the cell from one stage of the cell cycle to the 
next, through checkpoints like the restriction point. Image from Townsend et al (2007). 
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progression through G1 is supported by growth factor-mediated induction of cyclin D 
which complexes with CDK4/6 to phosphorylate (inactivate) pRb. The pRb is a 
transcriptional repressor of the E2F (a transcription factor required for S-phase initiation) it 
is bound to resulting in inhibition of G1 to S transition. E2F is released to complex with 
other proteins which activate the genes required at the G1/S checkpoint and S-phase 
(which are also controlled by cyclin E:CDK2 and cyclin A:CDK2) by Cyclin D:CDK4/CDK6 
hyper-phosphorylation of pRb at the restriction point (a point in late G1 at which the 
absence of growth factor stimulation does not inhibit cell cycle progression) (Figure 5). 
Cyclin A:CDK2 mainly controls the S-phase; G2/M checkpoint and the M-phase are 
controlled by cyclin A:CDK1 and cyclin B:CDK1, respectively. CDK1 is also known as 
Cdc2. Cells that divide are at a greater risk of acquiring mutations than cells that do not. 
Hence, to maintain genetic stability, the cell cycle has checkpoints occurring at G1/S, 
G2/M or M/G1. The events at these checkpoints in the cell cycle are regulated by several 
proteins seen in Figure 1.5. Some of these proteins detect errors in the cell’s DNA e.g. 
Rad 9, Rad 1 and Hus 1 (the 9-1-1 complex) recruited by Rad 17 in response to DNA 
damage, while some generate information through signal transduction pathways (e.g. 
CHK1, CHK2). Also, some proteins (e.g. p53, pRB) act as response elements to halt the 
progression of a cell in the cycle either for repair or apoptosis (if DNA damage is 
irreparable). (Pagano et al., 1992; Weinberg, 1995; Dyson, 1998; Kohn, 1999; 
Shackelford et al., 1999; Zhu and Gooderham, 2006).  
 
 
 
 
 
 
 
 
 
 
 
I N T R O D U C T I O N  T O  B R E A S T  C A N C E R   | 23 
 
p21
p53
+ +
+
Single-stranded breaks Double-stranded breaks
Rad 17
Rad 9-Hus 1-Rad 1
(9-1-1 complex)
ATR ATM
Cdc 25CHK 1 CHK 2
DNA damage
+
+
+
- -
-
MDM2
Cyclin E,A: 
Cdk 2
Cyclin B: Cdk 1
Early S-phase 
arrest
Late S-phase 
arrest
-
Cyclin D: 
Cdk 4/6
-
-
+
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
DNA damage at early (G1/S) or late (S/G2) S-phase initiates the ATM (ataxia 
telangiectasia mutated) and ATR (ataxia telangiectasia and Rad3-related protein) 
pathways. These mediators, respectively, activate downstream transducers checkpoint 2 
and 1 kinases (CHK2 and CHK1) which phosphorylate (activate) p53. The 
phosphorylation of p53 disrupts its interactions with MDM2, hence inhibiting the 
degradation and repression of p53 transcription (Figure 5). Activation of p53 induces 
expression of CKIs (cyclin kinase inhibitors e.g. p21, p27) which restrain cyclins:CDKs 
Figure 1.5 The cell cycle checkpoint signalling pathway. Sensor proteins (Rad 17 and 9-1-1 complex) 
detect DNA damage (single and double-stranded breaks) in chromatin. This facilitates ATR and ATM-
mediated phosphorylation of CHK 1 and CHK 2, respectively. CHK 1 and 2 activate effector proteins 
e.g. p53, that arrest the cell cycle for DNA repair or apoptosis. Activated p53 induces cyclin kinase 
inhibitors (CKI) e.g. p21, p16, which negatively regulate cyclins at different stages of the cell cycle. Cdc 
25 removes the activating phosphate of Cdk 1, therefore inhibiting progression of the S phase and the 
cell cycle. Image modified from Oesterreich and Fuqua (1999); Abraham (2001). 
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activity to enable DNA repair. Other important proteins involved in this interconnected 
regulatory process are p16 and p19 (Forsburg, 2002; Zhu and Gooderham, 2006; Junttila 
and Evan, 2009). Dysregulation in these proteins lead to cancer development. 
 
1.6 Biology of breast cancer 
Breast cancer is a complex heterogeneous disease which shows different 
histopathologies and clinical prognosis underlined by aberrant genetic, epigenetic and 
transcriptomic patterns that are distinct (vargo-Gogola and Rosen, 2007; Reis-Filho and 
Lakhani, 2008).  It is initiated in epithelial cells of TDLU (terminal ductal lobular units) 
(Zhan et al., 2008; Polyak, 2011). The probability of the morphological and physiological 
atypicality of breast tumours increases when mutations in key regulatory genes and 
abnormal amplifications in gene expression and gene products accrue (Lee and Muller, 
2010; Polyak, 2011).  The decision for a normal breast cell to proceed in the cell cycle, the 
duration of its mitotic division in the cycle and its discontinuation and exit from the cycle 
are controlled by signals from proteins of key genes grouped into proto-oncogenes and 
tumour suppressor genes (TSGs) (Murthy et al., 2002).  
For the tissues and organs of the human body to survival and develop, proto-oncogenes 
stimulate cell growth and inhibit cell differentiation and cell death. They do this by 
encoding certain proteins involved in a stepwise signal transduction cascade: Some of 
these proteins act as cell surface receptors which when bound to extracellular growth 
factor molecules, release growth signals into the cell for cell proliferation; some are 
intracellular proteins which control the transmission of the growth signal through the 
cytoplasm and others are transcription factors that enter the nucleus and directly turn on 
genes involved with cell division.  In contrast, the proteins encoded by TSGs, at certain 
checkpoints, inhibit cells from entering or completing the cell cycle. This ensures that cells 
with damaged DNA either die by apoptosis or are repaired to prevent the passage of 
mutated DNA copies onto the cell progeny by the parent cell. This way the DNA or 
genome integrity is maintained and cell transformation is averted (Cavenee and White, 
1995; Oliveira et al., 2005; Chial, 2008; Lee and Muller, 2010). Although there is a crucial 
functional balance between these key regulatory genes to stimulate and inhibit cell 
proliferation, respectively, a succession of permanent mutations of these genes, in a 
single cell, can make them defective and initiate the multi-step progression to breast 
cancer development (Osborne et al., 2004; Kenemans, et al., 2004).  
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Mutation in one of the two alleles of a proto-oncogene is enough for the gene to be 
activated into a dominant-acting oncogene that brings about dysregulated gain-of-function 
of transformed breast cells. This is different for a tumour suppressor gene because its 
genetic alteration inactivates the purpose of its gene product: loss of function. The ‘loss-
of-function’ effect is a recessive trait in that both functional copies (alleles) of the gene 
have to be mutated (Osborne et al., 2004; Michor et al., 2004; Lee and Muller, 2010; 
Inoue et al., 2013). This mutational event was discovered by Dr. Alfred Knudson, Jr., while 
trying to understand the genetic mechanisms behind inherited and acquired paediatric 
retinoblastoma.  In 1971, he developed the classical Knudson’s two-hit theory of tumour 
suppression (Figure 1.6), cited by Cavanee and White (1995), Oesterreich and Fuqua 
(1999) and Oliveira et al. (2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
He proposed that retinoblastoma was a consequence of the serial hits or defects of the 
two alleles of the retinoblastoma (RB1) gene which encodes the retinoblastoma tumour 
suppressor protein (pRb). Dr Knudson’s theory applies to all tumour suppressors. Using 
Figure 1.6 Model of the Knudson two-hit theory of inactivation of TSGs (e.g. RB). The white and 
yellow shapes represent paternally and maternally inherited allele, respectively, while the red 
lightning bolt shapes represent mutations at the TSG locus. The 1
st
 hit (which could be point mutation 
or small deletion) of the hereditary and non-hereditary forms of TSG inactivation were germ line and 
somatic mutations, respectively, occurring at the locus of the first TSG copy. This predisposes a 
sporadic 2
nd
 hit. The 2
nd
 hit at the locus of the second TSG copy, which causes LOH of the TSG, is a 
consequence of chromosomal mechanisms: (A) Non-disjunctional loss without mutation reduplication; 
(B) Non-disjunctional loss with mutation reduplication; (C and D) mitotic recombination; and physical 
loss of TSG region either by (E) Subchromosomal deletion or (F) An unbalanced translocation. The 
result of LOH or hemizygosity of TSGs institute the establishment of neoplastic phenotype. Image 
modified from Devilee et al (2001); Oliveira et al (2001) and Jozwiak et al (2008). 
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the RB1 gene as a reference, his theory explains that the ‘first hit’ of both inherited and 
acquired retinoblastoma require, respectively, germline and somatic mutations of one 
copy of the gene. If the disorder is inherited, all cells in the body will carry the defective 
copy and if acquired, only retinal cells will have the defective copy. However, tumour 
development in the retina does not occur unless a somatic mutation of the second RB1 
gene copy, which is independent of the first hit, occurs in both instances. The RB1 gene 
copies become homozygous because they are mutated and functionally defective. The 
loss of heterozygosity (LOH) due to mutation of the second functional copy describes the 
inactivation of any TSG. The second hit is usually point mutations, gene deletions, mitotic 
non-disjunction with or without reduplication, chromosomal breaks (or deletions) and in 
some cases, somatic recombination between the mutated and normal copy of the TSG 
that leads to replacement of normal gene copy with a mutant copy (Chial, 2008; Tischfield 
and Shao, 2003; Isola et al., 2003; Murthy et al., 2002).  
For oncogenic activation, alteration in the mutant copy is usually point mutations, 
deletions, gene amplification, chromosomal translocation (Siegel et al., 1994; Chial, 2008). 
This can also include retroviral transduction and retroviral integration of viruses like the 
HPVs (Human Papilloma Viruses) and the EBV (Epstein-Barr Virus) (Lawson and Heng, 
2010). Examples of proto-oncogenes mutated in breast cancer are: HER-2 (neu or ERBB-
2) and c-myc.  
On the basis of their function, TSGs can be categorized into gatekeepers, caretakers and 
landscapers. Gatekeepers directly inhibit tumour growth by inhibiting cell proliferation in 
the cell cycle and promoting apoptosis. The bi-allelic inactivation of these genes releases 
the brakes on cell proliferation and differentiation and directly contributes to cancer 
formation and development. Examples of gatekeeper genes linked to breast cancer are: 
p53 (or TP53), RB1, BRCA-1 and BRCA-2 genes. Caretakers are not directly involved in 
the controlling of the cell cycle: they maintain the integrity of the genome by involving in 
DNA repair. Hence, they are regarded as the ‘guardians of the genome’. The inactivation 
of both alleles of a caretaker gene does not directly initiate neoplasia but results in 
genome instability which leaves cells at a high risk of further mutations in other genes, 
including the gatekeepers. Cells that lose heterozygosity in their caretaker genes are said 
to have a mutator phenotype. Examples of caretakers linked to breast cancer are: BRCA-
1, BRCA-2, ATM and PTEN. The landscaper genes also do not directly control the cell 
cycle. The defects in their genes do not immediately affect cell proliferation but form a 
cellular or stromal environment that contribute to neoplastic cell transformation. Hence, 
the interactions between cells and their ECMs (extracellular matrices) are disrupted (Isola 
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et al., 2003; Loeb, 2001; Michor et al., 2004; Osborne et al., 2004; Oliveira et al., 2005; 
Hanahan and Weinberg, 2011; Schneider, 2011).  
1.6.1 Epigenetics of breast cancer 
Proto-oncogenes and TSGs may be the major culprits implicated in breast cancer and 
other cancers, but there are mechanisms that, when deregulated by an effector, cause 
cancer without any genetic mutation. These mechanisms can be inherited, self-
perpetuating and reversible and respond to developmental and environmental cues. 
These mechanisms are said to be ‘epigenetic’ (Riddihough and Zahn, 2010).  Epigenetics 
was defined by Dworkin et al. (2009) as the study of how changes in gene expression can 
be inherited independent of any alterations in the genetic sequence. The deregulation of 
these mechanisms may include: (1) Inappropriate expression of transcriptional repressors 
that inhibit the expression of tumour suppressors. (2) Inappropriate negative regulation of 
mRNA translation by small non-coding RNAs called microRNA. This inhibits the 
constitutive expression of tumour suppressors to degrade transcriptional activators. (3) 
Silencing of tumour suppressors by hypermethylation of CpG (cytosine-phosphate-
guanine) dinucleotides in the gene promoter. (4) Oncogene activation by ubiquitination of 
p53 protein, resulting in increased p53 proteolysis and inhibition of its function. (5) 
Disruption of key phosphorylation sites of tumour suppressor proteins that may result in 
mislocalization. (6) Permanent tumour suppressor silencing by methylation of histone H3 
on lysine 27 (H3K27) (Oesterreich and Fuqua, 1999; Osborne et al., 2004; Oliveira et al., 
2005; Dworkin et al., 2009; Huang et al., 2011). Examples of epigenetic effectors of breast 
tumorigenesis are polycyclic aromatic hydrocarbons (PAHs), hormones, viruses. 
PAHs are carcinogens present in cigarette smoke, diet and environmental pollution (e.g. 
radiation). At the cellular level, PAHs are linked to be the epigenetic cause of breast 
cancer by repressing the expression of the breast cancer susceptibility gene, BRCA-1 
(Jeffy et al., 2002; Pensabene et al., 2012). A Girl or a young woman who has not had her 
first full-term pregnancy is more susceptible to breast cancer than a woman who has. This 
is because her breast cells are immature stem cells. At the time of puberty, the breasts 
are most sensitive that these stem cells divide rapidly and can bind strongly to 
carcinogens, if exposed. Hence, the inefficient repair of carcinogen-mediated DNA 
damage by these immature undifferentiated cells affect the risk of breast cancer in later 
life (Brody and Rudel, 2003; Schkufza et al., 2010).  
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1.6.2 Hormonal influence of breast cancer 
The structure and function of the mammary gland vary from menarche to pregnancy to 
lactation to involution and to menopause. Very few anatomical changes occur pre-puberty: 
only a tiny duct of breast tissue at birth. Most of the changes to the anatomy of the breast 
begin at puberty. Puberty is the beginning of a girl’s first menarche and it is when the 
female breast develops: the mammary epithelial cells proliferate to form branches of many 
ducts that terminate at the milk-producing alveoli, thus forming terminal ductal-lobular 
units. These changes to the micro-environment, at puberty, are mainly influenced by 
exposure to the ovarian steroid hormones, oestrogen and progesterone (Winchester and 
Winchester, 2006). These hormones have been linked to increased risk of mammary 
epithelial cell oncogenesis.  
Oestrogen (E2 or 17β-estradiol) supports mammary epithelial cell proliferation through 
growth signal transduction pathways (Osborne et al., 2004; Darbre, 2012) such as the 
mitogen-activated protein kinase (MAPK) pathway (Zhang and Liu, 2002; Lim et al., 2006), 
cAMP signalling pathway (Aronica et al., 1994) and the phosphatidylinositol 3 kinase 
(PI3K) pathway (Sui et al., 2012). Via its cognate nuclear receptors, Estrogen Receptor α 
and β (ERα and β) (Harvey, 2009), oestrogen controls (genomically or non-genomically) 
several transcriptional factors and regulators in the G1 to S transition in the cell cycle 
(Mangelsdorf et al., 1995; Kocanova et al., 2010).  
Progesterone (P4 or 4-pregenene-3,20-dione) helps develop normal mammary glands by 
enabling breast cells to reach a G1 check point, inducing their  S-phase progression and 
preventing senescence.  Its proliferative effects may be mediated via its high-affinity 
receptor isoforms, PR-A and PR-B. These progesterone receptors (PRs) act either as 
canonical nuclear transcription factors (ligand-activation through binding of the C-terminal 
or N-terminal motifs to progesterone response elements) or as cytoplasmic signalling 
molecules that function via the MAPK pathway. However, the effects of the latter have 
been linked to be the main mechanism of cellular proliferation in progesterone-induced 
breast cancer (Skildum et al., 2005; Winchester and Winchester, 2006; Lange and Yee, 
2008). Progesterone induces genes that are involved in biological processes such as cell 
adhesion, cell survival and inflammation. However, progesterone-induced inflammation 
can risk breast cancer development (Cody et al., 2009). Early puberty may result in long 
term exposure to these hormones which can lead to deregulation of some of these 
pathways (Schkufza et al., 2010; Lee and Muller, 2010). 
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1.6.3 Metastasis of breast cancer 
Most patients with breast cancer die from its metastasis (Chaffer and Weinberg, 2011). 
Metastasis is a process by which cancer cells disseminate from their site of initiation to 
form secondary tumours at local (surrounding breast tissue), regional (to lymph nodes) 
and distant (other body organs) areas in the body via lymphatic and blood vessels 
(Weigelt et al, 2005). Metastasis of cancer cells can be inefficient because at various 
stages in the process the cancer cells can be inhibited (e.g. by host immune defence, lack 
of invasion or detachment factors etc.) (Hunter et al., 2008; Fidler, 2003). Although the 
axillary lymph nodes are the first site of breast cancer metastasis (Comen and Norton, 
2011); the liver, the lungs and the bones are the most common site of metastasis for this 
type of cancer (Irvin et al, 2011).  Chaffer and Weinberg (2011) proposed a two-stage 
process for metastasis: (1) the physical translocation of a cancer cell into circulation as a 
result of the pressure from its cell size (supported by the 1929 ‘mechanical trapping theory’ 
hypothesis by James Ewing, cited by Glinskii et al., 2005) and (2) its progression into a 
metastatic lesion or secondary tumour (supported by the 1889 ‘seed and soil’ hypothesis 
by Stephen Paget’s, cited by Fidler, 2003). The seed and soil theory states that, 
‘metastasis depends on the cross-talk between selected cancer cells (the seeds) and 
specific organ microenvironments (the soil).’ These hypotheses encompass distinct 
sequential steps that lead to the pathogenesis of cancer metastasis (Figure 1.7).  
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Breast cancer metastasis to specific organ sites relies on the effect of the tumour cell-host 
interactions to homeostatic factors that activate tumour cell proliferation (e.g. EGF, TGF-β, 
FGF), survival, angiogenesis, invasion (e.g. Epithelial-Mesenchymal Transition (EMT), 
loss of E-cadherin, epithelial cell polarity and cytokeratin), and metastasis. It also relies, 
genetically, on the expression of metastatic gene products for basal membrane 
degradation (e.g. matrix metalloproteinases), migration (e.g. autocrine motility factor) and 
anchorage-independence (Weber, 2008; Fidler, 2003; Kalluri and Weinberg, 2009). 
 
 
 
Figure 1.7 Steps in the formation of cancer metastasis. A cancer cell is able to initiate growth 
and division to form a primary tumour by secretion of vascular-generating angiogenic factors 
which facilitate extensive vascularisation of the tumour to access nutrients in the blood. As 
tumour size increases and disrupts adjacent cells, some cancer cells detach and travel through 
the bloodstream evading the host vessels of a secondary organ where they extravasate into 
the surrounding tissue of the secondary organ. If microenvironmental conditions are 
appropriate, they colonize the secondary site and form lesions to establish metastasis. Image 
modified from Fidler (2003). 
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1.7 Classification of breast cancer 
1.7.1 Histopathological classification 
As a result of the heterogeneic nature of breast cancer, a classification of the 
histopathology to determine prognosis and treatment was necessary. Breast cancer can 
be classified as non-invasive (in situ) and invasive or both (Gathani et al, 2005; Rakha et 
al, 2010).  
1.7.1.1 Non-invasive breast carcinomas 
 According to the American Cancer Society, non-invasive breast carcinomas are 
pre-cancerous cells. They are characterised by abnormal cell growth confined 
within the lining of the breast tissue where they start. They do not metastasize. 
Examples are DCIS (ductal carcinoma in situ) and LCIS (lobular carcinoma in 
situ). 
 DCIS are the most common earliest forms of non-invasive breast carcinoma that 
occur inside the milk duct of the breast. DCIS tumours produce lumps. The cells 
are non-uniform but similar to cells of the breast duct. Tumour necrosis of large 
area of breast tissue sample is an indication of DCIS progression to becoming 
IBC. An example of this type of DCIS is comedocarcinoma (Wiechmann and 
Kuerer, 2008). 
 LCIS occur inside the lining of the breast lobules and are common in pre-
menopausal women. Tumour cells of LCIS are uniform cells similar to cells of the 
breast lobules and produce no lumps. Although LCIS is not a true cancer, it 
increases the risk of IBC (Simpson et al, 2003).  
1.7.1.2 Invasive breast cancers (IBCs)  
 IBCs are aggressive tumours that can metastasize. Examples are invasive ductal 
carcinoma (IDC), invasive lobular carcinoma (ILC) (Wiechmann and Kuerer, 
2008); less common IBC’s (e.g. inflammatory breast cancer, Paget’s disease of 
the nipple, triple negative breast cancer (TNBC), phyllodes tumour and 
angiosarcoma) and rare breast cancer types (e.g. tubular breast cancer, 
mucinous breast cancer, medullary breast cancer, and papillary carcinoma) have 
also been documented by the American Cancer Society. 
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1.7.2 Molecular Classification 
The human mammary epithelium is made up of the inner luminal cells and the basal 
myoepithilia (adjacent the basal membrane). These two distinct cells types, which make 
up the lobules and ducts of the mammary gland, are the originators of most breast 
cancers. Most breast cancers occur in luminal cells rather than basal myoepithelial cells. 
The luminal cells line the apical surface of the mammary duct and have secretory 
properties while the basal myoepithelial cells surround the luminal cells and play a 
structural role (Figure 1.8) (Deugnier et al, 2002; Rakha et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
Immunohistochemical analysis and advanced molecular diagnostic techniques such as 
cDNA microarrays, have indicated the existence of four major molecular subtypes of 
breast cancer based on their hormone receptor (ER, PR) and human epidermal growth 
factor receptor (HER-2/neu) expressions (Andre and Pusztai, 2006; Cianfrocca and 
Gradishar, 2006). They are:  
 
 
 
Figure 1.8 The formation of a terminal end bud (TEB) of a developing terminal ductal-lobular unit 
(TDLU) of the mammary gland. The diagram shows the structural arrangement and orientation 
(inner luminal and outer myoepithelial layers) of the two distinct cell types of the breast: luminal 
cells line the lumen of the duct due to their secretory function while surrounded by the contractile 
myoepithelial cells which are in contact with the basement membrane. The caps cells are putative 
stem cells that divide, asymmetrically, to generate a new cap cell and an early transit cell of 
myoepithelial lineage or of luminal lineage (body cell) that would differentiate into terminal luminal 
or myoepithelial cell. Image modified from Smalley and Ashworth (2003). 
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1.7.2.1 Luminal A tumours  
These are ER+ (and/or PR+) and HER-2/neu-. They are low to moderate 
histological grade tumours due to their low expression of Ki67 antigen (Alfonso, 
2009). This subtype has p53 gene mutations (Yanagawa et al., 2012). 
1.7.2.2  Luminal B tumours  
These are ER+ (and/or PR+) and HER-2/neu+. They can also be HER2/neu–. 
Luminal B tumours are high histological grade tumours with high Ki67 expression, 
large tumour size, lymph node positivity and p53 gene mutations (Schnitt, 2011; 
Yanagawa et al., 2012). Patients with luminal A or B tumours can respond well to 
endocrine therapy due to their ER+ status. Hence both luminal tumours have 
high survival to recurrence ratio compared to HER2 and basal-like tumours 
(Goldhirsch et al., 2011; Andre and Pusztai, 2006; Voduc et al., 2010). 
1.7.2.3   HER2 tumours  
These are ER-, PR- but HER-2/neu+. Expression of HER-2 and p53 mutation is 
high. They are high histological grade, non-luminal, metastatic, lymph node 
positive tumours (Rakha et al., 2008; Schnitt, 2011; Goldhirsch et al., 2011). 
1.7.2.4   Basal-like tumours  
They occur in basal epithelial cells. Most basal-like tumours have triple negative 
immunophenotype (i.e. ER-, PR-, and HER2/neu-). Hence the name, triple 
negative breast cancer (TNBC). HER-1 and cytokeratin5/6 proteins are highly 
expressed. Most TNBCs have p53 mutations and dysfunctional BRCA1 gene. 
Because of the lack of targets for endocrine or hormone therapy, this aggressive 
subtype poses the worst prognosis and survival rate. They have a high 
histological grade, metastatic rate (Nielsen et al., 2004; Rakha et al., 2008; Reis-
Filho et al., 2011; Schnitt, 2011).   
 
1.8 Cell polarity and scribble (hScrib) 
Avascularity, mitotic capacity, structural integrity of cytoskeleton, specialized adherens 
junctions and cell polarity (apical-basalateral and planar) are a few of the properties 
epithelial cells possess. Loss of these properties is typical of breast cancer cells 
(Rubbelke, 1999; Radisky, 2005). Cell polarity is a highly controlled asymmetrical 
distribution of intracellular organelles, cytoskeleton and cell surface of epithelial cells. It is 
a phenomenon that is typified by chemically and structurally discrete apical-basal axis 
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which is significant to the determination of cell type and conserved cell function (Wodarz 
and Nathke, 2007; Bernd, 2010).  The loss of cell polarity is one of the properties of all 
cancers as the affected cells can overproliferate into tumours that are aggressive and 
invasive (Dow et al., 2003: Humbert et al., 2003). Epithelial cells are a coordinated group 
of adherent cell types whose polarity are regulated by proteins localized in appropriate 
plasma membrane domain (apical or basolateral membrane domain) of the cells (Figure 
1.9). The transformation of epithelial breast cells to become invasive and metastatic in 
nature has been linked to the epithelial-mesenchymal transition (EMT) they undergo. EMT 
is a biological process that alters the cytoskeletal organization, cell-cell and cell-ECM 
(extracellular matrix) interaction of polarized epithelial cells to achieve mesenchymal cell 
phenotype. EMT is induced in the cells by transcription factors e.g. Twist, Slug, Snail, that 
initiate, through signalling pathways, increased apoptotic resistance,  enhanced motility 
and invasiveness, increased ECM-component secretion, degradation of the basement 
membrane and loss of expression of the epithelial cell adhesion molecule called E-
cadherin. The loss of E-cadherin (a transmembrane glycoprotein) at the adherens junction 
between neighbouring epithelial cells is significant in breast cancer invasiveness and 
metastasis (Wijnhoven et al., 2000; Onder et al, 2008; Radisky, 2005; Kalluri and 
Weinberg, 2009; Mendez et al., 2010; Hanahan and Weinberg, 2011). The transformed 
epithelial breast cells begin to express mesenchymal proteins e.g. N-cadherin, vimentin. 
In addition to the loss of E-cadherin, proteins that give the cells their polarity are also 
affected (Qin et al., 2005).  
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These conserved planar polarity proteins, in Figure 1.9, that interact to maintain apical-
basal polarity are grouped into three protein complexes: the Scribble or Scrib complex, the 
PARtition or PAR complex, and the Crumbs or Crb complex. PAR (PAR3/PAR6/atypical 
protein kinase C (aPKC)) and Crb (Crb/PALS1, STD and PATJ) complexes maintain the 
apical domain while Scribble (Scribble, DLG and LGL) complex maintain the basolateral 
domain (Kaplan et al., 2009; Nelson, 2009; Lohia et al., 2012). In the context of breast 
cancer, studies on Scrib have shown that its knockdown, misfold or mislocalization from 
cell contact site, in mammary epithelial cells, faults the cell polarity pathway thereby 
obstructing intercellular adhesion and 3D morphogenesis. In effect, epithelial breast cells 
with mutant hScrib gene overproliferate and become aggressive and invasive tumours 
(Dow et al., 2003; Qin et al., 2005). According to the NCBI database, the human Scribble 
(hScribble or hScrib) gene is a highly conserved gene located on 8q24.3 of the human 
genome and has two alternative spliced variants (variant 1 and 2). These variants are 
translated into isoforms a (1655aa, MW= 177,594Da) and b (1630aa, MW= 174,885Da) 
respectively, with isoform a being the longer of the two isoforms due to the presence of an 
in-frame exon in transcript variant 1. Large multi-domain hScrib protein localizes in the 
Figure 1.9 The polarity complexes that regulate the apical and basolateral domain of epithelial 
cells. These complexes interact to inhibit mislocalization from their domains. Crumbs (Crb) complex 
interacts with Partition (Par) complex to repress Par (at tight junctions) from the sub-apical of the 
apical domain and vice versa. Likewise, Par complex interacts with Scribble complex to repress 
Scribble (at the basolateral domain) from the tight junctions of the apical domain. Protein 
interactions between epithelial cells, at the tight junctions and adherens junctions, involve occludin 
and β-catenin-E-cadherin complexes, respectively. Image modified from Dollar and Sokol (2007). 
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basolateral domain of the plasma membrane of epithelial cells. It belongs to a family of 
LAP (LRRs and PDZ domains) proteins with LRRs (leucine rich repeats) at its amino (N-) 
terminus, 4 PDZ (PSD-95/Dlg/ZO-1) domains and a carboxyl (C-) terminal domain. 
Furthermore, hScribble protein belongs to a subfamily of LAP’s called LAP4 (4 PDZ 
domains seen in Figure 1.10) (Bilder et al., 2000; Qin et al., 2005; Osmani et al., 2006; 
Buday and Tompa, 2010). 
 
 
 
 
 
 
 
Signal transduction and protein-protein interactions of hScribble are mediated by its LRRs 
and PDZ domains respectively (Humbert et al, 2003). The PSD (post-synaptic density) 
complex binds various receptor, cytoskeletal and signalling proteins. DLG is involved in 
cytoskeletal reorganization. The ZO-1 (Zonal Occludens-1) is a tight junction protein that 
provides the structural foundation for the epithelial cells. They act as assemblers of a 
diverse set of junctional protein complexes at the cytoplasmic surface of the intercellular 
junctions (Albertson et al., 2004; McNeil et al., 2006; Bauer et al., 2010; Buday and 
Tompa, 2010). The properties of these domains define hScrib’s conserved role as a 
scaffold protein. As a scaffold protein, hScrib acts as a molecular bridge that tethers into 
close interaction an ordered array of complex signalling proteins. Its allosteric property 
enables hScribble to efficiently play a role in a diverse array of biological processes such 
as: 1.) Intercellular adhesion by associating with E-cadherin-β-catenin complex; 2.) Cell 
proliferation by formation of hScrib (PDZ domains)-APC (adenomatous polyposis coil)-β-
catenin protein complex to regulate G1 to S phase progression of the cell cycle; 3.) 
Epithelial cell polarization (mediated in part by the LRR domain) by hScribble-ARHGEF7 
(β-PIX)- PAK1-3 (p21-activated kinases)- GIT protein complex, coordinated through 
MAPK signal transduction cascade. This represses the Par and Crumbs complexes, 
limiting extension of the apical domain, consequently regulating orientation and 
invasiveness of migrating cells i.e. EMT to MET and vice versa (Osmani et al., 2006; 
Good et al., 2011; Greenwood et al., 2011; Anastas et al., 2012; Lodish et al., 2013:59) 
Figure 1.10 The Domain map of hScrib based on a cartoon from a SMART database. It shows the 
LRRs and four PDZ domains that facilitate hScrib control of signalling pathways such as protein-protein 
interactions with membrane or cytoskeletal proteins for localisation and signal transduction. Image from 
Metodieva et al (2013). 
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and 4.) Tumour suppression (Bilder et al., 2000; Qin et al., 2005). Although a tumour 
suppressor, hScrib has been implicated in breast carcinogenesis (Greenwood et al, 2011). 
Therefore this study seeks to understand how the cell polarity and tumour suppressor 
protein, hScrib, is implicated in invasion and metastasis of triple-negative breast cancer 
(TNBC). 
1.9 Summary and context of study 
A study by Metodieva et al. (2013) on CD74 overexpression in metastatic triple-negative 
breast cancers (TNBCs) identified hScrib as a likely target of CD74. The study found 
changes in hScrib when CD74 was overexpressed. 1.) Localization: hScrib is a peripheral 
membrane protein but in the presence of CD74 overexpression, translocates to the 
cytoplasm of the cell. 2.) Pattern of post-translational modification: despite the total 
amount of hScrib remaining unaffected, the amount of three phosphopeptides at the C-
terminal of hScrib decreased significantly in CD74 overexpressing cells.  This was due to 
the change in phosphorylation pattern of four specific serine sites of the phosphopeptides 
which are at 1306, 1309, 1348 and 1448 positions of the amino acid sequence of hScrib. 
It was these findings that formed the basis of this research, with the objective of 
elucidating the mechanisms by which the phosphorylation of hScrib at serine positions 
1306, 1309, 1348, and 1448, affects its role in normal and cancer cells. The plan (aim) for 
achieving this objective include: 1.) Mutating the four serine sites found in the Metodieva 
et al. study to generate mutants that mimic unphosphorylated and phosphorylated hScrib, 
respectively; 2.) Study the effect of hScrib mutations on cellular localization; 3.) Study the 
effect of hScrib mutations on cell proliferation and migration/invasion; 4.) Study the effect 
of hScrib mutations on the cell cycle; 5.) Study the effect of hScrib mutations on 
interactions with its binding partners.        
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2. Materials and Methods  
 
2.1 Reagents 
Protein A/G magnetic beads, isopropanol, HCl, DMSO, TEMED, Tween 20, Triton X-100, 
BSA (Bovine Serum Albumin), Formalin (37% wt in ddH2O), MTT powder, Propidium 
iodide powder and RNase A solution were from Sigma-Aldrich. MTT solvent (acidic 
isopropanol) was prepared as a 1.5% (v/v) solution of HCl in isopropanol with 10% Triton 
X-100. TurboFect, DAPI, dNTP set, DTT, 10X tango buffer and Protease and 
Phosphatase inhibitor cocktail were from Thermo Scientific. Electrophoresis-grade 
agarose, SDS, Tris base, glycine, absolute ethanol and methanol were from Fisher 
Scientific. 6X orange loading dye solution, O’GeneRuler DNA ladder mix and PageRuler 
Prestained Protein Ladder were from Fermentas. VectaMount was purchased from Vector 
Laboratories. 30% Bis-acrylamide/acrylamide mix was from National Diagnostics. APS 
was from Bio Rad. Marvel original dried milk (non-fat).  
2.2 Media and enzymes 
DMEM and RPMI 1640 cell culture media were purchased from Lonza while FCS was 
from biosera. Tryptone, NaCl, yeast extract and agar, used for preparing LB 2xYT agars 
and broths, were purchased from Thermo Scientific. LB (LB broth= 10g tryptone, 10g 
NaCl, 5g yeast extract; LB agar= 1.5% agar added, H2O= 1L). 2xYT (2xYT broth= 16g 
tryptone, 5g NaCl, 10g yeast extract; 2xYT agar= 1.5% agar added, H2O= 1L). Trypsin, 
Pfu DNA polymerase, HindIII, EcoRI and DpnI were also purchased from Thermo 
Scientific.   
2.3 Antibiotic and antibodies 
The antibiotic, kanamycin disulfate salt, was purchased from Sigma-Aldrich. Anti-scribble 
antibody (Rb mAb to SCRIBBLE) was from abcam while GFP antibody (GFP (B-2) mouse 
monoclonal IgG2a) and Scrib antibody (Scrib (C-6) mouse monoclonal IgG2b) were 
purchased from Santa Cruz Biotechnology.  
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2.4 Buffers 
TAE (50X) buffer solution (121g Tris base, 18.6g disodium EDTA, 28.6mL glacial acetic 
acid in 500mL ddH2O). 0.5M Tris (12.1g Tris base in 200mL ddH2O, pH=6.8). 1.5M Tris 
(36.3g Tris base in 200mL ddH2O, pH=8.8). Tank (Running) buffer (5X) (15.1g Tris base, 
93.8g Glycine, 5% SDS in 1L ddH2O). Transfer buffer (5X) (15.1g Tris base, 72.1g Glycine 
in 1L ddH2O). TBS (10X) (24.2g Tris base, 80g NaCl in 1L ddH2O, pH=7.6). TBS-T (1X) 
(100mL TBS, 0.1% Tween 20 in 1L ddH2O).Transformation buffer (0.59g HEPES (4-(2-
hydroxyethyl) piperazine-1-ethanesulfonic acid), 0.55g CaCl2.2H2O, 4.65g KCl in 100mL 
ddH2O, pH= 6.7 + 2.7g MnCl2.4H2O). Lysis buffer (150mM NaCl, 10% IGEPAL, 100mM 
Tris, protease and phosphatase inhibitor cocktail). PBS (10X) (80mM Na2HPO4, 20mM 
KH2PO4, 1.37M NaCl, 27mM KCl, pH=7.4). PBS (1X) for tissue culturing was prepared by 
the kitchen staff in the School of Bioscience, University of Essex.  
Other materials: Nitrocellulose paper and 0.2mL PCR tubes were from Sigma-Aldrich. The 
plasmid miniprep kit was from Thermo Scientific (and also QIAGEN). Nalgene 0.20µm 
syringe filter was also purchased from Thermo Scientific. PVDF was purchased from 
Merck Millipore. 
2.5 Cell line, template and mutation primers 
HEK293T cell line was purchased from Thermo Scientific. The recombinant plasmid, 
pEGFP-C1-Scrib, that was used as a template in SDM was a kind gift from Professor Ian 
Macara from Vanderbilt University. The mutation primers designed were purchased from 
Eurofins MWG Operon.    
2.6 Bioinformatics  
Accession number Q14160, received from Dr. Metodiev from the University of Essex, was 
used to acquire the cDNA sequence (to design the mutation primers) of hScrib through 
the ‘tblastn’ program of BLAST (Basic Local Alignment Search Tool) on the NCBI website 
(http://www.ncbi.nlm.nih.gov/). 
DNA sequencing results were run through the ‘blastx’ program of BLAST to validate 
mutations at the desired sites in the amino acid sequence of hScrib.  
Enrichment analysis of statistically analyzed MS/MS data was performed using the KEGG 
and Wikipathways databases of WebGestalt (Web-based Gene set analysis toolkit). The 
reference set hsapiens_genome was chosen during the analysis.  
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2.7 The pEGFP-C1-Scrib recombinant plasmid 
The pEGFP-C1-Scrib is a recombinant plasmid comprised of the pEGFP-C1 vector and 
the wildtype hScrib gene. The construct has hScrib gene inserted between HindIII and 
EcoRI of pEGFP-C1 MCS which is downstream of the C-terminus of the EGFP gene 
(Figure 2.1), thereby enabling GFP-tagged hScrib protein expression when pEGFP-C1-
Scrib is transfected. The kanamycin resistant (KanR) gene in pEGFP-C1 vector was used 
as a selective marker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.8 Diagnostic restriction enzyme digestion of pEGFP-C1-Scrib 
To verify the molecular size of the hScrib gene (5201bp) in pEGFP-C1-Scrib 
(approximately 10kb), a diagnostic restriction enzyme digestion reaction (Table 2.1) was 
performed. 0.5µg of pEGFP-C1-Scrib was simultaneously digested with HindIII and EcoRI 
in 2X tango buffer, which was compatible with both enzymes. The total reaction volume 
(10µL) was left for 1.5hrs to incubate in a 37oC water bath.  
 
Figure 2.1 Restriction map of the 4.7kb pEGFP-C1 vector made into a recombinant plasmid 
by the fusion of hScrib gene into the MCS at the C-terminus of EGFP (enhanced green 
fluorescent protein). The integration of the hScrib gene (indicated by red arrow) was between 
HindII and EcoRI of the MCS. With the recombinant pEGFP-C1-Scrib as a template, the 
introduction of mutations into the hScrib gene was possible. Image was obtained from: 
http://www.snapgene.com/resources/plasmid_files/fluorescent_protein_genes_and_plasmids/
pEGFP-C1/. The nucleotide sequence of the cloning vector can be obtained from: 
http://www.ncbi.nlm.nih.gov/nuccore/U55763.1.  
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Table 2.1 Diagnostic restriction digest reaction 
 
 
 
 
 
 
 
 
 
2.9  Antibiotic preparation 
To facilitate selection, LB agar and broth were treated with kanamycin antibiotic. 50mg/mL 
(1000X) stock concentration of kanamycin was prepared by dissolving 0.5g of kanamycin 
disulfate salt in 10mL of milli-Q water, filter-sterilized with 0.20µm nalgene syringe filter 
(and a 10mL syringe) and stored at -20oC in 1.0mL aliquots. Kanamycin was used in 
1:1000 when preparing selective LB agar and broth.  
 
2.10  Replication, extraction, purification and measurement of pEGFP-C1-Scrib 
A glycerol stock of dam+ strain of E.coli containing pEGFP-C1-Scrib, under aseptic 
conditions, was streak-plated on a selective LB agar and incubated overnight at 37oC to 
yield individual colonies. One colony was picked and inoculated in selective LB broth and 
incubated at 37oC for 12-16hrs while shaking at 250rpm. Replicated pEGFP-C1-Scrib was 
extracted and purified using a plasmid miniprep kit (Thermo Scientific or QIAGEN) 
according to manufacturer’s instruction. The concentration and purity of pEGFP-C1-Scrib 
were measured with a Nanodrop 2000 UV absorbance spectrophotometer (A260/A280≥ 1.8; 
A260/A230≥ 2.2).  
2.11 Design of mutation primers of hScrib  
The positions of the four targeted serine residues in the amino acid sequence of hScrib 
and their corresponding codons were located from the cDNA sequence. These are: 1S 
In 2X tango buffer, EcoRI had 100% restriction enzyme activity while HindIII had 50-
100% restriction enzyme activity. An EcoRI only and HindIII only sample were 
prepared to observe what size supercoiled pEGFP-C1-Scrib would be when 
linearized by either restriction enzyme. It was also to observe which enzyme would 
produce star activity in the 2X tango buffer. No star activity was observed. 1X tango 
buffer was not compatible with both enzymes:  it was not recommended for EcoRI 
despite the 50-100% restriction enzyme activity with HindIII. The 2X tango buffer 
was derived from a stock concentration of 10X tango buffer.  
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(1306- TCC), 2S (1309- TCT), 3S (1348- TCC) and 4S (1448- TCC). The primer pairs were 
designed to completely overlap and have at least one base substitution in the target 
codons, flanked on either side by 15 bases.  These mutation primers substituted serine for 
alanine (A) and aspartate (D) (Table 2.2 and 2.3).  
 
Table 2.2 Primers designed to substitute the target serine residues for alanine (A) 
 
 
 
Table 2.3 Primers designed to substitute the target serine residues for aspartate (D) 
 
 
 
 
 
 
 
 
 
PRIMERS 
TARGET 
CODONS 
SEQUENCE 
S1306A TCC 
fwd 5’ GGCCAGCAGCCGCCCGCCCCGCCTTCTCCGGAT 3’ 
rvs 5’ ATCCGGAGAAGGCGGGGCGGGCGGCTGCTGGCC 3’ 
S1309A TCT 
fwd 5’ CCGCCCTCCCCGCCTGCTCCGGATGAGCTGCCC 3’ 
rvs 5’ GGGCAGCTCATCCGGAGCAGGCGGGGAGGGCGG 3’ 
S1348A TCC 
fwd 5’ CCTGGGCCTGCAGCCGCCCCGGAGCAGCTGTCC 3’ 
rvs 5’ GGACAGCTGCTCCGGGGCGGCTGCAGGCCCAGG 3’ 
S1448A TCC 
fwd 5’ AGGCAGAGCCCGGCGGCCCCCCCGCCCCTGGGA 3’ 
rvs 5’ TCCCAGGGGCGGGGGGGCCGCCGGGCTCTGCCT 3’ 
S[1306+1309]A TCC & TCT 
fwd 5’ CCGCCCGCCCCGCCTGCTCCGGATGAGCTGCCC 3’ 
rvs 5’ GGGCAGCTCATCCGGAGCAGGCGGGGCGGGCGG 3’ 
PRIMERS 
TARGET 
CODONS 
SEQUENCE 
S1306D TCC 
fwd 5’ GGCCAGCAGCCGCCCGACCCGCCTTCTCCGGAT 3’ 
rvs 5’ ATCCGGAGAAGGCGGGTCGGGCGGCTGCTGGCC 3’ 
S1309D TCT 
fwd 5’ CCGCCCTCCCCGCCTGATCCGGATGAGCTGCCC 3’ 
rvs 5’ GGGCAGCTCATCCGGATCAGGCGGGGAGGGCGG 3’ 
S1348D TCC 
fwd 5’ CCTGGGCCTGCAGCCGACCCGGAGCAGCTGTCC 3’ 
rvs 5’ GGACAGCTGCTCCGGGTCGGCTGCAGGCCCAGG 3’ 
S1448D TCC 
fwd 5’ AGGCAGAGCCCGGCGGACCCCCCGCCCCTGGGA 3’ 
rvs 5’ TCCCAGGGGCGGGGGGTCCGCCGGGCTCTGCCT 3’ 
S[1306+1309]D TCC & TCT 
fwd 5’ CCGCCCGACCCGCCTGATCCGGATGAGCTGCCC 3’ 
rvs 5’ GGGCAGCTCATCCGGATCAGGCGGGTCGGGCGG 3’ 
The base changes on the mutated primers were made on the forward strand and not the reverse strand of 
hScrib cDNA. Fwd= forward strand; Rvs= reverse strand. S[1306+1309]A also named S-AA implies serine 
sites S1306 and S1309 were simultaneously mutated to alanine. 
 
The base changes on the mutated primers were made on the forward strand and not the reverse strand of 
hScrib cDNA. Fwd= forward strand; Rvs= reverse strand. S[1306+1309]D also named S-DD implies serine 
sites S1306 and S1309 were simultaneously mutated to aspartate. 
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2.12  Site-directed mutagenesis of hScrib 
The site-directed mutagenesis (SDM) performed was a QuikChange mutagenesis method 
developed and described by Stratagene (La Jolla, CA). It was also PCR-mediated with the 
conditions set up in a thermocycler (Table 2.4).   
 
Table 2.4 PCR program setup 
 
The PCR reaction mix (Table 2.5) was set up on ice, in 0.2mL PCR tubes. Total volume of 
each mix was 50µL.   
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Table 2.5 PCR reaction setup to generate hScrib mutants (A and D) 
 
 
 
 
 
 
 
 
2.13  Dpn1 digestion 
To remove the template (pEGFP-C1-Scrib) following completion of the PCR, 1µL of Dpn1 
was added to the PCR products and incubated for 4hrs in a 37oC water bath.  
2.14  Gel electrophoretic verification of PCR product 
Agarose gel electrophoresis was performed on the PCR products, post-DpnI. 5µL of each 
PCR product was mixed with 1µL 6X orange loading dye solution and loaded into the 
wells of a 0.8% EtBr-infused agarose gel prepared with TAE buffer. 0.6µg pEGFP-C1-
Scrib (control) and 2.5µL DNA molecular marker (O’GeneRuler DNA ladder mix) were 
also loaded. The gel was run in TAE buffer at 100V for 50mins. DNA bands were 
visualised under a long-wave UV source and imaged (Meyers et al., 1976; Sambrook and 
Russell, 2001).   
 
 
  
This table shows the PCR reaction set up. Controls: NOP (No Primer added) was used to check for 
contamination of template with primers, NOT (No Template added) was used to check for contamination of 
primers with template. N= volume of milli-Q water added to the reaction and volume of template DNA 
(equivalent to 50ng) added to the reaction. PCR reactions for S[1306+1309]A and S[1306+1309]D were 
performed using positively validated S1306A and S1306D hScrib mutant plasmids as templates with 
corresponding 1309A and 1309D primers, respectively. High Fidelity Pfu DNA polymerase was added last 
after a manual hotstart (hotstart on the thermocycler was turned off). Due to high GC content in the template 
and primer pairs (>72%) which could cause secondary structures and favour primer dimer formation, DMSO 
was added. 10X Pfu Buffer with MgSO4 and dNTP (#R0181, Lot: 00135644) were from Thermo Scientific 
while DMSO was from Sigma Aldrich. Total volume of PCR mix= 50µL. 
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2.15  Optimization of SDM protocol  
Some of the expected mutants were generated but it was difficult to produce other 
expected mutants, especially mutants containing more than one mutation. In addition, 
there was the absence of bands of PCR products and smears from Dpn1 digestion when 
samples were run on agarose gel.   
 
One reason put forward was the presence of DMSO.  Due to high GC content in the 
template and primer pairs, there was the possibility of secondary structures (e.g. hairpin 
loops) and primer dimerization in the template and primers. DMSO was used to prevent 
these secondary structures (Capriotti and Capriotti, 2012). By binding to the primer pairs 
and in the minor and major grooves of the template DNA, DMSO interferes with the 
hydrogen bonding between bases of the primer pairs and between bases of the double 
helix structure of the template to enable the separation of dsDNA into ssDNA, with less 
energy, and favour primer-template specificity at the annealing step (Hardjasa et al., 
2010).  
 
The absence of any visible bands, post-Dpn1, suggested that PCR products were not 
formed and hence the absence of primer-template hybridization. If no pcr products were 
formed, then the synthetic primer pairs were not used and should be seen as low 
molecular weight bands. However, the absence of the low molecular weight bands of the 
primer pairs in the samples and NOT control suggested that the primer pairs did not 
dimerize but remained single-stranded whilst not annealing to the template.  Detection of 
ssDNA is very poor because very low affinity of EtBr for ssDNA (Sambrook and Russell, 
2001).  
 
The higher the GC contents of the primers (ranged from 57.9% to 84.6%), the higher the 
melting temperature (Tm) of the primers. Based on the Tm of each primer pair (ranged from 
75.7oC to 86.6oC), a new annealing temperature (Ta) was decided. Due to the range of 
Tm’s, too high Ta could cause insufficient or no specific primer-template hybridization and 
too low Ta could produce non-specific products from mis-match of base pairs. The initial 
Ta of 60
oC was low and provided not enough binding energy to overcome the energy, due 
to the presence of DMSO, which kept the primers and template single-stranded and 
caused the Pfu DNA polymerase to stall in catalyzing the extension phase of the program. 
By increasing the Ta to the extension temperature of 68
oC, there was enough binding 
energy to facilitate annealing with the added advantage of immediate extension of the 
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hybrids at that temperature. This theory facilitated the optimization of the initial three-step 
cycling program to a two-step cycling program (Table 2.6). 
 
Table 2.6 Optimized PCR program setup 
 
 
       
 
 
 
 
 
2.16  Transformation of PCR products 
The PCR products were transformed in chemically competent E.coli cells that were 
prepared (with transformation buffer) according to the protocol used by the proteomics 
laboratory at the University of Essex. The PCR products were mixed with competent cells 
(1:10) and incubated in ice for 30mins before heat shocking in a 42oC water bath for 
45secs and cooling in ice for 5mins. 500µL of 2xYT broth was asceptically added to the 
samples and incubated at 37oC in a shaker set at 250rpm for 1hr. The cells were pelleted 
at 25 oC and 10000 rpm for 2mins. 400µL of supernatant was discarded and the pellet 
resuspended in the remaining 100µL supernatant. The samples were spread-plated onto 
selective LB agar plates and incubated at 37 oC for 12-16hrs. 0.5µL GFP and pEGFP-C1-
Scrib plasmids were also transformed alongside the samples to gauge transformation 
efficiency and as positive controls. The colonies derived were inoculated in selective LB 
broth and incubated at 37oC in a shaker set at 250rpm for 12-16hrs. The extraction, 
purification and measurement of the plasmids were performed, as stated in Section 2.10.  
2.17  DNA sequencing of hScrib mutant plasmids  
For validation of mutation, samples of plasmids (derived from transformation) and 
mutation primers, according to the sample requirement of the company, were sent to 
either GATC biotech or Source BioScience for DNA sequencing.  
 
M A T E R I A L S  A N D  M E T H O D S    | 47 
 
Reagents Volume (mL)
1.5M Tris-HCl pH 8.8 2.50
30% Bis-acrylamide/acrylamide mix 3.00
Milli-Q H2O 4.50 (to 10mL)
APS 0.10
TEMED (added last) 0.01
2.18 Tissue culturing, transfection and harvesting. 
Human embryonic kidney cell line HEK293T was grown at 37oC and 6% CO2, in either 
DMEM or RPMI 1640 cell culture medium supplemented with 10% FCS.  The cells were 
passaged with trypsin every 48 hrs. Transient transfections were performed using 
TurboFect according to the manufacturer’s instruction. However, the reverse transfection 
protocol option was preferred to the conventional transfection because of inconsistency in 
transfection efficiency due to detachment of cells from the monolayer when the 
transfection mix was added. Pending requirement for analysis, the transfected cells were 
harvested by washing the cells with PBS and storing at -80oC.   
2.19  Protein sample preparation for Western blotting  
Samples of the transfected cells were mixed with 50µL of pre-chilled lysis buffer and 
incubated on ice for 15mins to permeabilize. The samples were cleared in a centrifuge 
(pre-cooled to 4 oC) for 15mins at 14000rpm. Following centrifugation, the supernatant of 
the samples were collected and total protein concentration was measured by dye-binding 
assay (1µL of sample, on nitrocellulose paper, was stained with amido dye and destained 
in destain solution). Samples with darker spots were diluted with 2X SDS loading buffer 
while lighter spots were diluted with 5X SDS loading buffer. Following this, the protein 
samples were reduced for 5mins in 15mM DTT and at 100 oC before centrifuging at 25 oC 
and 14000rpm for 30secs.  
2.20  Protein separation by SDS PAGE prior to Western blotting 
SDS PAGE gel layers to be cast were prepared as shown in Tables 2.7 and 2.8. 20µL of 
the reduced samples and 3.5µL of molecular weight marker (PageRuler Prestained 
Protein Ladder) were loaded and ran in tank buffer for 50mins at 180V.  
 
Table 2.7 Resolving gel (9%) 
 
 
 
 
 
 
 
Resolving gel was cast first. The volumes are for two mini gels to run A-
mutant and D-mutant hScrib protein samples. 
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Reagents Volume (mL)
0.5M Tris-HCl pH 6.8 2.50
30% Bis-acrylamide/acrylamide mix 1.30
Milli-Q H2O 6.20 (to 10mL)
APS 0.10
TEMED (added last) 0.01
Table 2.8 Stacking gel (4%) 
 
 
 
 
 
 
 
 
2.21 Western blot  
The SDS PAGE-resolved protein samples were transblotted (for 1hr at 100V) with transfer 
buffer onto PVDF membranes. Membranes were blocked with 5% non-fat dried milk in 
TBS buffer and incubated on a rocker, at room temperature for 45mins. After blocking, the 
membranes were incubated overnight at 4 oC with two primary antibodies in 1:500 ratio 
(5% non-fat milk, 0.1% Tween-20, 10µL mouse GFP Ab, 10µL rabbit scrib Ab, 10mL 
TBS). Following overnight incubation, the membranes were washed thrice with TBS-T 
(once every 5mins on a rocker) and incubated, in dark boxes,  at room temperature for 
45mins with two secondary antibodies in 1:10000 ratio (2.5% non-fat milk, 0.1% Tween-
20, 1µL anti-mouse GFP Ab, 1µL anti-rabbit scrib Ab, 10mL TBS). The membranes were 
washed a further three times with TBS-T before the proteins were visualized with 
ODYSSEY infrared imaging system (LI-COR Corporation).    
2.22  Staining, fixation and imaging of transfected HEK293T cells  
HEK293T cells were transfected on coverslips and washed with 1mL PBS. PBS was 
removed and replaced with 500µL of 3.7% formalin in PBS before incubating the cells at 
room temperature for 15mins. Formalin was aspirated and replaced with 500µL of 0.5% 
Triton in PBS. Triton was aspirated after incubating the cells at room temperature for 
5mins. Following this, the samples were washed with 500µL of 0.1% BSA in PBS. BSA 
was aspirated and 500µL of DAPI in PBS (1:1000) was added. The cells were covered in 
aluminium foil and incubated on a rocker, at room temperature for 15mins. After 
incubation, the coverslips were air-dried ‘cell side up’. A drop of Vectamount was placed 
on the coverslips, mounted onto microscope slides and left to set overnight at 4oC.  
Nikon A1-R confocal microscope was used to capture images of the localization of the 
GFP-tagged hScrib protein samples expressed in the cells.  
Stacking gel was cast after the resolving gel. Loading wells were made 
in the stacking gel. The volumes are for two mini gels to run A-mutant 
and D-mutant hScrib protein samples. 
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2.23  Cell-based assays  
  2.23.1     MTT assay 
Cells were seeded at 1.5x104cell/well, in a 96-well plate, on the day of 
transfection and incubated overnight at 370C in 6% CO2. 0.01g MTT powder 
was dissolved in 2mL PBS to prepare 5mg/mL MTT solution which was filter-
sterilized, wrapped in aluminium foil and stored at 4oC before use. 20µL MTT 
solution was added to the samples and incubated at 37oC for 4hrs. After 
incubation, the cell culture medium was aspirated and 300µL MTT solvent was 
added. The samples were covered in aluminium foil and incubated on a rocker, 
at room temperature for 15mins. Within 1hr, the absorbances of the samples 
were measured on a SpectraMAX Plus Microplate reader (with SoftMAX Pro 
software) set at 570nm with a 630nm reference.  
 2.23.2      Wound healing assay 
Cells were seeded at 0.9x105cell/well on the day of transfection and incubated 
overnight at 370C in 6% CO2. After incubation, a horizontal scratch was made 
across the cell monolayer .The cell culture medium was aspirated and 1mL 
fresh cell culture medium was added. Large stitched images (0% overlap) of the 
gap closures were acquired, in the brightfield, at T= 0 and T= 24hrs with Eclipse 
Ti-E widefield microscope (Nikon) while the gap closures were quantified with 
Java’s Image J software using the polygon selection tool (Liang et al., 2007; 
Yue et al., 2010; Riahi et al., 2012; Treloar and Simpson, 2013). The migration 
rate of the cells to closing the gap was expressed as a percentage of wound 
closure: 
% wound closure = [(A t=0 – A t=n)/A t=0] x 100 
Where At=0 is the mean area of the wound after making the scratch and At=n is 
the mean area of the wound healed (or gap closure) after 24 hours.   
 2.23.3      Flow cytometric assay and analysis 
Samples from the wound healing experiment were collected and pelleted at 
room temperature and 3000 rpm for 5mins to remove old cell culture medium. 
0.1% BSA in 50µL of PBS was used to wash the cells which were subsequently 
pelleted. 25µL of the supernatant was retained to re-suspend the cells. The 
cells were fixed with 1mL of ice cold 100% ethanol added dropwise while 
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vortexing. The fixed cells were left overnight at -20oC. Subsequently, the cells 
were pelleted and resuspended in 200µL of RNase A-containing PI solution 
(25µg/mL PI and 100µg/mL RNase A solution in PBS) to eliminate the 
interference of RNA (Nunez, 2001). To facilitate nucleic acid staining, the 
resuspended cells were incubated for 4hrs in a dark cupboard at room 
temperature. After incubation, the cells were run through a BD Accuri C6 flow 
cytometer set to run at 10,000 events. The results from these runs were 
analysed with a FCS express 4 software program created by DeNovo Software 
Company.   
2.24  Co-Immunoprecipitation (Co-IP) assay 
The whole-culture synchronization method was used (Cooper et al, 2006; Rosner et al, 
2013). Eight already harvested and frozen sample cultures of seven synchronous 
HEK293T cell line and one asynchronous HEK293T cell line were used. Two of the 
sample cultures were untransfected control samples (HEK293T and HEK293T(Noc)) while 
the other six were transfected with the following hScrib mutants: S[1348+1448]A, 
S[1348+1448]D, and recently generated mutants P1 (Glu1293stop) and P3 (Gly1624Stop). 
Volume of samples and buffers used are shown in Table 2.9. 
 
Table 2.9 Volumes used in the Co-IP assay 
 
 
Each transfected cell sample, except HEK293T control, was synchronized by treating with either 
nocodazole alone or both nocodazole and thymidine. Apart from the HEK293T and HEK293T(Noc) 
controls, the same volume of lysis buffer was added to each culture dish or centrifuge tube used to 
collect the samples. Not all the cell lysate obtained from each sample was used in the co-
immunoprecipitation (Co-IP) experiment. Some of the lysate was used in a western blot (WB) 
experiment.   
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These frozen sample cultures, in lysis buffer, were incubated at room temperature for 
5mins on a fine PCR rotator and spun down in a pre-cooled centrifuge at 4oC and 
14,000rpm for 20mins. The cell lysates obtained after centrifugation were split (for CoIP 
and Western blot use) (Table 2.9). Cell lysates for CoIP were diluted (1:1) with PBS and 
probed with antibody: 3µg of Scrib (C-6) mouse monoclonal antibody were added to 
HEK293T and HEK293T(Noc) while 3µg of GFP (B-2) mouse monoclonal antibody  were 
added to the other six samples. The probed samples were incubated at room temperature 
for 30mins on a rotator. 18µL of Protein A/G magnetic beads was added to each sample 
and incubated at room temperature for 1hr on the rotator. After incubation, the samples 
were placed on magnetic tube racks, to aggregate the beads, before removing the 
flowthrough. The magnetic beads were washed, four times, with 1mL wash buffer (0.1% 
triton in PBS) and aggregated to remove the wash buffer. After the fourth wash, the 
magnetic beads were resuspended in 1mL of PBS and split equally for western blot (WB) 
and mass spectrometry (MS) analysis. The flowthroughs of samples for MS and WB were 
discarded and the magnetic beads were stored at 4oC pending usage. During usage (for 
samples required for MS), 20µL of solution containing trypsin and 1M urea was added to 
the magnetic beads and incubated overnight at 30oC.     
2.25  Mass spectrometry 
Subsequent to Co-IP and trypsin digestion of the proteins into peptides, was the 
identification of the digested proteins with an electrospray ionization mass spectrometer 
which has a hybrid LTQ (Linear Trap Quadrupole)/Orbitrap Velos device coupled to a 
nanoscale HPLC (High Performance Liquid Chromatography) to ionize the peptides and 
enable high resolution of the peptide ions based on m/z (mass:charge). The mass 
spectrometer set-up (Greenwood et al., 2012) was performed by Dr. Metodiev (Supervisor) 
to generate LC-MS/MS spectral counts and corresponding intensity values of the peptide 
ions. Both measures of relative protein abundance can be used in proteomic analysis.  
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3. The effect of hSCRIB mutations on cellular localization  
 
3.1 Introduction  
A significant feature of breast cancer cells is the loss of epithelial cell polarity (Chatterjee 
et al., 2012; Royer and Lu, 2011; Bilder et al., 2000). Cell morphology, physiology, 
regulation of EMT and cell proliferation are influenced by cell polarity (Greenwood et al., 
2011; Chaffer and Weinberg, 2011; Royer and Lu, 2011). Cell polarity is regulated by 
conserved, planar polarity protein complexes localized in the plasma membrane domain 
of the cells. The presence and localization of these protein complexes are important in 
mediating the apical and basolateral architecture of epithelial cells (Humbert et al., 2003). 
Operating in the basolateral domain is the Scrib complex consisting of hScribble (hScrib), 
hDLG and LGL proteins (Kaplan et al., 2009).  
Breast cancer subtypes such as triple-negative breast cancer (TNBC) are difficult to treat 
because of the absence of established receptor markers to target. However, new 
molecules have been identified to be expressed in this breast cancer cells of which hScrib 
is implicated (Rakha et al., 2008; Greenwood et al., 2011). The hScrib is a scaffold protein 
whose function at intercellular junctions, to maintain cell polarity, affects cytoskeletal and 
tissue organization. Studies have shown that the mutation of the hScrib gene may affect 
the expression and mislocalization of its gene product from its typical basolateral domain, 
at the periphery of the plasma membrane, consequently disrupting the regulation of cell 
polarity. Epithelial breast cells lose cell proliferative and orientation control and become 
aggressive malignant tumours as a result (Dow et al., 2003; Qin et al., 2005; Metodieva et 
al., 2013). This indicates that the effect of hScrib protein in epithelial cells is significant to 
the suppression of tumours. Hence, it is identified as a tumour suppressor (Bilder et al., 
2000).  
In a study, it was found that hScrib was deregulated in metastatic breast tumour cells by 
the overexpression of CD74 (Metodieva et al., 2013): hScrib localized to the cytoplasm 
and the pattern of post-translational modifications (PTMs) of hScrib was affected, despite 
the total amount of the protein remaining unchanged. Following a combined genomic-
scale proteomic screen, four phosphoserine hotspots (S1306, S1309, S1348 and S1448) 
at the C-terminal part of hScrib protein were identified to be significantly affected by CD74 
overexpression. Therefore, by respectively substituting these four serines with alanine (to 
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mimic unphosphorylated state of hScrib) and with aspartate (to mimic phosphorylated 
state of hScrib); this experiment aims to study the effect of hScrib (a functional human 
homolog of Drosophila melanogaster tumour suppressor DmScribble) mutations on 
cellular localization.  
3.2 Molecular size of hScrib in pEGFP-C1-Scrib  
To initiate this study, gel verification, by diagnostic restriction enzyme digestion (Section 
2.8), of the molecular size of wildtype hScrib in pEGFP-C1-Scrib was performed and gel 
image of bands (Figure 3.1) was captured under UV light. 
 
 
 
 
 
 
 
 
 
 
 
 
The gel image above shows that in lane 5 there are different band sizes of undigested 
pEGFP-C1-Scrib which corresponds to the different conformations (supercoiled or 
covalently close-circular, linear and open-circular) it assumes (Jiang et al., 2010). Lanes 2 
and 3 each show a single band representing pEGFP-C1-Scrib digested by EcoRI and 
HindIII, respectively. Using lane 5 as a reference, these two lanes (2 and 3) show that 
when pEGFP-C1-Scrib is digested, its conformation becomes linear from supercoiled: its 
band size also changes to approximately 10kb from about 7kb (marker as reference).  
These observations are also true in lane 4 except there is more than one linear band of 
different sizes due to EcoRI + HindIII simultaneous digestion of pEGFP-C1-Scrib. EcoRI + 
6kb 
5kb 
4kb 
Figure 3.1 Gel electrophoresis image of diagnostic restriction enzyme digest of pEGFP-C1-
Scrib. From left to right: Lane 1= Marker; Lane 2= EcoRI; Lane 3= HindIII; Lane 4= EcoRI + 
HindIII; Lane 5= supercoiled pEGFP-C1-Scrib (0.3µg) as control. The loading volume for all 
samples, except marker (2.5µL), was 6.6µL. Supercoiled pEGFP-C1-Scrib was used as 
control to indicate the size of the recombinant plasmid when not digested by enzymes. 
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HindIII simultaneous digestion of pEGFP-C1-Scrib was expected to yield two bands but 
the presence of a third low abundance band with a size similar to lane 2 indicates 
digestion that could not be complete within the incubation time due to the 50-100% 
restriction activity of HindIII in the 2X tango buffer. However, the two closely similar lower 
band sizes in lane 4 indicate, to a large extent, a good double digestion. Using the marker 
(Lane 1) as a reference, one of the bands in lane 4 is just under 5kb and the other band is 
just over 5kb. This suggests that the latter, with a possible molecular size of 5.2kb 
(5201bp), may be the hScrib gene. Verification of the hScrib gene would be by DNA 
sequencing.  
3.3 The hScrib mutants generated 
After estimation of the molecular size of hScrib gene (in pEGFP-C1-Scrib) with diagnostic 
restriction enzyme digestion, pEGFP-C1-Scrib was used as template in the SDM process 
(Chapter 2.12). The mutants generated (Table 3.1) were validated by DNA sequencing.  
 
Table 3.1 Validated hScrib mutants generated 
 
 
 
 
 
 
 
The results were acquired through the ‘blastx’ program of BLAST which also verified the 
protein to be hScrib of human origin. Quality of the sequence results were examined on a 
chromatogram as shown for some of the mutants in Figures 3.2a, b, c, d, e and f. 
 
 
 
This table shows the hScrib mutants that were confirmed by DNA sequencing (except P3 (E1293Stop)) to 
have the expected site mutation(s). P1 (E1293Stop) was also confirmed by mass spectrometry as well as 
P3 (G1624Stop).  S[1306+1309]A and S[1306+1309]D are double mutations of hScrib also known as S-AA 
and S-DD, respectively. They were used as templates to generate the triple hScrib mutants.  
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Wildtype (S1448):  5’ AGG CAG AGC CCG GCG TCC CCC CCG CCC CTG GGA 3’ 
 
 
Figure 3.2a Chromatogram results of hScrib mutants S1448A and S1448D using Chromas Lite 2.1.1 software. 
The chromatograms show four different peak colours for each of the four bases: C = blue, A = green, T = red 
and G = black. The codon that was mutated is highlighted.  The wildtype codon position, S1448, is highlighted 
above.  
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Wildtype (S[1348+1448]): 5’ CCT GGG CCT GCA GCC TCC CCG GAG CAG CTG TCC 
    --- AGG CAG AGC CCG GCG TCC CCC CCG CCC CTG GGA 3’ 
 
 
 
 
Figure 3.2b Chromatogram results of hScrib mutants S[1348+1448]A using Chromas Lite 2.1.1 software. The 
chromatograms show four different peak colours for each of the four bases: C = blue, A = green, T = red and G 
= black. The codons that were mutated are highlighted.  The wildtype codon positions, S1348 and S1448, are 
highlighted above.  
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Wildtype (S[1348+1448]): 5’ CCT GGG CCT GCA GCC TCC CCG GAG CAG CTG TCC 
    --- AGG CAG AGC CCG GCG TCC CCC CCG CCC CTG GGA 3’ 
 
 
 
 
Figure 3.2c Chromatogram results of hScrib mutants S[1348+1448]D using Chromas Lite 2.1.1 software. The 
chromatograms show four different peak colours for each of the four bases: C = blue, A = green, T = red and G 
= black. The codons that were mutated are highlighted.  The wildtype codon positions, S1348 and S1448, are 
highlighted above.  
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Wildtype (S1445):  5’ C CCC ACC TCA AGG CAG AGC CCG GCG TCC CCC CC  3’ 
 
 
 
Figure 3.2d Chromatogram results of hScrib mutants S1445A (P6) and S1445D (P7) using Chromas Lite 2.1.1 
software. The chromatograms show four different peak colours for each of the four bases: C = blue, A = green, 
T = red and G = black. The codon that was mutated is highlighted.  The wildtype codon position, S1445, is 
highlighted above.  
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Wildtype (S[1445+1448]): 5’ C CCC ACC TCA AGG CAG AGC CCG GCG TCC CCC CC  
    --- AGG CAG AGC CCG GCG TCC CCC CCG CCC CTG GGA 3’ 
 
 
Figure 3.2e Chromatogram results of hScrib mutants S[1445+1448]A (P9) and S[1445+1448]D (P10) using 
Chromas Lite 2.1.1 software. The chromatograms show four different peak colours for each of the four bases: C 
= blue, A = green, T = red and G = black. The codons that were mutated are highlighted.  The wildtype codon 
positions, S1445 and S1448, are highlighted above.  
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Wildtype (C1297):  5’ GG AAG ATG GCT GAA TCT CCC TGC TCC CCT AGT GGC CAG 
   CAG 3’ 
 
Wildtype (P1449):  5’ AG AGC CCG GCG TCC CCC CCG CCC CTG GGA GG 3’ 
 
 
Figure 3.2f Chromatogram results of hScrib mutants C1297S (P4) and P1449A (P8) using Chromas Lite 2.1.1 
software. The chromatograms show four different peak colours for each of the four bases: C = blue, A = green, 
T = red and G = black. The codons that were mutated are highlighted.  The wildtype codon positions, C1297 
and P1449, are highlighted above.  
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3.4 Expression of hScrib mutant proteins  
Phosphorylation is a reversible PTM mechanism that is significant and prevalent in cells, 
occurring mostly on threonine, serine and tyrosine residues. Since these affected hotspots 
are serine sites, will the expression of hScrib be affected by the unphosphorylation and/or 
phosphorylation states of each of these selected phosphoserine sites?  To answer this 
question, each of the four serine site was substituted for an alanine residue and an 
aspartate residue. Alanine (A) was considered a neutral amino acid (small side chain with 
no functional group) because it cannot be ionized. Thus it was used to mimic 
unphosphorylated hScrib. Aspartate (D) was used to mimic phosphorylated hScrib 
because its side chain consists of a carboxylic functional group (-COOH) that can become 
ionized (deprotonated) just as serine amino acid when it is phosphorylated.  To test the 
expression of these phosphorylation states, the validated hScrib mutants (Table 3.1) were 
transfected in HEK293T cell line (Chapter 2.18) and imaged, live, on Eclipse Ti-E 
widefield microscope (Nikon), to capture their expression (Figures 3.3a and b).  
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WT SCRIB
A-mutants D-mutants
S1306A S1306D
S1309A S1309D
Figure 3.3a. Widefield images of live HEK293T cell lines transfected with WT hScrib and 
hScrib mutant DNA.  The green fluorescence signal is due to the expression of EGFP 
tagged to hScrib. This was detected by FITC filter. WT= wildtype hScrib (positive control); 
S1306A= mutant hScrib protein with single amino acid change of serine site S1306 to 
alanine; S1309A= mutant hScrib protein with single amino acid change of serine site 
S1309 to alanine; S1306D= mutant hScrib protein with single amino acid change of serine 
site S1306 to aspartate; S1309D= mutant hScrib protein with single amino acid change of 
serine site S1309 to aspartate. Scale bar: 10 µm.    
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Figure 3.3b. Widefield images of live HEK293T cell lines transfected with hScrib mutant 
DNA.  The green fluorescence signal is due to the expression of EGFP tagged to hScrib. 
This was detected by FITC filter. S1348A= mutant hScrib protein with single amino acid 
change of serine site S1348 to alanine; S1448A= mutant hScrib protein with single amino 
acid change of serine site S1448 to alanine; S-AA= double residue substitution of serine 
sites S1306 and S1309 to alanine; S1348D= mutant hScrib protein with single amino acid 
change of serine site S1348 to aspartate; S1448D= mutant hScrib protein with single 
amino acid change of serine site S1448 to aspartate; S-DD= double residue substitution of 
serine sites S1306 and S1309 to aspartate. Scale bar: 10 µm.  
 
S-DDS-AA
S1448DS1448A
S1348DS1348A
A-mutants D-mutants
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The widefield images observed (above), show good expression of the mutant hScrib 
proteins that is no different to the WT.   
In relation to abundance, Western blotting (Chapter 2.21) was performed. By observation, 
the Western blot results (Figures 3.4a, b and c) show good abundances. However, due to 
the absence of the use of a loading control to normalize the level of protein detected in the 
samples, a constant level of abundance (protein amount) between the different samples 
loaded cannot be inferred. Therefore, it cannot be said that the mutant hScrib proteins 
were expressed at the same level in the HEK293T cell line. In spite of this, the western 
blots show that each mutant hScrib protein has the same molecular size as WT hScrib 
(≈175kDa) and not truncated; EGFP= 32.7kDa. The low abundance of S1306A was loss 
of protein that may have been through contamination after live imaging or poor sample 
preparation)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4a Western blots showing the abundance of non-native WT and mutant hScrib proteins. 
Each sample is tagged to EGFP which is recognized by anti-GFP antibody and detected as 
green fluorescence at 800nm wavelength. Anti-scribble antibody recognises the hScrib epitope 
which is detected at 700nm as red fluorescence (not shown). Each mutant protein had the same 
band size equal to the molecular weight of the WT= 175kDa. M= protein marker; WT= wildtype 
hScrib (positive control); S1306A= mutant hScrib protein with single amino acid change of serine 
site S1306 to alanine; S1309A= mutant hScrib protein with single amino acid change of serine 
site S1309 to alanine; S1348A= mutant hScrib protein with single amino acid change of serine 
site S1348 to alanine; S1448A= mutant hScrib protein with single amino acid change of serine 
site S1448 to alanine; AA= double residue substitution of serine sites S1306 and S1309 to 
alanine; S1306D= mutant hScrib protein with single amino acid change of serine site S1306 to 
aspartate; S1309D= mutant hScrib protein with single amino acid change of serine site S1309 to 
aspartate; S1348D= mutant hScrib protein with single amino acid change of serine site S1348 to 
aspartate; S1448D= mutant hScrib protein with single amino acid change of serine site S1448 to 
aspartate; DD= double residue substitution of serine sites S1306 and S1309 to aspartate; NC= 
untransfected sample (negative control).   
 
M WT NC
kDa 
170 
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Figure 3.4b Western blots showing the abundance of non-native mutant hScrib proteins and 
EGFP. These were double and triple mutated hScrib samples. Each mutant protein is tagged to 
the C-terminal of EGFP to visualize and identify whether a mutation would truncate the protein, 
but all the samples have the same band size equal to the molecular weight of the WT hScrib = 
175kDa. S[1348+1448]A= double substitution of serine residues at sites S1348 and S1448 to 
alanine; S[1348+1448]D= double substitution of serine residues at sites S1348 and S1448 to 
aspartate; S-AA(1348A)= triple substitution of serines at S1306, S1309 and S1348 to  alanine; S-
DD(1348D)= triple substitution of serines at S1306, S1309 and S1348 to  aspartate; S-
AA(1448A)= triple substitution of serines at S1306, S1309 and S1448 to  alanine; EGFP= 
enhanced green fluorescent protein is 32.7kDa in molecular weight.   
Figure 3.4c Western blots showing the abundance of non-native WT and mutant hScrib proteins. 
These samples are new single and double mutations of hScrib at positions other than the four 
selected serine hotspots. All the samples had the same band size equal to the molecular weight 
of the WT= 175kDa. WT= wildtype hScrib; P4= C1297S= single substitution of a cysteine residue 
at site C1297 to serine; P6= S1445A= single substitution of a serine residue at site S1445 to 
alanine; P7= S1445D= single substitution of a serine residue at site S1445 to aspartate; P8= 
P1449A= single substitution of a serine residue at site P1449 to alanine; P9= S[1445+1448]A= 
double substitution of serine residues at sites S1445 and S1448 to alanine; P10= 
S[1445+1448]D= double substitution of serine residues at sites S1445 and S1448 to aspartate.   
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From these analyses, it may be said that the expression of hScrib is not affected by the 
unphosphorylation or phosphorylation of the hScrib hotspots (including the newly mutated 
positions in hScrib) but their level of expression may not be the same. Samples would 
need to be run with a loading control.  
3.5 Localization of mutant hScrib proteins  
If hScrib expression is not affected, does unphosphorylation or phosphorylation of the 
hotspots affect its cellular localization? To answer this question, a more detailed picture of 
the typical localization of hScrib in a cell was required. By using confocal fluorescent 
microscopy, images of transiently transfected HEK293T cells were analysed (Figures 3.5a 
and b). These confocal images were not to show expression but the destination point of 
hScrib (visualized with the aid of the EGFP-tag). To minimize spectral crossover and 
enable nucleus and cytoplasm differentiation and visualisation, DAPI (emission 
wavelength= 455nm) fluorochrome was used to stain the DNA of the nucleus while the 
FITC filter detected EGFP (emission wavelength= 509nm).  
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Figure 3.5a Confocal images of fixed HEK293T cell lines transfected with mutant hScrib plasmid 
DNA. To identify the nucleus, the cells DNA was stained blue with DAPI fluorochrome and the green 
fluorescence signal from the EGFP tag was detected by FITC filter. This was to observe the cellular 
localisation of hScrib; WT= wildtype hScrib (positive control); NC= negative control (untransfected 
sample). S1306A= mutant hScrib protein with single amino acid change of serine site S1306 to 
alanine; S1306D= mutant hScrib protein with single amino acid change of serine site S1306 to 
aspartate;S1309A= mutant hScrib protein with single amino acid change of serine site S1309 to 
alanine; S1309D= mutant hScrib protein with single amino acid change of serine site S1309 to 
aspartate. Scale bar: 10 µm.   
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Figure 3.5b Confocal images of fixed HEK293T cell lines untransfected and transfected with WT 
and mutant hScrib plasmid DNA. To identify the nucleus, the cells DNA was stained blue with DAPI 
fluorochrome and the green fluorescence signal from the EGFP tag was detected by FITC filter. 
This was to observe the cellular localisation of hScrib; S1348A= mutant hScrib protein with single 
amino acid change of serine site S1348 to alanine; S1348D= mutant hScrib protein with single 
amino acid change of serine site S1348 to aspartate S1448A= mutant hScrib protein with single 
amino acid change of serine site S1448 to alanine; S1448D= mutant hScrib protein with single 
amino acid change of serine site S1448 to aspartate; AA= double residue substitution of serine 
sites S1306 and S1309 to alanine; DD= double residue substitution of serine sites S1306 and 
S1309 to aspartate. Scale bar: 10 µm.  
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In comparison to the WT, which show the presence of hScrib at cytoplasmic and at cell-
cell contact site, the confocal images of the mutants show different localization 
phenotypes. A-mutants all showed cytoplasmic localization of hScrib. However, S1306A 
showed fragmented localization at the plasma membrane between cells and strong 
localization (thus interaction) to a structure in the cytoplasm (see arrow) with a tail-like 
extension away from the nucleus. This structure may be the protein tubulin. S-AA show 
localization at cell-cell contact. D-mutants also show cytoplasmic localization of hScrib. 
However, S1306D show localization at cell-cell contact (same as S1448D) but fragments 
of localization within the cytoplasm. S-DD show strong localization to two perinuclear 
structures (see arrow) that may be centrioles of a centrosome.  
 
3.6 Discussion 
To understand the disorganization, invasion and metastasis of cells in breast cancer, it is 
important to know what proteins contribute to the maintenance of cell shape and polarity, 
tissue organization and development and cell physiology. This is because the effective 
regulation of these cell properties, inhibit the establishment of breast cancer and its 
properties. A key protein in the regulation of epithelial cell and tissue polarity and 
organisation is a component of the Scribble complex (hScrib/Hugl/hDlg) called hScribble 
(Dow et al., 2003; Royer and Lu, 2011). This known tumour suppressor protein found to 
be expressed in invasive and metastatic TNBC (Greenwood et al., 2011), was also found 
to be deregulated or mislocalized from its basolateral plasma membrane domain in 
mammary epithelial tumours (Dow et al., 2003; Ivanov et al., 2010).  
Further quantitative proteomic analysis discovered that PTM patterns of four 
phosphoserine sites in the C-terminal part of this hScribble changed significantly with 
CD74 overexpression (Metodieva et al, 2013). The changes in these phosphorylation sites 
may be a significant reason for hScribble involvement in breast cancer invasion and 
metastasis. Therefore this experiment studied how changes in serine phosphorylation 
status at these sites affect the expression and localization of hScribble in a cultured cell 
line.  
The widefield images and Western blot results confirmed good expression of the 
hScribble mutants (both unphosphorylated and phosphorylated). This may indicate: (1) 
the unphosphorylation and phosphorylation of each hotspot is not a signal for proteosomal 
degradation of hScribble tumour suppressor protein seen in cancer caused by Human 
Papilloma Viruses (Lawson and Heng, 2010; Royer and Lu, 2011). This is because it was 
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found that some oncoproteins of HPV (such as E6) interact with the PDZ domains of 
polarity proteins e.g. Dlg, Patj (component of the Crumbs polarity complex), especially the 
phosphorylated forms, to disrupt cell cycle regulation. If it were, it would suggest that such 
PTM state is an underlying incentive for the loss of cell polarity and the aggressive 
invasion and metastasis of breast cancer (Zhan et al., 2008). (2) The mutated hotspots of 
hScribble are not signals for apoptosis of the cells as a result of hScribble expression 
being toxic or non-functionally accumulating in the cytosol (Coleman et al., 2001; Norman 
et al., 2012). (3) Each phosphorylation hotspot, either unphosphorylated or 
phosphorylated, facilitates a different conformational change in hScribble protein to 
localize and/or recognize and interact allosterically with other protein complexes to alter 
cell behaviour e.g. apical-basal polarity, cell cycle regulation, epithelial-mesenchymal 
transition (EMT) etc, via signalling pathways such as the MAPK (Good et al., 2011; Vaira 
et al., 2011; Metodieva et al., 2013).  
Images of A-mutants S1306A, S1309A and S-AA show the possibility that 
unphosphorylated hScrib localize to cell-cell contact site. A-mutant S1306A also shows 
the possibility that unphosphorylated hScrib may likely interact with a cytoskeletal element 
called tubulin. Tubulin is a polymerized microtubular protein involved in cell motility 
(Hammond et al., 2009) and hence may promote cell invasion in breast cancer. There is a 
large presence of hScribble in the cytosol in some of the A-mutants e.g. S1309A, A1348A, 
S1448A, S-AA and D-mutants e.g. S1306D to S1448D. This may be the interaction of 
hScribble with other cytoskeletal elements e.g. intermediate filaments (IFs). Interacting to 
these cytoskeletal elements, at different phosphorylation states, induces different cellular 
activities. IFs are cytoskeletal fibres that are more abundant in the cell than microtubules 
of tubulin. They associate with plasma membrane proteins to give mechanical support to 
the cell in cell-cell and cell-ECM contact (Lodish et al., 2000:19.6). An example of IF these 
hScrib mutant proteins may be interacting with are cytokeratins and vimentin. Cytokeratins 
(acidic keratin type 1 and basic keratin type 2) are IFs known to be highly expressed in 
basal-like breast tumours such as TNBC (Eerola et al., 2008). Vimentin is a type III IF 
known to induce a mesenchymal phenotype in epithelial cells, thus altering the 
morphology, adhesion and motility of epithelial cells (Mendez et al., 2010): the result of 
EMT.  
The fragments of hScrib in the cytoplasm, seen in S1306D of Figure 3.5a, is an indication 
that hScrib protein may be interacting with cytoskeletal elements to rearrange the 
distribution of molecules within the cell (Hammond et al., 2009). This event may be 
involved in the alteration of apical-basal cell polarity. The doubly phosphorylated D-mutant 
of hScrib, (S-DD), was also intriguing as it showed strong localization to what looked like 
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centrosome which is involved in mitosis. This is an indication of hScrib’s involvement in 
the cell cycle. The centrosome consists of a pair of centrioles made up of tubulin and 
perpendicular to one another. The centrioles not only play a role in cytokinesis, they 
organise microtubular spindles which contributes to the fidelity of chromosomal 
segregation during mitosis.  In addition, centrioles may also regulate cell-cycle 
progression, thus suggesting a signalling role for centrioles (Marshall, 2006). If this is true, 
then hScrib protein in the doubly phosphorylated state may be acting as a scaffold to 
concentrate and coordinate the tubular centrioles and other signalling molecules to enable 
the regulation of cell-cycle progression.  
Based on the results of the experiment, it is not suffice to infer that any of the identified 
phosphorylation hotspots of hScrib in phosphorylated or unphosphorylated state is a 
contributor to the invasion of breast cancer. Due to the heterogeneity of the cell lines used, 
more confocal images of the mutant proteins would be analysed. Also combinations of 
phosphorylation states where three and four phosphoserine hotspots are mutated in the 
hScrib gene e.g. S-AA(1348A), S-AAAA, S-DD(1348D), S-DD(1448D) and S-DDDD, 
would be studied. Furthermore, experiments to analyse the protein-protein interactions of 
hScrib in different phosphorylation state would be carried out to understand what role 
hScrib plays in breast cancer. 
Summary of the localization study of hScrib is tabled below (Table 3.2).  
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 4. The effect of hSCRIB on cell proliferation and migration 
 
4.1 Introduction  
In humans, hScribble or hScrib protein is a product of an important tumour suppressor 
gene, hScrib, with the role of inhibiting tissue overproliferation seen in tumours. Its tumour 
suppressive function is facilitated by its scaffolding property to enable its interaction with a 
diverse set of proteins (Albertson et al., 2004; McNeil et al., 2006; Bauer et al., 2010; 
Buday and Tompa, 2010) to regulate epithelial cell polarity which is essential for 
coordinated cell proliferation, migration and maintenance of intercellular adhesion (Dow et 
al., 2003).  
Cell proliferation is cell division through the universal cell cycle machinery, a highly 
ordered and regulated complex sequence of events that comprises four critical phases: G1, 
G2, S and M phases (Shackelford et al., 1999; Pinheiro and Sunkel, 2012), with the 
initiation and termination of each phase being controlled by proteins at checkpoints G1/S, 
G2/M or M/G1. In cancer cells, this machinery is ‘hijacked’ to cause loss of control of cell 
proliferative function which leads to an abnormal mass of cells. These abnormal cells may 
acquire further mutations, with the potential to migrate unregulated (Chow, 2010) and 
invade surrounding tissue. This ‘gain of function’ may be a result of the loss of function of 
tumour suppressor proteins like hScrib designated at certain cell cycle stages (Osborne et 
al., 2004; Lee and Muller, 2010). The function of hScrib is compromised when mutations 
of the hScrib gene cause loss of expression or mislocalization of its gene product. These 
mutations lead to the loss of cell polarity which induces lack of control of cell proliferation 
and abnormal migration of cancer cells (Dow et al., 2003; Qin et al., 2005; Hanahan and 
Weinberg, 2011; Feigin et al., 2014).  
In the context of breast cancer, the changes in the phosphorylation state of hScrib protein 
responsible for the occurrence of such cellular transformation are unknown, even though 
proteomic analysis from a recent study (Metodieva et al., 2013) discovered that the post-
translational patterns of four phosphoserine sites in the C-terminal part of hScrib protein 
changed significantly in TNBC overexpressing CD74. The changes in these 
phosphorylation sites may be significant to the involvement of hScrib in tumourigenesis 
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and breast cancer invasion and metastasis. Therefore, this experiment aims to study the 
effects of hScrib mutations on cell proliferation and migration by determining which 
mutant/s of hScrib protein, previously designed from the four phosphoserine sites, is/are 
involved cell proliferation and migration. 
4.2    Proliferation in hScrib transfected HEK293T cells  
The mutation of the hScrib gene may cause loss of expression or mislocalization of its 
gene product, hScrib protein. These changes lead to the loss of cell polarity, which is 
known to induce the lack of control of cell proliferation and migration in cancer cells (Dow 
et al., 2003; Qin et al., 2005). However, what changes in the amino acid sequence of 
hScribble protein responsible for such cellular transformation to occur are unknown even 
though proteomic analysis from a recent study (Metodieva et al., 2013) discovered that 
the post translational patterns of four phosphoserine sites in the C-terminal part of scribble 
changed significantly with TNBC overexpressing CD74. The changes in these 
phosphorylation sites may be significant to the involvement of hScrib in breast cancer 
invasion and metastasis. A feature of cancer cells is their abnormal, progressive 
proliferation (Humbert et al., 2003; Fidler, 2003). The proliferation rate of HEK293T cells 
transfected with A or D-mutants of hScrib were determined by MTT assay (Chapter 2.23). 
This is a colorimetric approach that utilizes the level of absorbance of the purple formazan 
produced in the mitochondria of living cells as a measure of cell proliferation (Price and 
McMillan, 1990; van de Loosdrecht et al., 1994; Freimoser et al., 1999; Chapdelaine, 
2012). Untransfected HEK293T cell lines was used as a reference for over proliferating 
breast cancer cells in this assay while wildtype (WT) hScrib-transfected HEK293T cells 
were used as a reference of inhibition of cell proliferation. As a result of the WT hScrib 
tagged to GFP, GFP-transfected HEK293T cells were included to rule out the effect GFP 
may have on the result of the WT and mutants in the assay (Table 4.1).   
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Figure 4.1 shows a bar chart of the mean absorbances of each mutant and controls after 
4 hours of MTT reduction to formazan. Although this experiment was not repeated (only 
one experiment with triplicates), it shows that the intensity of MTT conversion was more in 
the untransfected or untreated cells than any other samples: The untreated cells 
proliferated about 5 times more than WT hScrib; 4 times more than S-AA(1448A); 3 times 
more than S1306A, S1348A, S-AA and S1306D; twice more than S1309A, 
S[1348+1448]A, S1348D, S1448D, S-DD and S[1348+1448]D; except S1448A (6 times 
less than untreated) and S1309D(8.2% less than untreated).  
Statistically, Student’s t-test that was performed showed no significant difference in 
proliferation rate between the untreated control and one A-mutant (S1309A) and four D-
mutants (S1309D, S1348D, S-DD and S[1348+1448]D). As expected, there was a 
significant difference in the proliferation rate between the untreated control and WT hScrib 
control. Student’s t-test to determine whether GFP, tagged to the WT and hScrib mutants, 
affected their proliferation rate showed no significant difference in proliferation rate 
between GFP and GFP-tagged WT and hScrib mutants. However, between WT hScrib 
and its mutants, only D-mutants S1309D, S1448D, S-DD and S[1348+1448]D showed 
significant difference in proliferation rate as shown in asterisks in Figure 4.1. S1309D was 
Figure 4.1 Absorbance of formazan produced by untransfected and transfected HEK293T cell line. 
The graph showed that there was just about more formazan produced by the D-mutants than the A-
mutants. The results are expressed as mean ± stdev, p<0.05. The asterisks indicate the level of 
significant difference between the proliferation rate of WT-transfected cells and mutants. Mutants 
without the sign were not significant. 
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the most significant (2 asterisks). All other mutants, without the asterisk, were not 
significant. Therefore, this data suggests that D-mutants proliferate more than A-mutants. 
4.3 Migration in hScrib transfected HEK293T cells  
Cell migration is highly regulated. This is because it is a very intricate cellular event that is 
involved in several functional processes in the body e.g. embryogenesis, angiogenesis, 
organogenesis, tissue repair, immune response, and wound healing. It has also been 
proposed to be involved significantly in the invasion of cancer cells (Riahi et al., 2012) as 
this is required in the early stages of tumour metastasis (Fidler, 2003). A typical cell 
migration process involves a regulated modification of cell polarity for an epithelial cell to 
assume a mesenchymal phenotype. However, in invasive breast cancers like TNBC, this 
process is abnormal (Yamaguchi et al., 2005; Etienne-Manneville, 2008). As a polarity 
protein, known to be involved in regulated cell migration, the mutation or loss of 
expression of hScrib cause abnormal cell migration (Etienne-Manneville, 2008; Qin et al., 
2005). To study the effects of hScrib on cell migration, a wound healing or in vitro scratch 
assay (Chapter 2.23) was conducted. 
The mean areas (mm2) from T=0 to T=24hrs indicate reduction of the cell-free zones (gap 
closure). However, Due to the non-uniform scratch areas made in each sample at T=0, 
the mean areas do not show how fast the scratch was covered in each sample. Therefore, 
the migration rate of the cells to closing the scratch was expressed as a percentage of 
wound closure as seen in Table 4.1: 
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Table 4.1 Migration rate of transfected cells after 24 hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 shows that after 24 hours, the percentage of the scratch area covered by the 
untransfected cells (93.9%) was more than all other samples with approximately 13 times 
cell migration rate than the least migratory sample i.e. S1306D (7.5%). The least 
migratory of the A-mutant samples was S1348A with 9% migratory rate.  
 
 
 
 
 
 
 
 
This table shows the area of the scratch covered after 24 hours as a 
percentage wound closure for each sample to represent a measure of cell 
migration rate. 
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Figure 4.2 illustrates graphically that only S1448A, S-AA, S[1348+1448]A and S-
AA(1448A) of the A-mutant samples covered more than a quarter (i.e. 25%) of the scratch 
area. Student’s t-test showed significant difference in migration rate between WT hScrib 
and S1448A, S[1348+1448]A and S-AA(1448A) as shown in asterisks in Figure 4.2. 
S[1348+1448]A was the most significant (3 asterisks). All other mutants, without the 
asterisk, were not significant. Therefore, comparing the A and D-mutant samples, this 
data suggests that A-mutant-transfected cells migrated more the D-mutant-transfected 
cells.  
However, As more than 25% scratch area was covered by cells transfected with S1448A, 
S-AA, S[1348+1448]A and S-AA(1448A), a second wound healing assay with these four 
mutants was conducted to confirm their effect on the migratory rate of cells. D-mutant 
counterpart S1448D, S-DD and S[1348+1448]D were also tested. The migration rate of 
cells transfected with these mutants were calculated (Table 4.2).  
 
 
Figure 4.2 Wound closure of untransfected and transfected HEK293T cell line. The graph showed that 
after 24 hours, only S1448A, S-AA, S[1348+1448]A and S-AA(1448A) covered more than a quarter of 
the scratched area or cell-free zone. All the D mutant samples covered less than a quarter of the scratch 
area. The results are expressed as mean ± stdev, p<0.05. The asterisks indicate the level of significant 
difference between the migration rate of WT-transfected cells and mutants. Mutants without the sign 
were not significant. 
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Table 4.2 Migration rate of cells transfected with selected hScrib  
   mutants after 24 hours 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2 shows that once again, after 24 hours, the percentage of the scratch area 
covered by the untransfected cells (63.2%) was more than all other samples. The 
migration rate of cells transfected with S1448D (1.4%) and S-DD (1.6%) is similar to WT 
hScrib (1.3%) while cell transfected with S[1348+1448]D (5.4%) covered 3 to 4 times 
more scratch area than WT hScrib, S1448D and S-DD. Of the A-mutants, S[1348+1448]A 
(18.5%) had the highest migration rate: about 6 times more scratch area than A1448A 
(3.2%) and about twice more than S-AA (8.1%) and S-AA(1448A) (8.9%). Comparing 
these A and D-mutant counterparts, S1448A covered twice the scratch area of both WT 
hScrib and A1448D; S-AA migrated about 5 times more than S-DD; S[1348+1448]A 
migrated 3 times more than S[1348+1448]D while the scratch area covered by S-
AA(1448A) was 7 times more than WT hScrib, 3 times more than S1448A and 6 times 
more than S1448D and S-DD. Figure 4.3 shows this graphically.  
 
 
 
This table shows the percentage wound closure of the samples selected for the second 
wound healing assay. These percentages represent a measure of cell migration rate. 
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When Student’s t-test was applied, there was significant difference in migration rated 
between WT hScrib and the A-mutants, but also S[1348+1448]D. A[1348+1448]A and S-
AA(1448A) were the most significant (5 asterisks). All other mutants, without the asterisk, 
were not significant. Further Student’s t-test’s to test the cell migration difference between 
A-mutants and D-mutants of the same serine position presented significant differences, 
with A and D-mutants of the serine positions 1348+1448 displaying greater significant 
differences. Within the A-mutants, there was greater significant difference between 
S1448A and S[1348+1448]A than with the other A-mutant samples. There was no 
significant difference between S-AA and S-AA(1448A). Overall, the A-mutants migrated 
more than the D-mutants.     
Figures 4.4 and 4.5 below show the brightfield images of the wound closure captured at 
T=0 and 24hrs. 
 
 
 
 
Figure 4.3 Wound closure of untransfected and transfected HEK293T cell line. The graph showed again 
that after 24 hours, cells transfected with the selected A mutants migrated faster than cells transfected 
with their D mutant counterpart. The results are expressed as mean ± stdev, p<0.05. The asterisks 
indicate the level of significant difference between the migration rate of WT-transfected cells and 
mutants. Mutants without the sign were not significant. 
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S1448A 
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S[1348+1448]A 
S-AA(1448A) 
0 Hrs 24 Hrs 
Figure 4.4 Brightfield images of wound closure of HEK293T cell lines transfected 
with A-mutants. The images shown are representative of a full scratch acquired as 
large stitched images from an automated Nikon widefield microscope. Scale bar= 
100µm.   
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Figure 4.5 Brightfield images of wound closure of HEK293T cell lines untransfected 
and transfected with D-mutants and wt scrib. The untransfected cells were used as 
a control to model in vivo cell migration in breast cancer epithelial cells while wt scrib 
was used as a control to model in vivo restriction of cell migration. The images 
shown are representative of a full scratch acquired as large stitched images from an 
automated Nikon widefield microscope. For each sample, a polygon selection tool in 
imagej software was used to create regions of interest in the stitched scratch images 
to enable calculation of the areas. Scale bar= 100µm. 
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4.4 Discussion 
Amongst other molecules, hScrib was found to be expressed in breast cancer subtypes 
such as TNBC (Triple-negative Breast Cancer) (Metodieva et al., 2013). It implicates this 
known tumour suppressor and cell polarity protein in contributing to the propagation of 
breast tumour cells and their invasion. The changes to the phosphorylation pattern found 
to occur in four phosphoserine sites of hScrib, called hotspots, may be a reason for this 
implication. Therefore, experiments were set out to study what effects the changes in the 
hotspots have on hScrib function to restrict proliferation and regulate migration in epithelial 
cells of the breast: cell proliferation assay (MTT) and a cell migration assay (wound 
healing assay).  
The result of the MTT assay showed that all except S1306D of the D-mutants had a 
proliferation rate above 50% and all except S1309A of the A-mutants had a proliferation 
rate below 50%. This suggests that the phosphorylation of positions 1309, 1448, 
1306+1309, 1348+1448 and the phosphorylation or unphosphorylation of 1309 may result 
in a conformational change in the hScribble protein structure, which will expose its PDZ 
domains to interact with certain binding partners involved in driving the cell cycle 
progressively e.g. (cyclins) (Humbert et al., 2003). The Student’s t-test on: (1) the 
proliferation rate between untreated and the treated samples and (2) the proliferation rate 
between WT hScrib and the mutants would suggest, as a means of screening the mutants, 
that S1309D, S-DD and S[1348+1448]D are candidates that may indicate the implication 
of hScribble in the over proliferative behaviour of breast cancer cells. This is because 
Student’s t-test 1 (ttest 1) showed no significant difference in proliferation rate between 
the aforementioned D-mutants and the untreated sample but a significant difference in 
proliferation to WT hScrib in Student’s t-test 2 (ttest 2). S1309A and S1348D showed no 
significant difference in proliferation rate in both ttest 1 and 2 which suggests an 
uncertainty in the ability of such mutations to cause overproliferation in breast cancer cells.  
There were two wound healing assays conducted. The result of the first wound healing 
assay showed that all except S1448A, S-AA, S[1348+1448]A and S-AA(1448A) of the A-
mutants had above 25% recovery of the wounded area while none of the D-mutants did. 
This suggests that the unphosphorylation of positions 1448, 1306+1309, 1348+1448 and 
1306+1309+1448 may contribute to the ability of breast cancer cells to become invasive. 
Considering the first Student’s t-test (ttest 1) (not shown) to test the difference in cell 
migration between untreated and treated samples showed a significant difference but the 
second Student’s t-test (ttest 2) to test the cell migration difference between WT hScrib 
and hScrib mutants showed a significant difference in the migration rate for A-mutants 
S[1348+1448]A and S-AA(1448A) (Figure 4.2). To screen mutant hScrib candidates with 
R E S U L T S    | 84 
 
the cell migration potential, a second wound healing assay was conducted with S1448A, 
S-AA, S[1348+1448]A and S-AA(1448A). D-mutant counterpart S1448D, S-DD and 
S[1348+1448]D were also tested. The result of the second wound healing assay showed 
cells transfected with 1448 of the A-mutants and the D-mutant, respectively, had below 8% 
wound recovery compared to S-AA, S[1348+1448]A and S-AA(1448A) of the A-mutants. 
This suggests that double and triple unphosphorylation state of hScrib at serine positions 
1306+1309, 1348+1448 and 1306+1309+1448 may pose significantly to the capacity of 
breast cancer cells to metastasize. Although ttest 1 (not shown) to test the difference in 
cell migration between untreated and treated samples showed a significant difference, 
ttest 2 (not shown) to test the cell migration difference between WT hScrib and hScrib 
mutants revealed a significant difference in migration rate for all A-mutants and 
S[1348+1448]D (Figure 4.3). However, the p-value of S[1348+1448]A and S-AA(1448A) 
showed greater significance than the p-value of the other significant samples (similar to 
the first wound healing conducted).  
The results from the analysis suggest S[1348+1448]A may be a candidate for breast 
cancer invasion. S[1348+1448]A may be involved in a cascade of events that may involve 
the facilitation of a modified epithelial cell polarity to support a  mesenchymal phenotype 
which is a feature of invasive breast cancer cells (Radisky, 2005; Etienne-Manneville, 
2008; Yarrow et al., 2004; Chaffer and Weinberg, 2011; Metodieva et al., 2013).  
Findings of the cell migration and proliferation studies of hScrib are summarized in Table 
4.3 
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 5. The effect of hSCRIB on cell cycle 
 
5.1 Introduction  
Protein complexes that are known to control polarity at the cellular and tissue level also 
contribute to the regulation of cell proliferation, in addition to other cellular functions such 
as cell apoptosis, and the establishment of intercellular junctions (Qin et al., 2005; Huang 
and Muthuswamy, 2010; Macara and McCaffrey, 2013). One such polarity protein 
complex is the Scribble complex which comprises the proteins: hScrib, hDlg and Hugl 
(human homologues of the Drosophila melanogaster scrib, disc large and lethal giant 
larvae). The effects these proteins have on cellular activities depend on their subcellular 
localization e.g. the localization of hScrib at the basolateral region of epithelial cells is 
crucial for maintaining cell polarity and regulation of cell proliferation (Dow et al., 2003; 
Grifoni et al., 2004; Takizawa et al., 2006; Feigin et al., 2014).  
Mutation of any of these proteins cooperates with oncogenic Ras signalling to cause cell 
overproliferation, but only with the mutation of hScrib do the Ras-induced overproliferated 
cells become metastatic (Qin et al., 2005; Chatterjee et al., 2012). This outlines hScrib as 
a very important tumour suppressor protein against breast cancers and other cancers 
which are known to display, among others, the characteristic cell overproliferation due to 
excessive cell division (Hanahan and Weinberg, 2011; Royer and Lu, 2011). Although the 
loss of hScrib function (which may result from the loss of its expression level or subcellular 
localization) may be associated with the aberrant proliferative nature of cancers, it seems 
likely that there may also be an association between inappropriate post-translational 
modification e.g. phosphorylation of hScrib and cell overproliferation (Zhan et al., 2008; 
Anastas et al., 2012; Metodieva et al., 2013).  
Cell proliferation is cell division governed by a checkpoint-monitoring, four-phased cell 
cycle which sometimes could incur errors. After confocal images from Chapter 3 
suggested that hScrib might be involved in the cell cycle, screening assays (MTT and 
wound healing) were used to select candidates of hScrib with different phosphorylation 
statuses (unphosphorylated (Alanine, A) and phosphorylated (Aspartate, D)). These 
candidates originated from the four serine hotspots found in hScrib, by proteomic 
screening, to have altered post translational patterns in triple-negative breast cancer 
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(TNBC) overexpressing CD74 (Metodieva et al., 2013). To understand the effects of 
hScrib on the cell cycle, a flow cytometric assay was performed and analysis was done to 
generate a cell cycle model using FCS express 4 software program created by DeNovo 
Software Company.  
5.2 Reason for conducting flow cytometry 
In Chapter 3, it was reported that confocal images of the localization of hScrib in 
transfected HEK293T cell line (used as a model of triple-negative breast cancer cells) 
suggested that hScrib might be involved in the cell cycle. This was supported by a 
Nagasaka et al. (2006) study which demonstrated that hScrib negatively regulates G1 to S 
phase progression in the cell cycle by localizing at the basolateral membrane in epithelial 
cells. However, this study only used GFP-fused hScrib domain and deletion constructs 
and it did not look at how the phosphorylation pattern of hScrib affected the cell cycle. 
With hScrib implicated in breast cancer progression (Greenwood et al., 2012), could the 
changes in the pattern of phosphorylation of four serine sites, identified to be affected by 
CD74 overexpression in TNBC, be a contributor to the lack of inhibitive control exhibited in 
the cell cycle by breast cancer cells. To investigate this reasoning, a flow cytometric 
experiment and analysis was conducted on mutants of hScrib selected as possible 
candidates of breast cancer proliferation and invasion through MTT and wound healing 
assay screenings that were conducted and reported in Chapter 4. WT hScrib was used as 
a control.   
5.3    The cell cycle model and results of the flow cytometry 
Analysis of the flow cytometry result involved the introduction of a model that fits the 
histograms generated by the Accuri C6 flow cytometer to enable better analysis and 
comparison of the G1, S and G2/M phases between A and D-mutants, between hScrib 
mutants within each group and between hScrib mutants and control. The model used was 
from FCS express 4 created by DeNovo Software Company. The expression of GFP-
fused hScrib and its mutants was detected by the FL1 channel (FITC) while the 
fluorescence intensity (which indicates DNA content) of the PI-stained DNA was detected 
by the FL2 channel.  
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a. 
b. 
c. 
d. 
Figure 5.1 Gated histograms with a model of the distribution of FITC
+
+PI
+
 HEK293T cell line 
population transfected with wt hScrib and selected candidates of A and D mutants of hScrib. The 
same gating was applied to each sample and adjusted to find the model to fit their histograms. 
The x-axis (FL2-A) represents the total fluorescence intensity measured by the channel 
detecting PI-stained DNA of cell population that were positively expressing the respective hScrib. 
The y-axis (count) represents the number of cells under each cell cycle phase depicted by three 
red-patterned curves under the histogram. The histograms are in the order of A Vs D: a. 1448A 
and 1448D mutant hScrib. b. AA and DD mutant hScrib. c. [1348+1448]A and [1348+1448]D 
mutant hScrib. d. hScrib WT control and AA1448A. These mutants and control were ordered in 
this manner to enable easy comparison of their cell cycle phases. However, comparison was 
also made between mutants and control and between mutants of the same group. The results 
here are representative of the experiment conducted in duplicate for each mutant and control.   
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The histograms show a gated HEK293T cell population that not only had their DNA 
stained with propidium iodide (PI), but also positively expressed the respective hScrib 
DNA’s they were transfected with. Therefore, the cell population are FITC++PI+. The 
gating was to exclude untransfected cell population (FITC-+PI+), and as much as possible, 
cell aggregates, cell doublets and debris that developed during sample preparation. The 
edges of the histograms are traced, with as much fit as possible, by a green line which 
implies the application of a multicycle mathematical model (the polynomial S-fit model of 
Dean and Jett integrated by Phoenix Flow Systems in DeNovo Software) to the 
histograms. This was followed by the formation of three differently red-patterned curves 
under each green trace to compartmentalize the G1, S and G2/M phases. The same gate 
was used for all samples. By manually adjusting the gate to determine which of the six 
different multicycle models will fit the histograms, the best model with good S phase 
confidence and low B.A.D (background, aggregates and debris) was used to resolve what 
percentage of FITC++PI+ cell population were in the respective cell cycle phases. The 
peaks of G1 and G2 phases represent the average number of cells that had the maximum 
fluorescence intensity in the G1 and G2 phases, respectively.  Hence, the G1 and G2 
mean displayed in the DNA model summary statistic table under each histogram. The 
coefficient of variation (CV) determines the accuracy of DNA content measurement in the 
cell cycle and the quality of the histogram. It is a measure of the spread of DNA from cells 
under the G1 and G2 curves- the G1 more importantly. The smaller the CV, the better the 
estimated percentage of cells in each cell cycle phase (Carroll et al., 2007:226; Ormerod, 
2008). Expressed in Table 5.1, in tabular form, is a summary of the cell cycle results. 
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Table 5.1 Cell cycle model summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Chi-Square (χ2) is an indication of how well the mathematical model is fitting the 
histogram. The smaller the χ2, the better the fit of the model to the histogram. Although the 
result of each repeat of the samples have low χ2, they also have high CV values (>3%). 
This may be due to inadequate data analysis, improper staining conditions or 
inadequacies in sample preparation to minimize large number of dead cells, cell doublets, 
clumps and debris. Also, the use of cultured cells which have heterogeneous DNA content 
may play a part in the high CV values of the samples (Pozarowski and Darzynkiewicz, 
2004; Ormerod, 2008). From Table 5.1, the percentage of cells in the G1 phase that were 
transfected with S[1348+1448]A and S[1348+1448]D were significantly lower than other 
samples, with S[1348+1448]D (43.98±0.17%; p<0.01) more significantly lower than 
S[1348+1448]A (49.05±0.01%; p<0.01) (p values not shown). The percentage of cells in 
the S phase that were transfected with S[1348+1448]A (46.13±0.35%; p<0.01) were 
significantly higher than other A-mutants, D-mutants and WT hScrib. The percentage of 
cells in the G2 phase that were transfected with WT hScrib is the lowest compared to the 
mutant samples. However, this was not statistically significant when compared to the A-
mutants (4.68±0.14% vs 6.81±0.26%, 6.15±0.01%, 4.82±0.34% and 5.07±0.75%; p<0.01). 
Comparing WT hScrib or A-mutants to the D-mutants, there was a significant difference 
Each mutant sample and control (WT hScrib) was duplicated. Student ttest (not shown) was used to 
statistically analyse a two-tailed paired null hypothesis that there would be no significant difference 
between wt scrib and the scrib mutants on the percentage of cells in the G1, S and G2 phases of the 
cell cycle. Statistical significance was established at p<0.01. Stdev= standard deviation; χ
2
= chi-
square; %S= percentage of cells in the synthesis phase of the cell cycle; %G1= percentage of cells 
in the first preparatory or gap stage of the cell cycle, before the S phase; %G2= percentage of cells 
in the second preparatory or gap stage of the cell cycle, after the S phase but before the mitosis (M) 
phase.      
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as more than 10% of cells transfected with D-mutants progressed to the G2 phase i.e. two 
to three times more D-mutant-transfected cells in the G2 phase than the A-mutants and 
WT hScrib (Figure 5.2). 
 
 
 
 
 
The results, taken together, suggest D-mutants favour progression through the cell cycle 
thereby supporting cell proliferation, while A-mutants inhibit cell cycle progression to 
favour cell migration.    
 
5.4 Discussion 
The cell cycle controls cell proliferation. Breast cancer is initiated by inappropriate cell 
proliferation and hence a disease of the cell cycle (Collins et al, 1997; Sandal, 2002; Sa 
and Das, 2008). After employing the MTT and wound healing assays as screening 
processes, some hScrib A-mutants and their D-mutant counterpart were selected to study 
their effects on the cell cycle. As it was shown in Chapter 4 that the D-mutants in the MTT 
assay proliferated more than the A-mutants, it was also shown through the analysed flow 
Figure 5.2 Bar graph of HEK293T cell lines, transfected with hScrib samples, in the G2 phase of the cell 
cycle. The graph shows that more cells entered the G2 phase of the cell cycle when transfected with D-
mutants of hScrib than when transfected with A-mutants of hScrib or WT hScrib. Hence the probability 
that the cells would complete the cell division process. This supports the MTT proliferation assay in 
Chapter 3 that suggested that D-mutants proliferated more than the A-mutants of hScrib. The results are 
expressed as mean ± stdev, p<0.01. The error bars show the variability about the percentage mean for 
control and mutant sample. The asterisks indicate the level of significant difference of cells in the G2 
phases of the cell cycle between WT-transfected cells and mutants. Mutants without the sign were not 
significant. 
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cytometry results that D-mutants enabled progression of more cells into the G2/M phase 
(Figure 5.2) and therefore support cell proliferation. If D-mutants of hScrib support cell 
cycle progression, it indirectly suggests what phosphorylation state hScrib acts to restrict 
cell cycle progression and hence enact its tumour suppressive role (Chow A.Y. 2010) i.e. 
the serine hotspots identified have to be unphosphorylated. It also suggests that 
unphosphorylated hScrib may be functioning at the G1 restriction point or at the G1/S 
phase border to repress the cell cycle (Nagasaka et al., 2006).  
To contribute to the regulation of signalling pathways such as polarity, proliferation, 
migration and apoptosis, hScrib possesses a scaffold structure. This enables hScrib, by 
facilitating close interaction of proteins, to act as a molecular bridge to bring about the 
formation of complexes of proteins that establish cell signalling networks that are effective 
and specific to the respective signalling pathway. While enabling and moderating the 
signal strength of the cell signalling networks, the scaffolding property of hScrib also 
minimizes the crosstalk between these signalling networks. This is especially significant in 
the mitogen-activated protein a kinase (MAPK) pathway via which hScrib is likely to exert 
its tumour suppressive role in the cell cycle (Levchenko et al., 2000; Dhanasekaran et al., 
2007).   
The MAPK pathways are a family of protein kinases involved in phosphorylation cascades 
that control or are involved in multiple cellular activities e.g. cell growth, cell proliferation, 
cell differentiation, survival and apoptosis. The cell cycle mechanism of cell proliferation is 
controlled by the MAPK (mitogen-activated protein kinase) pathways which have been 
reported to be responsible for cancers and other human diseases (Seger and Krebs, 1995; 
Wada and Penninger, 2004; Zhan et al., 2008; Kim and Choi, 2010; Good et al., 2011; 
Greenwood et al., 2012). Of these MAPK pathways, the ERK signalling pathways 
(ERK1/2 and ERK5) have been implicated in the cell cycle (Chuderland and Seger, 2005; 
Wang and Tournier, 2006): the classical ERK1/2 activation via the Ras/Raf/MEK/ERK 
signal transduction cascade and the ERK5 activation via the Ras-
WNK1/MEKK/MEK5/ERK5 signal transduction cascade (Wang and Tournier, 2006; Moniz 
and Jordan, 2010). ERK1/2 and EKR5 are third tier protein kinases that are 
phosphorylated by MEK1/2 and MEK5, respectively. MEK1/2 activate ERK1/2 
translocation to the nucleus while MEK5 activates EKR5 phosphorylation which activates 
further downstream reactions. Ultimately, both signal transduction cascades activate 
protein kinases like RSK (ribosomal S6 kinase) and transcription factors like E2F, c-Myc, 
c-Fos, Sap1 and NF-kB, TCF (ternary complex factor), SRF (serum response factor), c-
Jun etc, to encode genes required for progression through G1, DNA replication of the S 
phase and subsequent cell cycle phases (Sears et al., 2000; Zhang and Liu, 2002; 
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Nashimoto and Nashida, 2006; Cude et al., 2007; Chen and Thorner, 2007; Gabay et al., 
2014; Lodish et al., 2013: 741 and 887).  
How D-mutants of hScrib enabled G2/M phase cell progression may come from the 
understanding of hScrib control of ERK activation. This is because hScrib has been found 
to control ERK activation. A study published in 2010, by Nagasaka et al, discovered that 
hScrib has two kinase interaction motif sites (N-terminal KIM and C-terminal KIM) with two 
corresponding downstream phospho-acceptor sites (S853 and S1448) that influence the 
effect of ERK by either (i) inhibiting upstream MEK phosphorylation of ERK or (ii) 
dephosphorylating activated ERK (phospho-ERK): ERK1/2 phosphorylated by MEK1/2 is 
activated for nuclear translocation but in the presence of hScrib, phospho-ERKs bind to 
the ERK docking sites (N-terminal KIM and C-terminal KIM) of hScrib and lose their 
phosphate to the phospho-acceptor sites on hScrib which becomes phosphorylated. 
Either way, hScrib controls when ERK is activated and translocated to the nucleus. ERK 
kinase function is inhibited and cell cycle progression is suppressed (Ramos, 2008; 
Nagasaka et al., 2010).  
A statistical ttest G2 (not shown) was conducted to compare the difference in the 
percentage of cells that entered the G2/M phase between WT hScrib and the selected 
hScrib D-mutants. It showed a highly significant percentage of cells transfected with the 
selected hScrib D-mutants entered G2/M phase, especially the D-mutants with the 
mutated S1448 site i.e. S1448D and S[1348+1448]D. This was because a further ttest G2 
D-mutant (not shown) to test, among the hScrib D-mutants, the difference in percentage 
of cells that entered G2/M phase showed a significant difference between phosphorylated 
S1448 site D-mutants (S1448D and S[1348+1448]D) and non-phosphorylated S1448 site 
D-mutants (DD). It could be that S1448 site phosphorylation (with or without S1348) 
changed hScrib conformation which compromised the orientation of the C-terminal KIM 
site and affected the interaction with ERK. Another reason could be that phosphorylation 
of the C-terminal phospho-acceptor S1448 site may have, rather than alter hScrib 
conformation, reduced the strong ERK-binding affinity of the C-terminal KIM site to 
weaken the interaction (Durek et al., 2009; Wu et al., 2009; Nagasaka et al., 2010; Sun et 
al., 2010). As Nagasaka et al. (2010) revealed ERK to be the main protein that 
phosphorylates hScrib at S1448, the presence of an already phosphorylated S1448 site 
may have prevented phospho-ERK from binding and phosphorylating hScrib at the S1448 
site. The consequence of these events occurring due to a mutated S1448 mean ERK is 
free to remain phosphorylated and activated by MEK1/2 and activated ERK cannot be 
regulated by hScrib phosphorylation. The ERK phosphorylation levels increase thus 
encouraging phospho-ERK translocation to the nucleus. Besides being significantly 
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different from WT hScrib and A-mutants, D-mutant DD i.e. S[1306+S1309]D, was also 
significantly different from the phosphorylated S1448 site D-mutants (S1448D and 
S[1348+1448]D). This could be due to its phosphorylation status which may have affected 
the conformation of the C-terminal KIM docking site downstream of its phosphorylated 
position. This conformational change may have caused weak interaction with ERK, not 
enough to repress G2/M cell entry but also not enough to reduce the amount of free 
phospho-ERK to translocate to the nucleus (Durek et al., 2009; Sun et al., 2010). These 
potentially inappropriate phosphorylations may be an incentive for initiation of oncogenic 
cell proliferation.  
The ERK1/2 signalling may not necessarily be the only pathway to G2/M cell progression 
as a study by Cude et al. (2007) found that G2/M cell cycle progression is via the ERK5 
(or BMK1) signalling pathway. MEK5-phosphorylation of ERK5 recruits and activates 
RSK2 (ribosomal S6 kinase 2) to mediate the release of NFkB from the cytosolic inactive 
IkB:NF-kB complex by phosphorylation of IkB for degradation. NF-kB translocation to the 
nucleus activates its DNA-binding ability to transcribe molecules required for G2-M 
transition. ERK5 functions similar to ERK1/2: (i) it can be stimulated by Ras (although 
enhanced by WNK1) and (ii) ERK5 can phosphorylate ERK1/2 substrates like Sap1, c-
myc, RSK (Nashimoto and Nashida, 2006) and probably hScrib (via KIM sites). If this is 
the case, at G2/M phase, phosphorylation of hScrib in the manner represented by the D-
mutant samples, either diminishes in its ability to interact with ERK5 to execute its 
inhibitive role on the cell cycle or re-configures hScrib to support ERK5 recruitment of 
RSK2 via its scaffolding structure (Durek et al., 2009; Wu et al., 2009; Good et al., 2011). 
Besides the mediation of G2/M cell cycle progression by the ERK5 or ERK1/2 signalling 
pathways, both signalling pathways may also mediate G1/S transition and S phase 
progression by inducing cyclin D1 expression for cyclin D1-cdk4/6 complex 
hyperphosphorylation (inactivation) of tumour suppressor pRb (retinoblastoma protein) at 
G1 restriction point and cyclin A expression to facilitate transcription of molecules required 
for DNA replication (Guttridge et al., 1999; Nagasaka et al., 2010; Nashimoto and Nashida, 
2006; Cude et al., 2007; Moniz and Jordan, 2010).   
From a statistical ttest G1 (not shown) conducted to compare the difference in the 
percentage of cells that arrested in G1 phase between WT hScrib and the hScrib mutants, 
it was found that the percentage of cells arrested in G1 when transfected with 
S[1348+1448]A or S[1348+1448]D was significantly lower than WT hScrib. Other mutants 
showed no significant difference. In addition, a ttest S (not shown) conducted to compare 
the percentage of cells arrested in the S phase between WT hScrib and the hScrib 
mutants showed the percentage of S[1348+1448]A transfected cells arrested in S phase 
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was significantly higher than WT hScrib. Other mutants showed no significant difference. 
Taken together, these suggest that S[1348+1448]D may be responsible for G2/M 
transition but S[1348+1448]A could be responsible for both G1/S transition and 
progression through the S phase. S[1348+1448]A may be an inappropriate 
phosphorylation state that engage in interactions that support the actions of cyclin D1-
cdk4/6, cyclin E-cdk2 and cyclin A-cdk2 complexes (Woo and Poon, 2003) to enable G1/S 
transition and the nucleic acid replication and transcription for S phase progression. Also, 
from the statistical ttest G1 conducted, it is possible that unphosphorylation of hScrib 
(other than S[1348+1448]A) enable G1 arrest by direct interaction with APC (Takizawa et 
al., 2006).  
APC (adenomatous polyposis coli) is a tumour suppressor that negatively regulates G1 to 
S phase cell cycle progression by binding to β-catenin (Ishidate et al., 2000; Wang et al., 
2008). Beta(β) catenin is a transcriptional co-activator of the Armadillo-domain subfamily 
of proteins found in the nucleus and at the intercellular adherens junction complexing with 
other cell-adhesion molecules like E-cadherin, p120 catenin, etc (Anastasiadis and 
Reynolds, 2000; McCrea and Gu, 2010; Lohia et al., 2012). β-catenin is regulated by the 
Wnt signal transduction pathway that is responsible for cell fate determination, apoptosis 
and also cell proliferation. APC binding to β-catenin promotes proteosome-mediated 
degradation of β-catenin, when β-catenin is in excess in the cytoplasm or nucleus 
(Henderson, 2000; Benchabane and Ahmed, 2009; MacDonald et al., 2009). This 
downregulatory mechanism of β-catenin by APC is facilitated by the interaction of APC 
with a member of the Scribble complex of polarity proteins, hDlg (Ishidate et al., 2000). 
hScrib is a member of the Scribble complex that is known to interact with hDlg at the 
basolateral membrane region to maintain cell polarity. hScrib-hDlg complex associate with 
cell junctional complexes to maintain cell-cell contact (Bilder et al., 2000; Nakagawa and 
Huibregtse, 2000; Dow et al., 2003). If the localization of hScrib at the basolateral 
membrane (which contributes to maintenance of cell polarity) is responsible for the G1 
arrest of cells in the cell cycle (Nagasaka et al., 2006), then it is likely facilitated by hScrib-
hDlg complex in the basolateral membrane recruiting APC from the cytoplasm to bind to 
and chaperone excess cytoplasmic or nuclear β-catenin for degradation in the cytoplasm. 
In addition to hScrib KIM site-dependent inactivation of ERK, proteins involved in G1 to S 
transition e.g. c-Myc, c-Fos, E2F, c-cdk4/6, cdk2, cyclin D1, cyclin E, etc, are 
downregulated. Hence cell proliferation is terminated. Phosphorylation of hScrib, as seen 
in Figure 5.2, may disrupt the localization and interaction of hScrib with its binding 
partners at the basolateral membrane to maintain cell polarity and the adherens junction: 
hScrib localizes to the cytoplasm and is unable control the ERK signal transduction 
R E S U L T S    | 96 
 
Method Objective A-mutants D-mutants
Flow cytometry Cell cycle progression G1 arrest G2/M arrest
pathway and enable APC-mediated proteosomal degradation of β-catenin. Thus cell 
proliferation is unchecked.  
The results so far suggest that although phosphorylation of hScrib enables G2/M 
transition, it does not facilitate the completion and exit from M phase as this requires its 
dephosphorylated. It is also possible that dephosphorylation of serine sites 1448 (most 
likely) and 1348 may be required for exit from M phase. However, these possibilities are 
only speculations until confirmed by results from the analysis of mass spectrometry Co-IP 
and WB Co-IP, which are pending.    
The findings of the cell cycle study of hScrib is summarized in Table 5.2 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Table 5.2  Summary of hScrib Cell cycle study 
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6. Protein-protein interactions of hSCRIB 
 
6.1 Introduction  
Proteins are the basic functional unit of a cell and hence living systems in the human body. 
They are dynamic as their functions are diverse. How proteins function determine how 
cells are organized and what their specific roles are. The diverse function of a protein, 
most likely, is through the formation of molecular networks by its interaction with other 
proteins within the cell to form protein complexes and/or cause cascades (Berg et al., 
2002:3; Spirin and Mirny, 2003).  One important cell behaviour governed by the formation 
of protein-protein interactions is in the maintenance of cell polarity (Humbert et al., 2003; 
Chatterjee and McCaffrey, 2014).  
Polarity at the cellular and tissue level contribute to the regulation of cell migration, cell 
proliferation, apoptosis, establishment of intercellular junctions, tissue organization and 
tumour suppression (Qin et al., 2005; Huang and Muthuswamy, 2010; Macara and 
McCaffrey, 2013; Chatterjee and McCaffrey, 2014). Known to be involved in facilitating 
these cell behaviours is the Scribble complex which comprises the proteins: hScrib, hDlg 
and Lgl. These components are also tumour suppressors (Su et al., 2012), of which one 
of the components, hScrib, was the focus of study.  
The hScrib was implicated in the invasion and metastasis of triple-negative breast cancer 
(TNBC) due to its protein interactions (Greenwood et al., 2012; Metodieva et al., 2013). 
Therefore, this experiment aims to study the effect of hScrib mutations on interactions with 
its binding partner so that the molecular mechanism by which hScrib provides a tumour-
suppressive function could be understood. By identifying the protein binding partners of 
hScrib when phosphorylated and unphosphorylated at given C-terminal serine sites of 
hScrib, a signalling pathway can be developed.  
Breast cancer, or any other cancer, is a disease of the cell cycle (Collins et al, 1997; 
Sandal, 2002) and a confocal image in chapter 3 (Figure 3.4b, S-DD) suggested hScrib 
may be involved in the cell cycle. At what stage of the cell cycle remains unknown. 
Therefore, to begin to identify the binding partners involved with hScrib in cell migration 
and at stages of the cell cycle, a co-immunoprecipitation (CoIP) assay that incorporated 
cell synchronization was performed. This was complemented with the use of a nanoscale 
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electrospray ionization hybrid LTQ/Orbitrap Velos mass spectrometer (MS) to identify the 
proteins from CoIP that were proteolytically treated before MS analysis. Computational 
predictions of probable interactions of hScrib with other proteins were applied to aid in 
developing the biological pathway/s through which it prevents or may be involved in 
invasion of breast cancer (Zahiri et al., 2013).          
6.2 Statistical analysis of MS results 
The mass spectrometer was used to measure the protein abundances of two conditions 
that were set up in the Co-IP assay: a negative control condition with a non-specific 
antibody and an experimental condition with GFP antibody to target GFP in the GFP-
tagged S[1306+1309]A and S[1306+1309]D mutants of hScrib used as baits, respectively. 
The result from the mass spectrometer was a proteomic dataset presented in Microsoft 
Excel spreadsheet. It contained 1195 identified proteins with their abundances in both 
conditions (dataset not shown). Each experimental condition (labelled aa-p1 to aa-p3 and 
dd-p1 to dd-p3  to represent S[1306+1309]A  and S[1306+1309]D pull-down, respectively) 
and the negative control condition of S[1306+1309]D pull-down (labelled dd-n1 to dd-n3) 
was in triplicate. The negative control condition for S[1306+1309]A pull-down was in 
duplicate (aa-n1 to aa-n2). Due to huge variations in the intensity values within the two 
conditions and to avoid the risk of false positive results during analysis, a spectral 
counting (MS/MS) approach (Heinecke et al., 2010) was adopted: each replicate was 
summed up e.g. aa-n1 + aa-n2, and the value of the total sum of the replicates in each 
condition was calculated i.e. Σ(aa-n1 + aa-n2). 
 For a biologically validated result, it was important to identify differences in protein 
abundances that show statistical significance when the hScrib mutants, used as bait, were 
expressed. This was in addition to minimizing the false discovery rate (FDR). To achieve 
these, a combination of statistical methods was applied:  1.) G-test of goodness-of-fit = 2Σ 
[O*ln (O/E)] of one nominal variable (protein abundance) with two conditions (negative 
control and experimental). The G-test measures, for each protein in the data, how far their 
observed MS/MS Count (O) is likely to be from their expected theoretical MS/MS Count (E) 
if null hypothesis is to be true. Therefore, it is also called a log-likelihood ratio test. In the 
G-test, all summed up MS/MS Counts with abundance of 0 were assigned a value of 1 to 
enable statistical computation i.e. spectral count + 1.  
However, the G-statistic values obtained do not prove statistical significance without 
comparing with 2.) The chi-squared distribution (CHIDIST) from Microsoft Excel. With a 
degree of freedom (n-1) of 1 i.e. 2 conditions minus 1, CHIDIST provides a measure, via 
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probability values (p-value), of how significant the G-statistic values are. In spite of this, 
stringency in the statistical significance was required because of the multiple gene set 
tested at the same time. Therefore, the question was asked: what is the probability that 
the p-value for each protein show true significance or non-significance? This question 
prompted the use of a multiple testing correction method called 3.) Bonferroni correction.  
The p-value of each protein was multiplied by the total number of identified proteins (1195) 
in the dataset to give an adjusted p-value (adjP). From the result of this operation, all 
corrected p-values of 1 and above were assigned the value of 1. This was to prevent the 
probability of a type 1 error or false-positive result (Bland and Altman, 1995; Noble, 2009; 
Heinecke et al., 2010). Hence, with a set threshold of p<0.05, the null hypothesis that 
there would be no significant difference in protein abundances between the negative 
control condition and the experimental conditions, were evaluated.  
These calculations produced two gene lists (Tables 6.1a and 6.1b and 6.2a and 6.2b) that 
showed, in decreasing order of significance, the proteins with significant difference in their 
abundance, when S[1306+1309]A and S[1306+1309]D hScrib mutant were expressed 
and used as bait.   
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Table 6.1a Significant binding partners of S[1306+1309]A hScrib 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order of adjusted p-value (Bonferroni correction), this table shows 39 out of the 79 proteins that 
present significant differential expression when HEK293T cell line was transfected with 
S[1306+1309]A mutant of hScrib and thus expressed. Based on spectral count + 1, it was possible to 
determine the G-test, p-value and, for stringency, an adjusted p-value at a threshold of significance of 
p<0.05. Highlighted in yellow is the hScrib protein identified by the mass spectrometer. Each protein 
has a uniprot accession code to enable identification of the gene of each protein in any bioinformatics 
database.  
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Table 6.1b  Significant binding partners of S[1306+1309]A hScrib (contd.)                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A continuation of the previous table. In order of adjusted p-value (Bonferroni correction), this table 
shows the remaining 40 of the 79 proteins that present significant differential expression when 
HEK293T cell line was transfected with S[1306+1309]A mutant of hScrib and thus expressed. 
Based on spectral count + 1, it was possible to determine the G-test, p-value and, for stringency, 
an adjusted p-value at a threshold of significance of p<0.05.      
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Table 6.2a  Significant binding partners of S[1306+1309]D hScrib                  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order of adjusted p-value (Bonferroni correction), this table shows 46 out of the 92 proteins that 
present significant differential expression when HEK293T cell line was transfected with 
S[1306+1309]D mutant of hScrib and thus expressed. Based on spectral count + 1, it was possible to 
determine the G-test, p-value and, for stringency, an adjusted p-value at a threshold of significance of 
p<0.05. Highlighted in yellow is the hScrib protein identified by the mass spectrometer. Each protein 
has a uniprot accession code to enable identification of the gene of each protein in any bioinformatics 
database.      
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Table 6.2b  Significant binding partners of S[1306+1309]D hScrib (contd.)  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A continuation of the previous table. In order of adjusted p-value (Bonferroni correction), this table 
shows the remaining 46 of the 92 proteins that present significant differential expression when 
HEK293T cell line was transfected with S[1306+1309]D mutant of hScrib and thus expressed. 
However, the red highlighted row with Gene Name C11orf48 has no uniprot accession code. Based on 
spectral count + 1, it was possible to determine the G-test, p-value and, for stringency, an adjusted p-
value at a threshold of significance of p<0.05.      
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6.3 Bioinformatics analysis of results with WebGestalt 
Respectively, the two gene lists were put through enrichment analysis via a web-based 
gene set analysis toolkit (WebGestalt). To enter these lists, ‘hsapiens’ i.e. Homo sapiens 
(human), as organism of interest was selected, ‘hsapiens_uniprot_swissprot_accession’ 
was selected to specify the gene type ID and the list of uniprot codes for S[1306+1309]A 
and S[1306+1309]D were respectively copied and pasted into the ‘upload gene list’ box.  
Once each gene list was entered, a GO (Gene Ontology) Slim Classification that gives an 
overview of the categories of the Biological Process, the Molecular Function and the 
Cellular Component classification the proteins in the given gene lists were observed. This 
overview is in the form of a bar chart for each classification where each category in a 
classification is represented by bars and the height of each bar represents the number of 
proteins, from the list, that were observed in the category. The bars are in order of 
decreasing height. There were only 70 out of 79 proteins in the list for S[1306+1309]A 
(Tables 6.1a and 6.1b) that could be clearly mapped to unique Entrez Gene IDs in the GO 
database while the other 9 could not. Only 91 uniprot codes could be entered into 
WebGestalt, for S[1306+1309]D (Tables 6.2a and 6.2b), because C11orf48 has no code. 
83 out of the 91 proteins could be clearly mapped to unique Entrez Gene IDs in the GO 
database while the other 8 could not. There are 13 Biological Processes and 15 Molecular 
Functions identified by WebGestalt from both lists. WebGestalt also identified 18 Cellular 
Components categories for S[1306+1309]A compared to 16 for S[1306+1309]D.  
To enable comparison between categories of S[1306+1309]A and S[1306+1309]D pull-
downs, these bars have been merged together (Figures 6.1, 6.2 and 6.3).  
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Figure 6.1 shows that, in general, the number of proteins pulled down by S[1306+1309]D, 
in each biological process category, was more compared to S[1306+1309]A. However, 
Figure 6.1 also shows that the same number of proteins was observed in the biological 
F
ig
u
re
 6
.1
 B
a
r 
c
h
a
rt
 o
f 
th
e
 c
a
te
g
o
ri
e
s
, 
u
n
d
e
r 
th
e
 G
O
 S
lim
 c
la
s
s
if
ic
a
ti
o
n
 o
f 
b
io
lo
g
ic
a
l 
p
ro
c
e
s
s
e
s
, 
w
h
e
n
 S
[1
3
0
6
+
1
3
0
9
]A
 a
n
d
 S
[1
3
0
6
+
1
3
0
9
]D
 w
e
re
 
e
x
p
re
s
s
e
d
. 
T
h
e
 g
re
e
n
 a
n
d
 y
e
llo
w
 b
a
rs
 r
e
p
re
s
e
n
t 
a
 c
a
te
g
o
ry
 t
h
a
t 
S
[1
3
0
6
+
1
3
0
9
]A
 a
n
d
 S
[1
3
0
6
+
1
3
0
9
]D
 p
u
ll
-d
o
w
n
s
 w
e
re
 o
b
s
e
rv
e
d
 i
n
, 
re
s
p
e
c
ti
v
e
ly
. 
T
h
e
 h
e
ig
h
t 
o
f 
e
a
c
h
 b
a
r 
re
p
re
s
e
n
ts
 t
h
e
 n
u
m
b
e
r 
o
f 
g
e
n
e
s
 i
n
 t
h
e
 g
iv
e
n
 g
e
n
e
 l
is
ts
 o
b
s
e
rv
e
d
 i
n
 t
h
a
t 
c
a
te
g
o
ry
. 
O
n
ly
 7
 g
e
n
e
s
 o
u
t 
o
f 
th
e
 7
0
 a
n
d
 8
 g
e
n
e
s
 
o
u
t 
o
f 
8
3
 w
e
re
 m
a
p
p
e
d
 a
s
 u
n
c
la
s
s
if
ie
d
 i
n
 S
[1
3
0
6
+
1
3
0
9
]A
 a
n
d
 S
[1
3
0
6
+
1
3
0
9
]D
 p
u
ll
-d
o
w
n
s
, 
re
s
p
e
c
ti
v
e
ly
. 
T
h
e
 b
la
c
k
 a
rr
o
w
 i
n
d
ic
a
te
s
 t
h
e
 c
a
te
g
o
ry
 
in
 w
h
ic
h
 t
h
e
 s
a
m
e
 n
u
m
b
e
r 
o
f 
p
ro
te
in
s
 p
u
ll-
d
o
w
n
 b
y
 S
[1
3
0
6
+
1
3
0
9
]A
 a
n
d
 S
[1
3
0
6
+
1
3
0
9
]D
, 
re
s
p
e
c
ti
v
e
ly
, 
w
e
re
 o
b
s
e
rv
e
d
. 
T
h
e
 r
e
d
 c
o
lo
u
re
d
 4
-p
o
in
t 
s
ta
rs
 i
n
d
ic
a
te
 t
h
e
 c
a
te
g
o
ri
e
s
 t
h
a
t 
c
o
n
ta
in
 p
ro
te
in
s
 w
h
ic
h
 s
h
o
w
e
d
 s
ig
n
if
ic
a
n
c
e
 b
e
tw
e
e
n
 t
h
e
 p
u
ll
-d
o
w
n
s
 (
F
ig
u
re
 6
.3
).
 
 
R E S U L T S    | 106 
  
051
0
1
5
2
0
2
5
3
0
3
5
4
0
4
5
5
0
Number of genes
M
o
le
cu
la
r 
fu
n
ct
io
n
 c
a
te
g
o
ry
B
a
r 
ch
a
rt
 o
f 
M
o
le
cu
la
r 
fu
n
ct
io
n
 f
o
r 
S
[1
3
0
6
+
1
3
0
9
]A
 a
n
d
 S
[1
3
0
6
+
1
3
0
9
]D
 p
u
ll-
d
o
w
n
s
S[
1
3
0
6
+
1
3
0
9
]A
 p
u
ll-
d
o
w
n
S[
1
3
0
6
+
1
3
0
9
]D
 p
u
ll-
d
o
w
n
process of cell proliferation in S[1306+1309]A  and S[1306+1309]D pull-downs, 
respectively (black arrow).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 shows that there are 5 molecular function categories with the same number of 
proteins observed in S[1306+1309]A  and S[1306+1309]D pull-downs, respectively (black 
arrow). These are: lipid binding, molecular adaptor activity, electron carrier activity, 
carbohydrate binding and molecular transducer activity. There were more proteins 
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observed in nucleotide binding and hydrolase activity in S[1306+1309]A pull-down 
compared to S[1306+1309]D pull-down. Proteins from S[1306+1309]D pull-down were 
observed more in the other 8 molecular function categories than S[1306+1309]A pull-
down.   
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In Figure 6.3, only proteins from S[1306+1309]A pull-down were observed in the 
endosome and extracellular space. Proteins from S[1306+1309]A pull-down were 
observed more in mitochondrion, vesicle and golgi apparatus. Cell projection, 
endoplasmic reticulum (ER) and microbody are the only cellular component categories 
where the same number of proteins from S[1306+1309]A and S[1306+1309]D pull-downs, 
respectively (black arrow), were observed. The remaining 10 cellular components show 
that there were more proteins observed from S[1306+1309]D pull-down than from 
S[1306+1309]A pull-down.   
An important biological validation of the result was identifying proteins abundances that 
show statistical significance between S[1306+1309]A and S[1306+1309]D pull-downs i.e. 
when S[1306+1309]A assumed the negative control condition and S[1306+1309]D 
assumed the experimental condition. The spectral counting approach was also used. 
Each replicate of S[1306+1309]A (aa-p1 to aa-p3) and S[1306+1309]D (dd-p1 to dd-p3) 
were summed up, respectively, and the value of the total sum of the replicates in each 
assumed condition was calculated i.e. Σ(aa-p1 + aa-p2 + aa-p3). The same statistical 
methods and stringency in statistical significance were applied and the same threshold of 
significance (p<0.05) was set to test the null hypothesis that there would be no significant 
difference in protein abundances between the S[1306+1309]A and S[1306+1309]D pull-
downs. The result was a third gene list of six proteins that showed significant difference in 
their abundance (Table 6.3). The result was the same when performed in the reverse i.e. 
where S[1306+1309]D= negative control condition, S[1306+1309]A= experimental 
condition. 
Table 6.3 Proteins with significant abundance when S[1306+1309]A and 
   S[1306+1309]D pull-downs were compared statistically 
 
 
 
 
 
 
 
In increasing order of adjusted p-value (Bonferroni correction), this table shows 6 proteins that 
present significant differential expression when comparing the expressions of  HEK293T cell line 
transfected S[1306+1309]A and S[1306+1309]D mutants of hScrib, respectively. Based on 
spectral count + 1, it was possible to determine the G-test, p-value and, for stringency, an 
adjusted p-value at a threshold of significance of p<0.05. Highlighted in yellow is the hScrib 
protein identified by the mass spectrometer. Each protein has a uniprot accession code to enable 
identification of the gene of each protein in any bioinformatics database.  
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Biological Process
No. of 
proteins
Molecular Function
No. of 
proteins
Cellular Component
No. of 
proteins
Metabolic process 2 Protein binding 5 Macromolecular complex 6
Biological regulation 5 Ion binding 4 Cytosol 3
Cellular component organization 5 Nucleotide binding 2 Nucleus 1
Multicellular organismal process 6 Structural molecule activity 2 Membrane 3
Developmental process 6 Hydrolase activity 3 Cytoskeleton 5
Response to stimulus 5 Cell projection 3
Localization 4
Reproduction 2
Multi-organism process 1
Cell communication 2
Cell proliferation 2
Death 1
This gene list was run through WebGestalt and all six proteins were mapped and GO Slim 
Classification was performed. There are 12 Biological Processes, 5 Molecular Functions 
and 6 Cellular Components identified by WebGestalt. These are indicated with red 4-point 
stars in Figures 6.1, 6.2 and 6.3. Table 6.4 contains the list of categories in each 
classification the proteins from Table 6.3 were observed in. 
 Table 6.4 List of categories that contain proteins with significant abundance    
   between the pull-downs 
 
 
 
 
 
 
 
 
 
 
Table 6.4 shows that all six proteins, in Table 6.3, are observed in two biological 
processes: multicellular organismal process and developmental process. Only 1 of 6 
proteins was observed in multi-organism process and death.   
The 12 biological processes occur through 5 molecular function categories that the six 
proteins were observed in. Most of these proteins are observed in protein binding (5) and 
ion binding (4). Half of these proteins were observed in hydrolase activity. 
For these 5 molecular functions to occur, these proteins were present in 6 cellular 
components. All six proteins form macromolecular complex and half of them are present 
in the cytosol, membrane and cell projection (for motility). Only 1 protein is present in the 
nucleus.  
GO Slim Classification show that one protein can be involved in and also be found in one 
or more than one process and cellular component. 
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As part of the enrichment analysis, over-represented (or under-represented) proteins in 
each gene list were searched for using Gene Ontology (GO) Analysis. The reference set 
selected for enrichment analysis was hsapiens_genome. For enrichment evaluation 
analysis, hypergeometric statistical method was selected and due to testing multiple 
genes sets at the same time, a multiple test adjustment of p-values based on Benjamini 
and Hochberg (1995), BH, was selected. To enable identification of the 10 pathways with 
the most significant p-values, the significance level was left on the ‘Top 10’ default option 
before running the enrichment analysis. The result of running GO analysis is a GO 
analysis tree which displays enriched gene numbers in red (significant), their non-enriched 
parents in black and non-significant genes in brown (Zhang et al., 2005).  
GO analysis identified for S[1306+1309]A and S[1306+1309]D pull-downs, respectively, 
10 enriched categories under biological process, molecular function and cellular 
component, respectively. These categories are represented in Venn diagrams (Figures 
6.4, 6.5 and 6.6).  
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Figure 6.4 shows that there are 10 significantly enriched biological processes for both pull-
downs. Intermediate filament-based process (adjP=1.58e-08) and Intermediate filament 
cytoskeleton organization (adjP=1.58e-08) were the most significantly enriched in 
S[1306+1309]A pull-down while while translational termination (adjP=1.06e-11) and 
mRNA metabolic process (adjP=1.06e-11) were the most significantly enriched in 
S[1306+1309]D pull-down. Although translational termination and mRNA metabolic 
process are the common biological processes in both pull-downs, they are more 
significant in S[1306+1309]D than S[1306+1309]A pull-down. The list for both pull-downs, 
outside the Venn diagram intersection, is in order of significance.  
 
 
 
 
Figure 6.4 Venn diagram of significantly enriched biological processes in S[1306+1309]A and S[1306+1309]D 
pull-downs. There are 10 significantly enriched biological processes in both pull-downs.  
Enriched biological processes 
in S[1306+1309]A pull-down 
Enriched biological processes 
in S[1306+1309]D pull-down 
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Figure 6.5 also shows 10 significantly enriched molecular functions for both pull-downs 
but 9 molecular functions are common to both pull-downs. Structural constituent of 
cytoskeleton (adjP=1.06e-11) was most significantly enriched molecular function in 
S[1306+1309]A pull-down (although 18 times less significant than that from 
S[1306+1309]D pull-down) while structural molecule activity (adjP=7.89e-17) was the 
most significant in S[1306+1309]D pull-down. Small molecule binding and protein 
deacetylase activity are enriched in S[1306+1309]A and S[1306+1309]D, respectively.    
 
 
 
 
Enriched molecular functions 
in S[1306+1309]A pull-down 
Enriched molecular functions 
in S[1306+1309]D pull-down 
Figure 6.5 Venn diagram of significantly enriched molecular functions in S[1306+1309]A and S[1306+1309]D 
pull-downs. There are 10 significantly enriched molecular functions in both pull-downs.  
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Figure 6.6 also shows 10 significantly enriched cellular components for both pull-downs. 7 
cellular components are common to both pull-downs. Although common to both pull-
downs, macromolecular complex (adjP=3.76e-10) and intermediate filament (adjP=3.76e-
10) were the most significantly enriched in S[1306+1309]A pull-down. Macromolecular 
complex (adjP=4.76e-13) and cytosolic ribosomes (adjP=4.76e-13) were the most 
significantly enriched in S[1306+1309]D. The intermediate filament for S[1306+1309]A 
pull-down comprised 12 intermediate filament encoding genes (NEFM, KRT5, KRT14, 
KRT1, KRT2, KRT9, VIM, KRT10, DSP, KRT6A, KRT16 and INA), most of which are 
keratin (KRT) filaments enriched in S[1306+1309]A pull-down only. The intermediate 
filament for S[1306+1309]D pull-down comprised 14 intermediate filament encoding genes 
(the same 12 intermediate filaments as above and keratin filaments  KRT17 and KRT78). 
The cytosolic ribosomes comprised 12 cytosolic ribosomes encoding genes (RPL35, 
RPS16, RPL23, RPL17, RPS29, RPL38, RPS24, RPL37A, RPS18, RPS23, RPS13, and 
RPL23A), all of which are part of the ribosomal subunit enriched in S[1306+1309]D pull-
down only.  
Enriched cellular component 
in S[1306+1309]A pull-down 
Enriched cellular component 
in S[1306+1309]D pull-down 
Figure 6.6 Venn diagram of significantly enriched cellular component in S[1306+1309]A and S[1306+1309]D 
pull-downs. There are 10 significantly enriched cellular components in both pull-downs.  
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Biological Process
No. of 
proteins
Molecular Function
No. of 
proteins
Cellular Component
No. of 
proteins
Taxis 5 ADP binding 2 Synapse 4
Chemotaxis 5 Calmodulin binding 2
Neuromuscular 
junction
3
Cell development 6 Actin filament binding 2 Protein complex 6
Cell part morphogenesis 5 Hydrolase activity, acting on acid anhydrides 3 Cytoskeletal part 5
Cell projection morphogenesis 5
Hydrolase activity, acting on acid anhydrides, 
in phosphorus-containing anhydrides 
3 Actin cytoskeleton 4
Cell morphogenesis involved in 
differentiation
5 Motor activity 3 Actin filament bundle 3
Neuron projection development 5 Microfilament motor activity 2 Actomyosin 3
Cell morphogenesis involded in 
neuron differentiation
5 ATPase activity 3 Myosin complex 4
Neuron projection morphogenesis 5 ATPase activity, coupled 3 Myosin II complex 3
Axonogenesis 5 Actin-dependent ATPase activity 3 Stress fiber 3
Comparing the GO classification of both pull-downs suggest that although S[1306+1309]A 
and S[1306+1309]D pull-downs may share 2 common biological processes (mRNA 
metabolic process and translational termination), 9 molecular functions and  7 cellular 
components, they facilitate different cellular behaviour.  
When the third gene list was run for GO enrichment analysis, 10 enriched categories were 
identified under biological processes, molecular function and cellular component, 
respectively (Table 6.5).  
Table 6.5 List of categories from GO analysis that are significantly enriched    
   between the pull-downs  
 
 
 
 
 
 
 
 
 
There were five most significantly enriched categories under biological process: taxis 
(adjP=2.30e-05), chemotaxis (adjP=2.30e-05), neuron projection morphogenesis 
(adjP=2.30e-05), cell morphogenesis involved in neuron differentiation (adjP=2.30e-05) 
and axonogenesis (adjP=2.30e-05). MYH9, MYL6, MYH10, MYL12B and SCRIB were 
found in the list of enriched taxis and chemotaxis locomotion in response to chemical 
stimulus. 
Under molecular function, the actin-dependent ATPase activity (adjP=1.16e-07) was the 
most significantly enriched with MYH9, MYL6 and MYH10 involved in this activity.  
Under cellular component, myosin complex (adjP=1.26e-07) of the cytoskeletal 
macromolecular complex was the most significantly enriched followed by myosin II 
complex (adjP=1.00e-06) involving MYH9, MYH10 and MYL12B. 
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From the GO analysis enrichment result on the third gene list, it suggests that these 
proteins in the gene list may be involved in formation of cellular projections or processes, 
in response to chemical stimulus, to facilitate cell movement. They accomplish this 
biological process as macromolecular myosin complexes, which require actin-dependent 
ATPase enzyme activity. 
With 3 gene lists created, what biological pathways would be enriched? To identify the 
biological pathways, the candidate proteins in the individual gene list were ran through the 
KEGG (Figure 6.7) and Wikipathways Analysis (Figure 6.8) databases, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 shows that the cell cycle pathway is enriched only in S[1306+1309]D pull-down. 
This supports the results from Chapter 4 and 5 that suggested D-mutants of hScrib may 
be involved in cell proliferation. Results also from Chapter 4 suggest A-mutants of hScrib 
may be involved in cell migration. This requires the actin cytoskeleton regulation 
(Lambrechts et al., 2004) which is also a pathway enriched in S[1306+1309]D pull-down 
as seen in the Venn diagram intersection above. Also common to both pull-downs is the 
ribosome pathway. It was the most significant pathway of both pull-downs. The pathway 
list for both pull-downs, outside the Venn diagram intersection, is in order of significance.      
Figure 6.7 Venn diagram of significantly enriched KEGG pathways in S[1306+1309]A and 
S[1306+1309]D pull-downs. There are 10 significantly enriched pathways in both pull-downs.  
Enriched KEGG pathways 
in S[1306+1309]A pull-down 
Enriched KEGG pathways 
in S[1306+1309]D pull-down 
R E S U L T S    | 116 
  
FAS pathway and stress 
induction of HSP regulation
SIDS susceptibility 
pathways
SREBP signalling
Muscle cell TarBase
Cytoplasmic ribosomal proteins
Regulation of actin cytoskeleton
mRNA processing
Glycolysis and 
Gluconeogenesis
AMPK signalling
Fatty acid biosynthesis
Cell cycle
Corticotropin-releasing hormone
Diurnally regulated genes 
with circadian orthologs
Lymphocyte TarBase
Integrin-mediated
cell adhesion
Epithelium TarBase
 
 
 
 
 
 
 
 
 
 
 
 
 
Wikipathways analysis in Figure 6.8 supports the KEGG pathway analysis in Figure 6.7 by 
suggesting that D-mutants support cell proliferation and A-mutants support cell migration 
but both cellular behaviours may require the regulation of actin cytoskeleton.  
According to the flow chart in Figure 6.9, S[1306+1309]A pulled down GIT1, MYH10 and 
ARHGEF7 while S[1306+1309]D pulled down GIT1, ARHGEF6 and ARHGEF7. These 
proteins are enriched in the enriched pathway of regulation of actin cytoskeleton. 
S[1306+1309]D also pulled down HDAC1, CDK1 and PRKDC proteins enriched in the 
enriched cell cycle pathway. hScrib was not in the list of enriched proteins involved in 
these enriched pathways.  
 
 
 
 
 
Enriched Wikipathways in 
S[1306+1309]A pull-down 
Enriched Wikipathways in 
S[1306+1309]D pull-down 
Figure 6.8 Venn diagram of significantly enriched Wikipathways in S[1306+1309]A and 
S[1306+1309]D pull-downs. There are 10 significantly enriched pathways in both pull-downs.  
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When the third gene list was run in KEGG analysis, 3 significantly enriched pathways 
were identified (Figure 6.10): 1.) Tight junction (adjP=1.67e-6) 2.) Regulation of actin 
cytoskeleton (adjP=3.53e-6) 3.) Viral myocarditis (adjP=3.88e-5). The tight junction 
pathway was the most significantly enriched. All 3 pathways did not list hScrib as one of 
the enriched proteins. 
 
 
 
 
  
 
 
 
 
 
 
Figure 6.9 Flow chart of KEGG and Wikipathway enrichment analysis of S[1306+1309]A and 
S[1306+1309]D pull-downs, their respectively enriched pathways and proteins involved. 
Figure 6.10 Flow chart of KEGG enrichment analysis between S[1306+1309]A and S[1306+1309]D 
pull-downs, the pathways enriched and the proteins involved. 
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However, when run in Wikipathways analysis database, only the TSH (thyroid-stimulating 
hormone) pathway (Figure 6.11) was identified and was found to have 2 enriched proteins 
which include hScrib and MYL12B. 
 
 
 
 
 
 
 
 
The third gene list (Table 6.3) contains proteins with statistically significant differences in 
abundance between the S[1306+1309]A and S[1306+1309]D pull-downs. Figure 6.12 
shows their relative abundances. 
 
 
 
 
Figure 6.12 Logarithmic bar graph proteins that were identified in both the S[1306+1309]A and 
S[1306+1309]D pull-downs but showed significant differences in their abundance between the 
pull-downs. Bar graph y-axis was to a log scale of 10 with log transformed error bars calculated 
as (uncertainty)/ (mean MS/MS Count).  Log graph was used to display variations abundance, 
between pull-downs, of each of the protein identified to be a significant binding partner of both 
S[1306+1309]A and S[1306+1309]D.   
Figure 6.11 Flow chart of Wikipathway enrichment analysis between S[1306+1309]A and 
S[1306+1309]D pull-downs, the pathway enriched and the proteins involved. 
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Figure 6.12 shows that MYH9, MYH10, MYL12B and MYL6 were significantly pulled down 
with S[1306+1309]A than with S[1306+1309]D: 89.5% more MYH9, 91.8% more MYH10, 
96.2% more MYL12B and 69.1% more MYL6 were pulled down with S[1306+1309]. 
S[1306+1309]D pulled down 40.7% more NEFM than S[1306+1309]A. 10.7% more 
S[1306+1309]D was pulled down than S[1306+1309]A, but this may be due to loss of 
some S[1306+1309]A in the washing steps of the Co-IP assay.   
Statistical analysis of the results from S[1306+1309]A and S[1306+1309]D pull-downs 
were performed separately to determine the biological pathways (Figure 6.7 and 6.8) 
affected by S[1306+1309]A and S[1306+1309]D and the proteins involved as a result. 
However, there were a few pathways similar to both S[1306+1309]A and S[1306+1309]D. 
This was why both pull downs were statistically compared (Table 6.3) to identify the 
biological pathway/s specific to S[1306+1309]A and S[1306+1309]D, respectively. It was 
by determining the proteins that were more abundant in S[1306+1309]A than in 
S[1306+1309]D and vice versa (Figure 6.12).  
 
6.4 Discussion 
It is true that the complex and diverse biological processes that occur in the cells of a 
human body are as a result of the dynamic nature of a group of subcellular biomolecules 
called proteins. The diverse bio-processes are credited to unique attributes of proteins 
which include the ability of a protein to interact with another and also the ability to form 
macromolecular complexes. These attributes facilitate the establishment of a network of 
transduction or cascade of a biological signal (Berg et al., 2002:3; Spirin and Mirny, 2003) 
to establish cell properties such as cell polarity which contributes to the regulation of cell 
proliferation, cell migration, apoptosis, tissue organization and tumour suppression 
(Humbert et al., 2003; Qin et al., 2005; Huang and Muthuswamy, 2010; Chatterjee and 
McCaffrey, 2014) to name a few. Abnormalities in protein interactions cause unregulated 
cell properties which could lead to diseases such as cancer (Dow et al., 2003; Qin et al., 
2005). Therefore identifying protein binding partners under given conditions, would give 
insights into the cellular function of the protein-protein interactions, an understanding of 
the disease that could arise because of or without the protein-protein interaction and 
enable discovery of novel drug targets to aid treatment in disease cases such as cancer.  
In cancer, loss of epithelial cell polarity is a common characteristic (Chatterjee et al., 2012; 
Royer and Lu, 2011; Bilder et al., 2000). Cell polarity complex proteins such as the 
Scribble complex (hScrib, hDlg and Lgl) are affected. One component of the Scribble 
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complex, hScrib, was the focus of study because it was implicated in an aggressive form 
of breast cancer called TNBC (Greenwood et al., 2012; Metodieva et al., 2013). This 
polarity protein is also a tumour suppressor (Su et al., 2012). By using mass spectrometry 
and bioinformatics toolkits, the aim was finding the binding partners of hScrib, at different 
phosphorylations states, to identify which pathway/s its uses to establish cell polarity, 
tumour suppression and breast cancer invasion and metastasis. Using the toolkits (GO, 
KEGG and Wikipathways) in WebGestalt on hScrib double mutants S[1306+1309]A and 
S[1306+1309]D pull-downs, it was found that regulation of actin cytoskeleton occurred 
more with expressed S[1306+1309]A while cell cycle pathway occurred with expressed 
S[1306+1309]D. It was also found that there were 6 proteins (MYH9, MYH10, SCRIB, 
MYL12B, MYL6 AND NEFM) significantly enriched between S[1306+1309]A and 
S[1306+1309]D pull-downs and 4 of the proteins (MYH9, MYH10, MYL12B and MYL6) 
were more abundant in the S[1306+1309]A pull-down. These proteins are involved in the 
tight junction and regulation of actin cytoskeleton pathways. 
The tight junction pathway allows intercellular adhesion while providing partitioning 
between the membranes of adjacent epithelial cells. This partitioning or barrier regulates 
the paracellular traffic of substances across the epithelium and keeps membrane proteins 
(claudins and occludins) and other proteins (e.g. ZO-1, -2 and -3) at the apical domain of 
a cell from membrane proteins (E-cadherin) and other proteins (p120-catenin, β-catenin 
and α-catenin) at the basolateral domain of the cell (Hartsock and Nelson, 2008; 
Anderson and Van Itallie, 2009; McCaffrey and Macara, 2012). MYH10, MYH9 and 
MYL12B were found in the tight junction pathway (Figure 6.13). Tight junction is 
established through Rho (ras homolog family member A)/ ROCK (Rho-associated coiled-
coil containing protein kinase) inhibition of Rac. Rho/ROCK phosphorylatory suppression 
of the phosphatase activity of MLCP (protein phosphatase regulatory subunit) on MLC 
(which includes MYL12B) increases the levels of phosphorylated MLC to activate myosin 
II (MYH9 and MYH10). Myosin II actively binds to stress fibres of stably polymerized actin 
(also mediated by Rho/ROCK) to form actomyosin contraction (Amano et al., 2010). This 
re-organization of the actin cytoskeleton allows interaction of actin cytoskeleton with 
proteins that support tight junction formation and hence contribute to cell adhesion.  
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Figure 6.13 Establishment of the tight junction pathway through regulation of the actin 
cytoskeleton. Black arrows show the direction of signalling cascades. The big black bent arrow 
connector indicates the reactions that link regulation of actin cytoskeleton by Rho/ROCK to tight 
junction formation in epithelial cells. Rho/ROCK facilitate rearrangement of actin cytoskeleton 
assembly to enable interaction with tight junction transmembranes (claudins, occludins and 
junctional adhesion molecules (JAMs)) via zonal occludens complex (Zo-1, -2 and -3) to form 
and maintain the tight junctions between cells. Image adapted from 
http://www.kegg.jp/pathway/hsa04530+4627+4628+103910  
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Correlating with these enriched pathway proteins were 12 intermediate filament encoding 
genes (from GO cellular component analysis in Figure 6.6) found to be enriched. These 
proteins are part of the components of the cytoskeleton. This suggests that the enriched 
pathway proteins initiate the downstream formation and disassembly of macromolecular 
complex of the intermediate filaments. This may also suggest how the interaction of 
vimentin (VIM) (one of the 12 enriched intermediate filament genes) with hScrib 
translocates hScrib to the plasma membrane to regulate vesicle and organelle localization, 
maintain intercellular interaction and also control cell migration (Phua et al., 2009). The 
identification of these enriched proteins suggest that the effect of S[1306+1309]A is 
upstream of its identified protein partners involved in the regulation of actin cytoskeleton 
pathway to facilitate the establishment and maintenance of cell polarity or cause cell 
invasion in breast cancer . 
Actin cytoskeleton is required for maintaining cell shape. This is important as, in the 
processes of cell-cell contact, intracellular transport, cell migration and proliferation (via 
cell cycling), the cytoskeleton is required to disassemble and re-organize at certain stages 
(Lodish et al., 2000:18.1; Heng and Koh, 2010). Both S[1306+1309]A and S[1306+1309]D 
pulled down proteins (GIT1, ARHGEF7 and MYH10 for S[1306+1309]A; GIT1, ARHGEF7 
and ARHGEF6 for S[1306+1309]D) that were enriched in regulation of the actin 
cytoskeleton pathway. Through this pathway, GIT1, ARHGEF7 and MYH10 mediate focal 
adhesion of migrating cells via RTK (receptor tyrosine kinase) and GPCR (G-protein 
coupled receptor) in response to chemotactic stimuli (Figure 6.14). It was found, through 
the Biological General Repository for Interaction Datasets (BioGRID), that GIT1 and 
ARHGEF7 interact. GIT1 and ARHGEF7 (red arrows) interaction mediate focal adhesion 
by inducing focal adhesion assembly (actin polymerization) at the leading edge of the cell 
through PAK (protein (Cdc42/Rac)-activating kinases) (blue arrow) phosphorylation of 
ARHGEF7 and ARHGEF7 inhibition of RhoGEF of the Rho/ROCK tight junction initiation 
pathway. This enables migrating cells to make cell-ECM (extracellular matrix) contact with 
their lamellipodia (or filopodia) at the leading edge, therefore contributing to the 
maintenance of anterior-posterior polarity (Phua et al., 2009).  
A study on GIT1 found GIT1-ERK1/2(phosphorylated) interaction in focal adhesion 
caused cell migration while GIT1-PXN (paxillin) interaction caused focal adhesion 
disassembly (Zhang et al., 2009). ARHGEF7 mediates actin organization and focal 
adhesions (Wozniak et al., 2004; Yu et al., 2015). A study by Sun and Bamji (2011) also 
found ARHGEF7 to form cadherin-β-catenin-hScrib-ARHGEF7 complexes to mediate 
actin polymerization to regulate localization of vesicles and constitutes apico-basal polarity 
(Iden and Collard, 2008). Chahdi and Raufman (2013) found ARHGEF7 to directly interact 
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with β-catenin and initiate cell proliferation in colon cancer but through hScrib (possibly 
unphosphorylated)-hDlg-APC complex interactions, as discussed in Chapter 5, β-catenin 
is degraded leading to G1 arrest of the cell cycle (Ishidate et al., 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14 Regulation of actin cytoskeleton pathway. Black arrows show the direction of a signalling 
cascade. The blue arrow identifies PAK (protein-activated kinase) to be activated by both Cdc42 (cell division 
cycle 42) and Rac. PAK, subsequently phosphorylates PIX (ARHGEF7) (1
st
 red arrow) which then activates 
GIT1 (G protein-coupled receptor kinase interactor 1) (2
nd
 red arrow) to inhibit PXN and facilitate interactions 
that lead to focal adhesion assembly at the front of the lamellipodia. As new cell-ECM contact is established 
at the anterior of the migrating cell, old cell-ECM contact is terminated by contraction of the posterior of the 
cell from the ECM which requires the formation of ATP-dependent assembly of polymerized actin 
microfilament and myosin complex II (green arrow), regulated by phosphorylation of MLC (orange arrow 
which includes MYL12B) through PAK inhibitory phosphorylation of MLCK. This mechanism aids controlled 
directional migration of cells. When proliferation, rather than migration, is required, ARHGEF6 acts as 
Rac1GEF (purple arrow) to activate Rac1 (member of Rac subfamily) which transduces the signal for cell 
proliferation via the MAPK signalling pathway. While regulation of actin cytoskeleton is used for migration and 
proliferation, it could also lead to invasion of breast cancer cells if, in the case of hScrib, the wrong 
phosphorylation state is established. Image adapted from 
http://www.kegg.jp/pathway/hsa04810+4627+4628+103910  
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MYH10 was one of the proteins identified to be more abundant in the S[1306+1309]A pull-
down than in the S[1306+1309]D pull-down. MYH10, MYH9 and MYL12B were found to 
be involved in regulation of the actin cytoskeleton pathway. MYH10 and MYH9 interact 
(BioGRID). MYH10 mediates focal adhesion by forming myosin II complex (green arrow) 
with MYH9 and effecting actomyosin assembly contraction to retract the trailing edge of 
migrating cells from the ECM. The actin-dependent ATPase activity of the myosin II 
complex catalyzes this energy-dependent process which is activated by phosphorylation 
of MYL12B (orange arrow) (Kondo et al., 2012). MYL12B (member of myosin regulatory 
light chain, MLC) of myosin II complex is activated when PAK inhibits MLCK (myosin light 
chain kinase) by phosphorylation. The inactivation of MLCK releases MYL12B to be 
phosphorylated. Activated MYL12B translocates to the regulatory site on myosin II 
complex. This phosphorylates and activates the ATPase activity of myosin II leading to 
association of myosin II complex with polymerized actin microfilaments. MYH10 was 
found to mediate centrosome re-orientation and centriole migration during ciliogenesis 
(Avasthi and Marshall, 2012; Hong et al., 2015). MYH9 is a motor protein whose 
association with F-actin, a polymerized form of G-actin, produces intracellular contractile 
forces to power retraction (pull back) in cell migration and cytokinesis (Betapudi, 2010; 
Elliot et al., 2015).  
Regulation of actin cytoskeleton, in the case of S[1306+1309]D, does not require the 
myosin II complex component MYH10, but ARHGEF6 as well as GIT1 and ARHGEF7 
(Figure 6.14). While GIT1 and ARHGEF7 mediate focal adhesion, for cell ECM interaction, 
ARHGEF6 acts as a guanine nucleotide exchange factor for Rac1 (a member of Rac 
subfamily). It exchanges bound GDP for GTP to activate Rac1 GTPase activity. Hence, 
Rac1GEF (purple arrow). Activating Rac1 signals the induction of the MAPK signalling 
pathway for cell proliferation which occurs via the cell cycle pathway. Proteins found to be 
enriched in the cell cycle pathway were HDAC1, CDK1 and PRKDC. Studies show that 
HDAC1 is known to repress gene transcription by mediating condensation of the 
chromatin to enable G2 to M phase transition in the cell cycle. This occurs when the 
expression level of HDAC1 gradually increases from late G1 phase as pRb1, at cell cycle 
restriction point, becomes hyper-phosphorylated (deactivated) and HAT, which mediates 
gene transcription by chromatin remodelling, almost reaches peak expression levels. 
Without the HDAC1, cells arrest in G1 or G2 phase (Ropero and Esteller, 2007; Senese et 
al., 2007; Haberland et al., 2009). CDK1 (or Cdc 2), an M-phase promoting factor (MPF) 
that phosphorylates RB1, cyclins A and B for G1/S and G2/M transition (Xi, et al., 2015) 
was enriched. HDAC1 and CDK1 proteins are complemented by PRKDC, a kinase that 
binds to DNA and serves as a molecular sensor for DNA double-stranded breaks and 
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repair. Without the repair of DNA double-stranded breaks, PRKDC interactions with 
ARHGEF6 and p53 (tumour suppressor protein) induce apoptosis in the cell (Maiti, 2010). 
PRKDC also localizes to centrosomes and kinetochores during metaphase and at 
midbody during cytokinesis to prevent abnormal nuclear morphology after mitosis 
(Anderson and Lees-Miller, 1992; Jette and Lees-Miller, 2015). The cell cycle pathway 
was the second most significantly enriched when S[1306+1309]D was expressed.  
The most significantly enriched pathway was the ribosome pathway which comprised 12 
enriched genes that encode cytosolic ribosomes (Figure 6.6). These cytosolic ribosomes 
may form macromolecular complexes to facilitate translational termination of, possibly, 
certain structural constituents of the cytoskeleton, that enable the structural molecule 
activity associated with S[1306+1309]A pull-down. In addition to translational termination 
in the ribosome pathway was the cellular metabolic process of mRNA metabolic process 
(also part of the ribosome pathway), performed by 23 enriched cytosolic-ribosome-
encoding genes. The mRNA metabolic process involves mRNA splicing, translational 
initiation, polypeptide formation and polypeptide folding. The genes involved in this 
process seem to be linked to cell cycle regulation (Kondoh et al., 1996; Gerecitano, 2014; 
Bansal et al., 2014).  
Figure 6.12 showed SCRIB to be more abundant (10.7%) with S[1306+1309]D pull-down 
than S[1306+1309]A pull-down but Figure 6.11 identified involvement of SCRIB and 
MYL12B in the TSH (thyroid-stimulating hormone) signalling pathway (Figure 6.15). The 
TSH pathway is a major pathway, used by almost every cell in the body, required for 
cellular metabolic processes such as the cell proliferation (Goel et al., 2011; Brent, 2012). 
In the regulation of actin cytoskeleton and tight junction pathway, the light chain motor 
protein regulator, MYL12B, was phosphorylated. In the TSH pathway MYL12B is 
dephosphorylated. Since the 10.7% increase in abundance of S[1306+1309]D is 
significant, it would suggest that the expression of S[1306+1309]D may indirectly lead to 
the inactivation (dephosphorylation) of MYL12B by phosphorylated inhibition of ROCK via 
ERK signalling pathway, to increase the dephosphorylation activity by MLCP on MLC 
(which includes MYL12B). This action would inhibit cell migration and induce expression 
of transcription factors that promote cell proliferation via the cell cycle.  
The findings of the protein-protein interaction study of hScrib are summarized in Table 6.6. 
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Figure 6.15 The involvement of SCRIB and MYL12B in the TSH signalling pathway. The TSH 
pathway is used by virtually every cell for metabolic processes including the cell proliferation 
process. What the different coloured arrows illustrate is depicted in the legend shown in this 
image. From the pathway, SCRIB is involved in a protein-protein interaction with intracellular 
domain of the TSH receptor. This SCRIB is S[1306+1309]D and through the ERK signalling, 
indirectly initiates the dephosphorylation of MYL12B (a member of MLC). This inhibits cell 
migration to enable cell proliferation to occur. Image adapted from 
http://www.kegg.jp/pathway/hsa04810+4627+4628+103910        
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7. Concluding remarks, limitations, relevance and future studies 
S[1306+1309]A and S[1306+1309]D are some of the mutants of hScrib designed to mimic 
unphosphorylated (A) and phosphorylated (D) hScrib protein, respectively, in the cell. 
They were designed by site-directed mutagenesis to study how changes in the 
phosphorylation pattern of serine sites at the C-terminal of hScrib implicate hScrib in the 
invasion of breast cancer.  
The confocal images (Figures 3.4a and 3.4b) of HEK cells transfected with the generated 
hScrib mutants showed hScrib had varied localization. Besides being present at cell to cell 
contact, hScrib, when unphosphorylated, localized to a tail-like cell structure suggested to 
be microtubules and when phosphorylated, localized to two structures proximal to the 
nucleus that were believed to be centrioles of a centrosome. This prompted the use of 
biochemical assays to test whether hScrib affected cell proliferation and cell migration, 
common features that are uncontrollable in breast cancer cells.  
Wound healing and MTT assays were conducted in Chapter 4 to test cell migration and 
cell proliferation, respectively.  The results suggested significant cell migration with 
unphosphorylated hScrib and significant cell proliferation with phosphorylated hScrib. To 
get more credible proof of this comparison, cell cycle assays were conducted (Chapter 5). 
This would give more detail, through cell cycle analysis, of which mimicked 
phosphorylation state of hScrib would support progressive transition of cells in the cell 
cycle and to what stage i.e. G1, S or G2/M. The results showed that cells transfected with 
D-mutants of hScrib arrested more in the G2/M phase than cells transfected with A-
mutants of hScrib, which arrested more in the G1 phase of the cell cycle. Although there 
were no significant differences between the number A-mutant and D-mutant transfected 
cells arrested in the S phase, this was further proof of phosphorylated hScrib progressive 
transition of cells in the cell cycle.  
To consolidate this proof, proteins that interact with hScrib in the different phosphorylation 
states had to be identified and their function in relation to hScrib profiled. hScrib was used 
as bait, in a CoIP assay, to pull down potential candidates of hScrib. The captured 
proteins were analysed for abundance and identified using a mass spectrometer. To avoid 
false positive results, stringent statistical analysis was performed on these candidates and 
the significance of their abundances with and without bait hScrib was determined. Three 
gene lists of significantly abundant protein partners were created and ran in a 
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bioinformatics toolkit called WebGestalt to search for the enrichment of these proteins and 
the pathway/s that they would significantly be involved in. Using the mass spectrometry 
dataset from S[1306+1309]A and S[1306+1309]D pull-downs, S[1306+1309]A expression 
was found to be involved in cell migration and tight junction formation by potentially 
interacting with proteins such as GIT1, ARHGEF7, MYL12B to effect the regulation of 
actin cytoskeleton through downstream effectors of MYH9, MYH10 and intermediate 
filaments. The actions of regulating actin cytoskeleton through the Cdc42/Rac (cell 
migration of anterior-posterior polarity) (Figures 6.14) and Rho/ROCK (tight junction of 
planar and apico-basal polarity) (Figures 6.13) contribute to maintaining epithelial cell 
polarity and morphology while suppressing cell proliferation. However, it is known that 
cancer cells can use either the Rho/ROCK-dependent or the Rac-dependent migration to 
invade (Amano et al., 2010). Therefore, it is possible that uncontrolled expression of 
S[1306+1309]A of hScrib could encourage this. A possible molecular mechanism is 
illustrated below (Figure 7.1).  
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Figure 7.1 The possible molecular mechanism of breast cancer cell migration/invasion involving 
unphosphorylated hScrib S[1306+1309]A. S[1306+1309]A interacts with and tethers GIT1, ARHGEF7 
and MYH10. GIT1 and ARHGEF7 interact and through Cdc42/Rac phosphorylation of ARHGEF7 facilitate 
focal adhesion assembly at the leading edge. MYH10 interacts with MYH9 to form myosin II complex. 
Through Cdc42/Rac inhibition of MLCK, MYL12B is phosphorylated and translocates to the regulatory 
subunit of myosin II complex to activate the actin-dependent ATPase activity (assembling myosin II 
filaments) of myosin II complex, facilitating actomyosin contraction to retract the trailing edge. This 
mechanism leads to cell motility and hence cell invasion.   
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Conversely, S[1306+1309]D expression was found to be involved, via the thyroid-
stimulating hormone signalling pathway, in cell proliferation by potentially interacting with 
proteins such as HDAC1, CDK1, PRKDC and indirectly inactivating MYL12B, the light 
chain regulator for ATP-driven actomyosin assembly contraction of cell movement. This 
suggests that cell proliferation also requires the regulation of actin cytoskeleton but for the 
purpose of cell cycling and not motility. This is because S[1306+1309]D expression 
enriched GIT1, ARHGEF6 and ARHGEF7, which contribute to regulating the cytoskeletal 
elements in the cell. By directly inactivating MYL12B via the ERK signalling, HDAC1, 
CDK1, PRKDC can function in the S and G2/M phases of the cell cycle pathway, hence 
suggesting that phosphorylated hScrib facilitates G2 to M phase transition (Figure 5.2) of 
cells while suppressing cell migration through regulation of actin cytoskeleton. In the event 
of DNA double-stranded breaks (sensed by PRKDC), S[1306+1309]D may enable 
ARHGEF6-PRKDC interaction to enable ARHGEF6-PRKDC-p53 interaction to facilitate 
cell apoptosis (if DNA break is irreparable). 
However, uncontrolled expression of S[1306+1309]D or S[1306+1309]D not facilitating 
ARHGEF6-PRKDC interaction may be exploited by breast cancer cells to favour tumour 
formation. A possible molecular mechanism is illustrated below (Figure 7.2).  
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Figure 7.2 The possible molecular mechanism of breast cancer cell proliferation involving phosphorylated 
hScrib S[1306+1309]D. The binding of thyroid-stimulating hormone (TSH) to its receptor initiates a signal 
transduction beginning with the thyroid-stimulating hormone receptor (TSHR) interaction with 
S[1306+1309]D which tethers it and proteins HDAC1, PRKDC and Cdk1. These proteins contribute to 
facilitating various phases of the cell cycle pathway for cell proliferation. Also, S[1306+1309]D interacts and 
tethers GIT1, ARHGEF7 and ARHGEF6. ARHGEF6, via ERK signalling, dephosphorylates MYL12B. 
MYL12B, unable to translocate, enables GIT1-ARHGEF7-ARHGEF6 interaction to reorganize the 
cytoskeleton during cell cycling to facilitate cell proliferation.  
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The molecular mechanisms (Figure 7.1 and 7.2) show that the action of the binding 
partners of both unphosphorylated and phosphorylated hScrib appear to be antagonistic 
than complementary in that cell migration and proliferation may not occur simultaneously.  
Summary of the overall research is tabled below in Table 7.1. 
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Limitations  
Although, conclusions have been drawn, the overall study was not without limitations: 
Serine is a polar and uncharged residue with hydroxyl functional group (-OH) that can be 
phosphorylated when deprotonated (hydrogen donor). The choice of mutation model, 
substituting serine for alanine (A) and aspartate (D), to mimic unphosphorylation and 
phosphorylation hScrib, respectively, is limited. This is because alanine is hydrophobic 
and non-polar and due to its hydrophobicity would affect the conformity of hScrib as 
unphosphorylated hScrib. Aspartate may be polar, but it is a charged acidic residue that 
can not only be deprotonated, but also forms strong ionic bonds which may also affect the 
conformity of hScrib as phosphorylated hScrib. These slight changes in conformity that 
occur due to these deliberate substitutions to mimic hScrib phosphorylation states, may 
affect how hScrib interacts with its binding partners in vitro and hence, the pull-down. 
The use of HEK293T cell line was because it was easily transfectable. However, results 
obtained and conclusions drawn from the assays performed with this cell line may not be 
directly representative of what may occur in breast cancer cells in the study of invasion 
and proliferation.   
Western blot is a good detection system of protein of choice but errors that affect its result 
could be incurred due to the many steps and buffers it involves. These include trapped air 
bubbles during electro-transblotting or antibody probing. Protein of interest could be lost 
by poor sample preparation and if transfer time is too much or insufficient. There is the 
probability of secondary antibody reaction to label a non-specific protein. Western blot is 
not quantitative i.e. amount of protein detected cannot be determined.  
The reproducibility of the wound healing assay is limited due to the variability in the size 
and shape of the gap made in each experiment. This makes comparison between 
experiments difficult. The creation of a mechanical scratch with a scratch tool may cause 
injury to the cells: cell contents and debris from the scratch tool are released into the gap. 
This is hard to control. Although the wound healing assay was conducted to study cell 
migration, during the course of the assay cells that migrate into the gap also proliferate. 
This is may interfere with the measurement of migrating cells and interfere with the 
process. 
MTT assay is not reproducible. It measures metabolic activity and not cell viability. 
Contact inhibition may occur and cells no longer become in their most active phase of 
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growth i.e. log phase. As it is an absorbance-based assay, MTT assay is not very 
sensitive at picking out minor changes in formazan colour intensity.  
The flow cytometry analyses, with PI staining method, used a single time point to measure 
cellular DNA content and show the percentage of cells in G1, S and G2/M phases of the 
cell cycle. However, it does not provide information about the rate at which the transfected 
cells progress through the cell cycle i.e. cell cycle kinetics. This is an indication of how fast 
the cells are proliferating, as an increased rate is common in breast cancer and other 
cancers. 
Co-IP was used to capture potential binding partners of hScrib, when unphosphorylated 
and phosphorylated. However, it may be difficult to capture and detect in vitro, low-affinity 
binding partners as well as potential binding partners that have very low level of 
expression. There could also be non-specific interaction, due to the mutation model 
adopted, that may lead to false positive results.  
Relevance of study 
The findings of this research bear relevance in the Cell biology area of tissue homeostasis 
because it shows hScrib may contribute to determining cell proliferation as well as 
apoptosis through the possible molecular mechanism shown in Figure 7.2.  Through the 
illustrated possible mechanisms of action of hScrib (with its binding partners) in regulating 
cell migration and proliferation, respectively, an insight into the possibility of designing 
therapeutic drugs that may target certain hScrib phosphorylation and binding sites (and 
also binding partners) of hScrib that may influence tumour formation and invasion of 
breast cancer may be established. 
Cell polarity is the asymmetric distribution of intracellular organelles, cytoskeleton and cell 
surface of epithelial cells. The research findings suggest that the scaffolding structure of 
hScrib (unphosphorylated) enables the positioning (through regulation of actin 
cytoskeleton) of certain binding partners to interact, hence, mediating anterior-posterior 
polarity to regulate cell motility and apical-basal polarity to maintain tight junction. This 
also suggests that the study by Metodieva et al., 2013:  where CD74 interacts with hScrib 
and hScrib translocates from cell-to-cell contacts at the plasma membrane to the 
cytoplasm causing enhanced motility and invasiveness of breast cancer cells, may be a 
consequence contributed by inappropriate unphosphorylation of one or more of the 
selected C-terminal serine site in hScrib.  
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By hScrib (phosphorylated) scaffolding structure mediating binding partners ARHGEF6 
and PRKDC interaction, to enable their interaction with p53 to facilitate apoptosis (due to 
irreparable DNA double-stranded breaks) at S and G2/M phases of the cell cycle, it 
exemplifies hScribs function as a TSG. However, this TSG function of hScrib may be 
related to tumour formation and progression when hScrib (phosphorylated) does not 
enable ARHGEF7-PRKDC interaction to occur to facilitate apoptosis with p53. This 
contributes to favouring G2 to M phase transition of the affected cells with no means of 
halting or exiting the cell cycle, therefore establishing an abnormal mass of breast 
epithelial cells. This is a finding that contributes to increased knowledge of tumourigenesis 
and progression.   
Future studies 
There is progress towards getting a clear picture as to how hScrib is involved in the 
invasion of breast cancer and developing a mechanism/s for its tumour suppressive and 
cell polarity functions. Bioimaging studies would be conducted with constructed 
S[1306+1309]A tagged differently to S[1306+1309]D and co-transfected to distinguish 
their cellular localization and correlate the result to the pathways they are involved in. 
Colocalization studies of the protein partners of S[1306+1309]A and S[1306+1309]D 
would be performed to identify any direct interactions and where in the cell these 
interactions between hScrib and a protein partner occurs. To build a bigger picture 
requires further work to be done by using breast cancer cell lines (e.g. MCF7, MDA-231) 
with the hScrib mutants (Metodieva et al., 2013) and the other C-terminal amino acid sites 
in the hScrib protein newly validated (Table 3.1). This could reveal one or more of the 
generated phosphorylation patterns of hScrib are responsible for hScribs involvement in 
breast cancer invasion, tumourigenesis and progression. Also more mass spectrometry 
combined with bioinformatics (WebGestalt and BioGRID) would be conducted with the 
end result of identifying candidate biomarkers and new drug targets for the treatment of 
breast cancer.        
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Appendix A 
Alignment results of DNA sequenced hScrib mutants (in Chapter 3) as displayed by blastx 
of the basic local alignment search tool (BLAST). Red arrows indicate the position of 
change made on ‘query’ sequence. The primers (forward or reverse) were used in the 
sequencing of the mutants.   
 
 
 
ALIGNMENTS OF POSITIVELY VALIDATED hSCRIB MUTANT PROTEINS 
 
 
Single Mutations (A-mutants) 
S1306A + 1448A Reverse primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH14632.2|Length: 832Number of Matches: 1 
Related Information 
Gene-associated gene details 
Map Viewer-aligned genomic context 
Range 1: 370 to 605GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
387bits(995) 4e-125 Compositional matrix adjust. 234/236(99%) 235/236(99%) 0/236(0%) -3 
Query  797  LTHGEAVQLLRSVGDTLTVLVCDGFEASTDAALEVSPGVIANPFAAGIGHRNSLESISSI 618 
            LTHGEAVQLLRSVGDTLTVLVCDGFEASTDAALEVSPGVIANPFAAGIGHRNSLESISSI 
Sbjct  370  LTHGEAVQLLRSVGDTLTVLVCDGFEASTDAALEVSPGVIANPFAAGIGHRNSLESISSI 429 
 
Query  617  DRELSPEGPGKEKELPGQTLHWGPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGA 438 
            DRELSPEGPGKEKELPGQTLHWGPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGA 
Sbjct  430  DRELSPEGPGKEKELPGQTLHWGPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGA 489 
 
Query  437  AGGKMAEspcspsgqqppappsPDELPANVKQAYRAFAAVPTSHppedapaqpptpgpaa 258 
            AGGKMAESPCSPSGQQPP+PPSPDELPANVKQAYRAFAAVPTSHPPEDAPAQPPTPGPAA 
Sbjct  490  AGGKMAESPCSPSGQQPPSPPSPDELPANVKQAYRAFAAVPTSHPPEDAPAQPPTPGPAA 549 
 
Query  257  sPEQLSFREXQKYFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQM  90 
            SPEQLSFRE QKYFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQM 
Sbjct  550  SPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQM  605 
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S1309A + 1448A Reverse primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH14632.2|Length: 832Number of Matches: 1 
Related Information 
Gene-associated gene details 
Map Viewer-aligned genomic context 
Range 1: 361 to 605GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
405 bits(1042) 4e-132 Compositional matrix adjust. 242/245(99%) 243/245(99%) 0/245(0%) -1 
Query  811  EVNQQSLLGLTHGEAVQLLRSVGDTLTVLVCDGFEASTDAALEVSPGVIANPFAAGIGHR 632 
            EVNQQSLLGLTHGEAVQLLRSVGDTLTVLVCDGFEASTDAALEVSPGVIANPFAAGIGHR 
Sbjct  361  EVNQQSLLGLTHGEAVQLLRSVGDTLTVLVCDGFEASTDAALEVSPGVIANPFAAGIGHR 420 
 
Query  631  NSLESISSIDRELSPEGPGKEKELPGQTLHWGPEATEAAGRGLQPLKLDYRALAAVPSAG 452 
            NSLESISSIDRELSPEGPGKEKELPGQTLHWGPEATEAAGRGLQPLKLDYRALAAVPSAG 
Sbjct  421  NSLESISSIDRELSPEGPGKEKELPGQTLHWGPEATEAAGRGLQPLKLDYRALAAVPSAG 480 
 
Query  451  SVQRVPSGAAGGKMAEsxcspsgqqppsppaPDELPANVKQAYRAFAAVPTSHppedapa 272 
            SVQRVPSGAAGGKMAES CSPSGQQPPSPP+PDELPANVKQAYRAFAAVPTSHPPEDAPA 
Sbjct  481  SVQRVPSGAAGGKMAESPCSPSGQQPPSPPSPDELPANVKQAYRAFAAVPTSHPPEDAPA 540 
 
Query  271  qpptpgpaasPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGAXDLRKMQEEEARKLQQ  92 
            QPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGA DLRKMQEEEARKLQQ 
Sbjct  541  QPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQ 600 
 
Query  91   KRAQM  77 
            KRAQM 
Sbjct  601  KRAQM  605 
 
 
 
S1348A + 1448A Reverse primer 
SCRIB protein, partial [Homo sapiens] 
Sequence ID: gb|AAH09490.2|Length: 450Number of Matches: 1 
Related Information 
Gene-associated gene details 
Map Viewer-aligned genomic context 
Range 1: 106 to 198GenPeptGraphicsNext MatchPrevious Match 
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
146 bits(368) 8e-39 Compositional matrix adjust. 
92/93(99%) 
93/93(100%) 0/93(0%) -2 
 
Query  403  DELPANVKQAYRAFAAVPTSHppedapaqpptpgpaaaPEQLSFRERQKYFELEVRVPQA  224 
            DELPANVKQAYRAFAAVPTSHPPEDAPAQPPTPGPAA+PEQLSFRERQKYFELEVRVPQA 
Sbjct  106  DELPANVKQAYRAFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQA  165 
 
Query  223  EGPPKRVSLVGADDLRKMQEEEARKLQQKRAQM  125 
            EGPPKRVSLVGADDLRKMQEEEARKLQQKRAQM 
Sbjct  166  EGPPKRVSLVGADDLRKMQEEEARKLQQKRAQM  198 
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S1448A + 1306A Forward primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH14632.2|Length: 832Number of Matches: 1 
Related Information 
Gene-associated gene details 
Map Viewer-aligned genomic context 
Range 1: 524 to 814GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
348 bits(892) 3e-108 Compositional matrix adjust. 290/291(99%) 291/291(100%) 0/291(0%) +1 
Query  25   RAFAAVPTSHppedapaqpptpgpaaspEQLSFRERQKYFELEVRVPQAEGPPKRVSLVG 204 
            RAFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVG 
Sbjct  524  RAFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVG 583 
 
Query  205  ADDLRKMQEEEARKLQQKRAQMlreaaeagaearlaldgetlgeeeqedeqppWASPSPT 384 
            ADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSPT 
Sbjct  584  ADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSPT 643 
 
Query  385  SRQSpaappplgggapVRTAKAERRHQERLRVQSPEPPAPERALSPaelraleaekralw 564 
            SRQSPA+PPPLGGGAPVRTAKAERRHQERLRVQSPEPPAPERALSPAELRALEAEKRALW 
Sbjct  644  SRQSPASPPPLGGGAPVRTAKAERRHQERLRVQSPEPPAPERALSPAELRALEAEKRALW 703 
 
Query  565  raarMKSLEQDALRAQMVLSRSQEGRGTRGPLERLAEapspaptpsptpVEDLGPQTSTS 744 
            RAARMKSLEQDALRAQMVLSRSQEGRGTRGPLERLAEAPSPAPTPSPTPVEDLGPQTSTS 
Sbjct  704  RAARMKSLEQDALRAQMVLSRSQEGRGTRGPLERLAEAPSPAPTPSPTPVEDLGPQTSTS 763 
 
Query  745  PGRLSPDFAEELRSLEPSPSPGPQEEDGEVALVLLGRPSPGAVGPEDVALC  897 
            PGRLSPDFAEELRSLEPSPSPGPQEEDGEVALVLLGRPSPGAVGPEDVALC 
Sbjct  764  PGRLSPDFAEELRSLEPSPSPGPQEEDGEVALVLLGRPSPGAVGPEDVALC  814 
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Single Mutations (D-mutants) 
S1306D + 1448D Reverse primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH14632.2|Length: 832Number of Matches: 1 
Related Information  
Gene-associated gene details 
Map Viewer-aligned genomic context 
Range 1: 329 to 605GenPeptGraphics Next Match Previous Match First Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
421 bits(1081) 1e-137() Compositional matrix adjust. 273/277(99%) 273/277(98%) 0/277(0%) -1 
Features:  
Query  924  RXPPDEGIFISKVSPTgaagrdgrlrvglrlLEVNQQSLLGLTHGEAVQLLRSVGDTLTV 745 
            R P DEGIFISKVSPTGAAGRDGRLRVGLRLLEVNQQSLLGLTHGEAVQLLRSVGDTLTV 
Sbjct  329  RDPTDEGIFISKVSPTGAAGRDGRLRVGLRLLEVNQQSLLGLTHGEAVQLLRSVGDTLTV 388 
 
Query  744  LVCDGFEASTDAALEVSPGVIANPFAAGIGHRNSLESISSIDRELSPEGPGKEKELPGQT 565 
            LVCDGFEASTDAALEVSPGVIANPFAAGIGHRNSLESISSIDRELSPEGPGKEKELPGQT 
Sbjct  389  LVCDGFEASTDAALEVSPGVIANPFAAGIGHRNSLESISSIDRELSPEGPGKEKELPGQT 448 
 
Query  564  LHWGPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMAEspcspsgqqppd 385 
            LHWGPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMAESPCSPSGQQPP  
Sbjct  449  LHWGPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMAESPCSPSGQQPPS 508 
 
Query  384  ppspDELPANVKQAYRAFAAVPTSHppedapaqpptpgpaasPEQLSFRERQKYFELEVR 205 
            PPSPDELPANVKQAYRAFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVR 
Sbjct  509  PPSPDELPANVKQAYRAFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVR 568 
 
Query  204  VPQAEGPPKRVSLVGAXDLRKMQEEEARKLQQKRAQM  94 
            VPQAEGPPKRVSLVGA DLRKMQEEEARKLQQKRAQM 
Sbjct  569  VPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQM  605 
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S1309D + 1448D Reverse primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH14632.2|Length: 832Number of Matches: 1 
Related Information  
Gene-associated gene details 
Map Viewer-aligned genomic context 
Range 1: 337 to 605GenPeptGraphics Next Match Previous Match First Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
409 bits(1051) 2e-133() Compositional matrix adjust. 266/269(99%) 266/269(98%) 0/269(0%) -1 
Features:  
Query  898  FXXKVSPTgaagrdgrlrvglrlLEVNQQSLLGLTHGEAVQLLRSVGDTLTVLVCDGFEA 719 
            F  KVSPTGAAGRDGRLRVGLRLLEVNQQSLLGLTHGEAVQLLRSVGDTLTVLVCDGFEA 
Sbjct  337  FISKVSPTGAAGRDGRLRVGLRLLEVNQQSLLGLTHGEAVQLLRSVGDTLTVLVCDGFEA 396 
 
Query  718  STDAALEVSPGVIANPFAAGIGHRNSLESISSIDRELSPEGPGKEKELPGQTLHWGPEAT 539 
            STDAALEVSPGVIANPFAAGIGHRNSLESISSIDRELSPEGPGKEKELPGQTLHWGPEAT 
Sbjct  397  STDAALEVSPGVIANPFAAGIGHRNSLESISSIDRELSPEGPGKEKELPGQTLHWGPEAT 456 
 
Query  538  EAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMAEspcspsgqqppsppdpDELP 359 
            EAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMAESPCSPSGQQPPSPP PDELP 
Sbjct  457  EAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMAESPCSPSGQQPPSPPSPDELP 516 
 
Query  358  ANVKQAYRAFAAVPTSHppedapaqpptpgpaasPEQLSFRERQKYFELEVRVPQAEGPP 179                 
     ANVKQAYRAFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPP 
Sbjct  517  ANVKQAYRAFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPP 576 
 
Query  178  KRVSLVGADDLRKMQEEEARKLQQKRAQM  92 
            KRVSLVGADDLRKMQEEEARKLQQKRAQM 
Sbjct  577  KRVSLVGADDLRKMQEEEARKLQQKRAQM  605 
 
S1348D + 1448D Reverse primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH14632.2|Length: 832Number of Matches: 1 
Related Information 
Gene-associated gene details 
Map Viewer-aligned genomic context 
Range 1: 395 to 626GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
329 bits(843) 2e-103 Compositional matrix adjust. 227/232(98%) 227/232(97%) 0/232(0%) -1 
Query  722  EASTDAALEVSPXVIANPFAAGIGHRNSLESIXSIDRELSPEGPGKEKELPGQTLHWGPE  543 
            EASTDAALEVSP VIANPFAAGIGHRNSLESI SIDRELSPEGPGKEKELPGQTLHWGPE 
Sbjct  395  EASTDAALEVSPGVIANPFAAGIGHRNSLESISSIDRELSPEGPGKEKELPGQTLHWGPE  454 
 
Query  542  ATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMAEspcspsgqqppsppsPDE  363 
            ATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMAESPCSPSGQQPPSPPSPDE 
Sbjct  455  ATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMAESPCSPSGQQPPSPPSPDE  514 
 
Query  362  LPANVKQAYRAXXAVPTSHppedapaqpptpgpaadpeQLSFRERQKYFELEVRVPQAEG  183 
            LPANVKQAYRA  AVPTSHPPEDAPAQPPTPGPAA PEQLSFRERQKYFELEVRVPQAEG 
Sbjct  515  LPANVKQAYRAFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEG  574 
 
Query  182  PPKRVSLVGADDLRKMQEEEARKLQQKRAQMlreaaeagaearlaLDGETLG  27 
            PPKRVSLVGADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLG 
Sbjct  575  PPKRVSLVGADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLG  626 
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S1448D + 1306D Forward primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH14632.2|Length: 832Number of Matches: 1 
Related Information 
Gene-associated gene details 
Map Viewer-aligned genomic context 
Range 1: 524 to 815GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
350 bits(898) 2e-109 Compositional matrix adjust. 291/292(99%) 291/292(99%) 0/292(0%) +1 
Query  22   RAFAAVPTSHppedapaqpptpgpaaspEQLSFRERQKYFELEVRVPQAEGPPKRVSLVG 201 
            RAFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVG 
Sbjct  524  RAFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVG 583 
 
Query  202  ADDLRKMQEEEARKLQQKRAQMlreaaeagaearlaldgetlgeeeqedeqppWASPSPT 381 
            ADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSPT 
Sbjct  584  ADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSPT 643 
 
Query  382  SRQSpadppplgggapVRTAKAERRHQERLRVQSPEPPAPERALSPaelraleaekralw 561 
            SRQSPA PPPLGGGAPVRTAKAERRHQERLRVQSPEPPAPERALSPAELRALEAEKRALW 
Sbjct  644  SRQSPASPPPLGGGAPVRTAKAERRHQERLRVQSPEPPAPERALSPAELRALEAEKRALW 703 
 
Query  562  raarMKSLEQDALRAQMVLSRSQEGRGTRGPLERLAEapspaptpsptpVEDLGPQTSTS 741 
            RAARMKSLEQDALRAQMVLSRSQEGRGTRGPLERLAEAPSPAPTPSPTPVEDLGPQTSTS 
Sbjct  704  RAARMKSLEQDALRAQMVLSRSQEGRGTRGPLERLAEAPSPAPTPSPTPVEDLGPQTSTS 763 
 
Query  742  PGRLSPDFAEELRSLEPSPSPGPQEEDGEVALVLLGRPSPGAVGPEDVALCS  897 
            PGRLSPDFAEELRSLEPSPSPGPQEEDGEVALVLLGRPSPGAVGPEDVALCS 
Sbjct  764  PGRLSPDFAEELRSLEPSPSPGPQEEDGEVALVLLGRPSPGAVGPEDVALCS  815 
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Double Mutations (A-mutants) 
S[1306+1309]A  + 1448A Reverse primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH14632.2|Length: 832Number of Matches: 1 
Related Information 
Gene-associated gene details 
Map Viewer-aligned genomic context 
Range 1: 363 to 626GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
400 bits(1029) 6e-130 Compositional matrix adjust. 257/264(97%) 259/264(98%) 0/264(0%) -3 
Query  830  NQQSLXXLTHGEAVQLLRSVGDTLTVLVCDGFEASTDAALEVSPGVIANPFAAGIGHRNS  651 
            NQQSL  LTHGEAVQLLRSVGDTLTVLVCDGFEASTDAALEVSPGVIANPFAAGIGHRNS 
Sbjct  363  NQQSLLGLTHGEAVQLLRSVGDTLTVLVCDGFEASTDAALEVSPGVIANPFAAGIGHRNS  422 
 
Query  650  LESISSIDRELSPEGPGKEKELPGQTLHWGPEATEAAGRGXQPLKLXYRALAAVPSAGSV  471 
            LESISSIDRELSPEGPGKEKELPGQTLHWGPEATEAAGRG QPLKL YRALAAVPSAGSV 
Sbjct  423  LESISSIDRELSPEGPGKEKELPGQTLHWGPEATEAAGRGLQPLKLDYRALAAVPSAGSV  482 
 
Query  470  QRVPSGAAGGKMAEspcspsgqqppappaPDELPANVKQAYRAFAAVPTSHppedapaqp  291 
            QRVPSGAAGGKMAESPCSPSGQQPP+PP+PDELPANVKQAYRAFAAVPTSHPPEDAPAQP 
Sbjct  483  QRVPSGAAGGKMAESPCSPSGQQPPSPPSPDELPANVKQAYRAFAAVPTSHPPEDAPAQP  542 
 
Query  290  ptpgpaasPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKR  111 
            PTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKR 
Sbjct  543  PTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKR  602 
 
Query  110  AQMlreaaeagaearlxLDGETLG  39 
            AQMLREAAEAGAEARL LDGETLG 
Sbjct  603  AQMLREAAEAGAEARLALDGETLG  626 
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S[1348A+1448]A + 1306-09A Forward primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH14632.2|Length: 832Number of Matches: 1 
Related Information 
Gene-associated gene details 
Map Viewer-aligned genomic context 
Range 1: 525 to 815GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
303 bits(777) 3e-90 Compositional matrix adjust. 278/291(96%) 280/291(96%) 0/291(0%) +3 
 
Query  21   AFAAVPTSHppedapaqpptpgpaaapEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGA  200 
            AFAAVPTSHPPEDAPAQPPTPGPAA+PEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGA 
Sbjct  525  AFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGA  584 
 
Query  201  DDLRKMQEEEARKLQQKRAQMlreaaeagaearlaldgetlgeeeqedeqppWASPSPTS  380 
            DDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSPTS 
Sbjct  585  DDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSPTS  644 
 
Query  381  RQSpaappplgggapVRTAKAERRHQERLRVQSPEPPAPERALSPaelraleaekralwr  560 
            RQSPA+PPPLGGGAPVRTAKAERRHQERLRVQSPEPPAPERALSPAELRALEAEKRALWR 
Sbjct  645  RQSPASPPPLGGGAPVRTAKAERRHQERLRVQSPEPPAPERALSPAELRALEAEKRALWR  704 
 
Query  561  aarMKSLEQDALRAQMVLXRSQEGRGTRGPLERLAEapspaptxsptxVEDLGPXTXTSP  740 
            AARMKSLEQDALRAQMVL RSQEGRGTRGPLERLAEAPSPAPT SPT VEDLGP T TSP 
Sbjct  705  AARMKSLEQDALRAQMVLSRSQEGRGTRGPLERLAEAPSPAPTPSPTPVEDLGPQTSTSP  764 
 
Query  741  GRLSPDFAEELRSLxpspspxpxEEDGExxlvllGRRSPGAVGPEDVALCS  893 
            GRLSPDFAEELRSL PSPSP P EEDGE  LVLLGR SPGAVGPEDVALCS 
Sbjct  765  GRLSPDFAEELRSLEPSPSPGPQEEDGEVALVLLGRPSPGAVGPEDVALCS  815 
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Double Mutations (D-mutants) 
S[1306+1309]D + 1448D Reverse primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH14632.2|Length: 832Number of Matches: 1 
Related Information 
Gene-associated gene details 
Map Viewer-aligned genomic context 
Range 1: 371 to 626GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
378 bits(971) 2e-121 Compositional matrix adjust. 248/256(97%) 248/256(96%) 0/256(0%) -1 
Query  798  THGEAVQXLRSVGDTLTXLVCDGFEASTDAALEVSPGVIANPFAAGIGHRNSLESIXSID  619 
            THGEAVQ LRSVGDTLT LVCDGFEASTDAALEVSPGVIANPFAAGIGHRNSLESI SID 
Sbjct  371  THGEAVQLLRSVGDTLTVLVCDGFEASTDAALEVSPGVIANPFAAGIGHRNSLESISSID  430 
 
Query  618  RELSPEGPGKEKELPGQTLHWGPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAA  439 
            RELSPEGPGKEKELPGQTLHWGPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAA 
Sbjct  431  RELSPEGPGKEKELPGQTLHWGPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAA  490 
 
Query  438  GGKMXEspcspsgqqppdppdpDELPANVKQAYRAXAAVPTSHppedapaqpptpgpaas  259 
            GGKM ESPCSPSGQQPP PP PDELPANVKQAYRA AAVPTSHPPEDAPAQPPTPGPAAS 
Sbjct  491  GGKMAESPCSPSGQQPPSPPSPDELPANVKQAYRAFAAVPTSHPPEDAPAQPPTPGPAAS  550 
 
Query  258  PEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMlreaa  79 
            PEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMLREAA 
Sbjct  551  PEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMLREAA  610 
 
 
Query  78   eagaearlxLDGETLG  31 
            EAGAEARL LDGETLG 
Sbjct  611  EAGAEARLALDGETLG  626 
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S[1348D+1448]D + 1306-09D Forward primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH14632.2|Length: 832Number of Matches: 1 
Related Information 
Gene-associated gene details 
Map Viewer-aligned genomic context 
Range 1: 526 to 816GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
271 bits(693) 3e-78 Compositional matrix adjust. 235/291(81%) 237/291(81%) 0/291(0%) +2 
  
 
    
Query  23   FXAVPTSHppedapaqpptpgpaadpxQLSFRDRQKYFELEVRVPXAEGPPNRVSLVGAD  202 
            F AVPTSHPPEDAPAQPPTPGPAA P QLSFR+RQKYFELEVRVP AEGPP RVSLVGAD 
Sbjct  526  FAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGAD  585 
 
Query  203  DLRKMXEEEARKLLQKRAQMlreaaeagaearlaldgetlgeeeqedeqppWASPSPTSR  382 
            DLRKM EEEARKL QKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSPTSR 
Sbjct  586  DLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSPTSR  645 
 
Query  383  QSpadppplgggapVRTAKAERRLXXRLXVQSPXXPAXXXXLSPAXXRVLXAXXRALWRX  562 
            QSPA PPPLGGGAPVRTAKAERR   RL VQSP  PA    LSPA  R L A  RALWR  
Sbjct  646  QSPASPPPLGGGAPVRTAKAERRHQERLRVQSPEPPAPERALSPAELRALEAEKRALWRA  705 
 
Query  563  ASMKSLEQDALXAXMVLSKSQXGXDTRGPLERLXEapspaptpsptpVEDLGXXTXTSXG  742 
            A MKSLEQDAL A MVLS+SQ G  TRGPLERL EAPSPAPTPSPTPVEDLG  T TS G 
Sbjct  706  ARMKSLEQDALRAQMVLSRSQEGRGTRGPLERLAEAPSPAPTPSPTPVEDLGPQTSTSPG  765 
 
Query  743  XLSPXFXXXLRSLXPSRSPAPYEEDGEVALXFLGXXSXIAVXPEXVXLCSS  895 
             LSP F   LRSL PS SP P EEDGEVAL  LG  S  AV PE V LCSS 
Sbjct  766  RLSPDFAEELRSLEPSPSPGPQEEDGEVALVLLGRPSPGAVGPEDVALCSS  816 
 
Triple Mutations (A-mutants) 
S-AA(1348A) + 1448A Reverse Primer  
 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH09490.2|Length: 450Number of Matches: 2 
Related Information 
Gene-associated gene details 
Range 1: 45 to 231GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
228 bits(581) 4e-68 Compositional matrix adjust. 183/187(98%) 186/187(99%) 0/187(0%) -3 
Query  586  GPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMAEspcspsgqqppappa 407 
            GPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMAESPCSPSGQQPP+PP+ 
Sbjct  45   GPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMAESPCSPSGQQPPSPPS 104 
 
Query  406  PDELPANVKQAYRAFAAVPTSHppedapaqpptpgpaaaPEQLSFRERQKYFELEVRVPQ 227 
            PDELPANVKQAYRAFAAVPTSHPPEDAPAQPPTPGPAA+PEQLSFRERQKYFELEVRVPQ 
Sbjct  105  PDELPANVKQAYRAFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQ 164 
 
Query  226  AEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMlreaaeagaearlaLDGETLGeeeqe  47 
            AEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQE 
Sbjct  165  AEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQE 224 
 
Query  46   xeQPPWA  26 
             EQPPWA 
Sbjct  225  DEQPPWA  231 
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S-AA(1448A) + 1306-09A Forward primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH14632.2|Length: 832Number of Matches: 1 
Related Information 
Gene-associated gene details 
Map Viewer-aligned genomic context 
Range 1: 525 to 815GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
309 bits(791) 2e-92 Compositional matrix adjust. 281/291(97%) 283/291(97%) 0/291(0%) +2 
Query  23   AFAAVPTSHppedapaqpptpgpaaspEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGA 202 
            AFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGA 
Sbjct  525  AFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGA 584 
 
Query  203  DDLRKMQEEEARKLQQKRAQMlreaaeagaearlaldgetlgeeeqedeqppWASPSPTS 382 
            DDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSPTS 
Sbjct  585  DDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSPTS 644 
 
Query  383  RQSpaappplgggapVRTAKAERRHQERLRVQSPEPPAPERALSPaelraleaekralwr 562 
            RQSPA+PPPLGGGAPVRTAKAERRHQERLRVQSPEPPAPERALSPAELRALEAEKRALWR 
Sbjct  645  RQSPASPPPLGGGAPVRTAKAERRHQERLRVQSPEPPAPERALSPAELRALEAEKRALWR 704 
 
Query  563  aarMKSLEQDALRAQMVLXRSQEGRGTRGPLERLAEapspaptpsptpVEDLGPXTXTSP 742 
            AARMKSLEQDALRAQMVL RSQEGRGTRGPLERLAEAPSPAPTPSPTPVEDLGP T TSP 
Sbjct  705  AARMKSLEQDALRAQMVLSRSQEGRGTRGPLERLAEAPSPAPTPSPTPVEDLGPQTSTSP 764 
 
Query  743  GRLSPDFAEELRslxpspspgpxxEDGELALVLLGRPSPXAVXPEDVALCS  895 
            GRLSPDFAEELRSL PSPSPGP  EDGE+ALVLLGRPSP AV PEDVALCS 
Sbjct  765  GRLSPDFAEELRSLEPSPSPGPQEEDGEVALVLLGRPSPGAVGPEDVALCS  815 
 
 
Triple Mutations (D-mutants) 
S-DD(1348D) + 1448A Reverse Primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH14632.2|Length: 832Number of Matches: 2 
Related Information 
Gene-associated gene details 
Range 1: 430 to 605GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
216 bits(550) 4e-73 Compositional matrix adjust. 159/176(90%) 161/176(91%) 0/176(0%) -2 
Query  651  DREVSPEGXGKEKEXXGQXXHXGPEATEAAGRGXQPLXLDYRALAAVPSAGSVQRVPSGA 472 
            DRE+SPEG GKEKE  GQ  H GPEATEAAGRG QPL LDYRALAAVPSAGSVQRVPSGA 
Sbjct  430  DRELSPEGPGKEKELPGQTLHWGPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGA 489 
 
Query  471  AGGKMgespcspsgqqppdppdpdemPANVKQAYRAFAAVPTSHppedapaqpptpgpaa 292 
            AGGKM ESPCSPSGQQPP PP PDE+PANVKQAYRAFAAVPTSHPPEDAPAQPPTPGPAA 
Sbjct  490  AGGKMAESPCSPSGQQPPSPPSPDELPANVKQAYRAFAAVPTSHPPEDAPAQPPTPGPAA 549 
 
Query  291  dpeQLSFRERQKYXXXEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQM  124 
             PEQLSFRERQKY   EVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQM 
Sbjct  550  SPEQLSFRERQKYFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQM  605 
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S-DD(1448D) + 1348A Forward Primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH09490.2|Length: 450Number of Matches: 1 
Related Information 
Gene-associated gene details 
Range 1: 155 to 249GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
113 bits(283) 2e-27 Compositional matrix adjust. 94/95(99%) 94/95(98%) 0/95(0%) +2 
Query  29   YFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMlreaaeagaearlald 208 
            YFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALD 
Sbjct  155  YFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALD 214 
 
Query  209  getlgeeeqedeqppWASPSPTSRQSPADPPPLGG  313 
            GETLGEEEQEDEQPPWASPSPTSRQSPA PPPLGG 
Sbjct  215  GETLGEEEQEDEQPPWASPSPTSRQSPASPPPLGG  249 
 
 
Mutations in addition to specified c-terminal serine sites 
E1293Stop + 1348A Reverse Primer  
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH44627.1|Length: 682Number of Matches: 1 
Related Information 
Gene-associated gene details 
Range 1: 422 to 634GenPeptGraphics Next Match Previous Match First Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
345 bits(885) 4e-111() Compositional matrix adjust. 212/213(99%) 212/213(99%) 0/213(0%) -1 
Features: 
Query  670  PRDPTDEGIFISKVSPTgaagrdgrlrvglrlLEVNQQSLLGLTHGEAVQLLRSVGDTLT 491 
            PRDPTDEGIFISKVSPTGAAGRDGRLRVGLRLLEVNQQSLLGLTHGEAVQLLRSVGDTLT 
Sbjct  422  PRDPTDEGIFISKVSPTGAAGRDGRLRVGLRLLEVNQQSLLGLTHGEAVQLLRSVGDTLT 481 
 
Query  490  VLVCDGFEASTDAALEVSPGVIANPFAAGIGHRNSLESISSIDRELSPEGPGKEKELPGQ 311 
            VLVCDGFEASTDAALEVSPGVIANPFAAGIGHRNSLESISSIDRELSPEGPGKEKELPGQ 
Sbjct  482  VLVCDGFEASTDAALEVSPGVIANPFAAGIGHRNSLESISSIDRELSPEGPGKEKELPGQ 541 
 
Query  310  TLHWGPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMA*spcspsgqqpp 131 
            TLHWGPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMA SPCSPSGQQPP 
Sbjct  542  TLHWGPEATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMAESPCSPSGQQPP 601 
 
Query  130  sppsPDELPANVKQAYRAFAAVPTSHPPEDAPA  32 
            SPPSPDELPANVKQAYRAFAAVPTSHPPEDAPA 
Sbjct  602  SPPSPDELPANVKQAYRAFAAVPTSHPPEDAPA  634 
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C1297S + 1348A Reverse Primer  
SCRIB protein, partial [Homo sapiens] 
Sequence ID: gb|AAH44627.1|Length: 682Number of Matches: 1 
Related Information 
Gene-associated gene details 
Range 1: 489 to 629GenPeptGraphicsNext MatchPrevious MatchFirst Match 
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
226 bits(577) 1e-66() Compositional matrix adjust. 134/141(95%) 134/141(95%) 0/141(0%) -2 
Features: 
Query  460  EXSXDAALEVSPGVIANPFAAGIGHRNSLESISSIDRELSPEGPGKEKELPGQTLHWGPE 281 
            E S DAALEVSPGVIANPFAAGIGHRNSLESISSIDRELSPEGPGKEKELPGQTLHWGPE 
Sbjct  489  EASTDAALEVSPGVIANPFAAGIGHRNSLESISSIDRELSPEGPGKEKELPGQTLHWGPE 548 
 
Query  280  ATEAAGRGLQPLKLXXXALAAVPSAGSVQRVPSGAAGGKMAEspsspsgqqppsppsPDE 101 
            ATEAAGRGLQPLKL   ALAAVPSAGSVQRVPSGAAGGKMAESP SPSGQQPPSPPSPDE 
Sbjct  549  ATEAAGRGLQPLKLDYRALAAVPSAGSVQRVPSGAAGGKMAESPCSPSGQQPPSPPSPDE 608 
 
Query  100  LPANVKQAYRAFAAVPTXHPP  38 
            LPANVKQAYRAFAAVPT HPP 
Sbjct  609  LPANVKQAYRAFAAVPTSHPP  629 
 
 
 
 
S1445A + 1306A Forward Primer 
SCRIB protein, partial [Homo sapiens] 
Sequence ID: gb|AAH09490.2|Length: 450Number of Matches: 1 
Related Information 
Gene-associated gene details 
Range 1: 116 to 261GenPeptGraphicsNext MatchPrevious Match 
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
130 bits(328) 3e-32 Compositional matrix adjust. 138/146(95%) 139/146(95%) 0/146(0%) +3 
 
Query  30   YXAFAAVPTSHppexapaqpptpgpaaspEQLSFRERQKYFELEVRVPQAEGPPKRVSLV  209 
            Y AFAAVPTSHPPE APAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLV 
Sbjct  116  YRAFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLV  175 
 
Query  210  GADDLRKMQEEEARKLQQKRAQMlreaaeagaearlaldgetlgeeeqedeqppWASPSP  389 
            GADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSP 
Sbjct  176  GADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSP  235 
 
Query  390  TSRQapasppplgggapVRXXXXXRR  467 
            TSRQ+PASPPPLGGGAPVR     RR 
Sbjct  236  TSRQSPASPPPLGGGAPVRTAKAERR  261 
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S1445D + 1306A Forward Primer  
SCRIB protein, partial [Homo sapiens] 
Sequence ID: gb|AAH09490.2|Length: 450Number of Matches: 1 
Related Information 
Gene-associated gene details 
Range 1: 116 to 331GenPeptGraphicsNext MatchPrevious Match 
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
204 bits(519) 4e-59 Compositional matrix adjust. 202/216(94%) 202/216(93%) 0/216(0%) +1 
Query  31   YXAFAAVPTSHppedapaqpptpgpaaspEQLSFRERQKYFELEVRVPQAEGPPKRVSLV  210 
            Y AFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLV 
Sbjct  116  YRAFAAVPTSHPPEDAPAQPPTPGPAASPEQLSFRERQKYFELEVRVPQAEGPPKRVSLV  175 
 
Query  211  GADDLRKMQEEEARKLQQKRAQMlreaaeagaearlaldgetlgeeeqedeqppWASPSP  390 
            GADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSP 
Sbjct  176  GADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSP  235 
 
Query  391  TSRQDpasppplgggapVRTAKAERRHQERLRVQSPEPPAPERALSPaelraleaekral  570 
            TSRQ PASPPPLGGGAPVRTAKAERRHQERLRVQSPEPPAPERALSPAELRALEAEKRAL 
Sbjct  236  TSRQSPASPPPLGGGAPVRTAKAERRHQERLRVQSPEPPAPERALSPAELRALEAEKRAL  295 
 
Query  571  wraarMXSLEQDALXXXMVLXRSXXXRGXRGXLXXL  678 
            WRAARM SLEQDAL   MVL RS   RG RG L  L 
Sbjct  296  WRAARMKSLEQDALRAQMVLSRSQEGRGTRGPLERL  331 
 
 
 
S1449A + 1348A Forward Primer  
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH09490.2|Length: 450Number of Matches: 1 
Related Information 
Gene-associated gene details 
Range 1: 155 to 295GenPeptGraphics Next Match Previous Match First Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
145 bits(365) 1e-37() Compositional matrix adjust. 128/141(91%) 129/141(91%) 0/141(0%) +1 
Features: 
Query  25   YFELEVRVPXAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMlreaaeagaearlald 204 
            YFELEVRVP AEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALD 
Sbjct  155  YFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALD 214 
 
Query  205  getlgeeeqedeqppWASPSPTSRQspasapplgggapVRTVKAERRXQERLXVQSPEXP 384 
            GETLGEEEQEDEQPPWASPSPTSRQSPAS PPLGGGAPVRT KAERR QERL VQSPE P 
Sbjct  215  GETLGEEEQEDEQPPWASPSPTSRQSPASPPPLGGGAPVRTAKAERRHQERLRVQSPEPP 274 
 
Query  385  APXRALSPADFXALEXXKRAC  447 
            AP RALSPA+  ALE  KRA  
Sbjct  275  APERALSPAELRALEAEKRAL  295 
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S[1445+1448]A + 1348A Forward Primer 
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH09490.2|Length: 450Number of Matches: 2 
Related Information 
Gene-associated gene details 
Range 1: 190 to 331GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
121 bits(303) 1e-32 Compositional matrix adjust. 138/142(97%) 140/142(98%) 0/142(0%) +2 
 
Query  125  KLQHKRAQMlreaaeagaearlaldgetlgeeeqedeqppxASPSPTSRQapaappplgg 304 
            KLQ KRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPP ASPSPTSRQ+PA+PPPLGG 
Sbjct  190  KLQQKRAQMLREAAEAGAEARLALDGETLGEEEQEDEQPPWASPSPTSRQSPASPPPLGG 249 
 
Query  305  gapVRTAKAERRHQERLRVQSPEPPAPERALSPaelraleaekralwraarMKSLEQDAL 484 
            GAPVRTAKAERRHQERLRVQSPEPPAPERALSPAELRALEAEKRALWRAARMKSLEQDAL 
Sbjct  250  GAPVRTAKAERRHQERLRVQSPEPPAPERALSPAELRALEAEKRALWRAARMKSLEQDAL 309 
 
Query  485  RAQMVLSRSQEGRGTRGPLERL  550 
            RAQMVLSRSQEGRGTRGPLERL 
Sbjct  310  RAQMVLSRSQEGRGTRGPLERL  331 
 
 
 
S[1445+1448]D + 1348A Forward Primer  
SCRIB protein, partial [Homo sapiens]  
Sequence ID: gb|AAH09490.2|Length: 450Number of Matches: 1 
Related Information 
Gene-associated gene details 
Range 1: 155 to 249GenPeptGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
112 bits(279) 6e-27 Compositional matrix adjust. 93/95(98%) 93/95(97%) 0/95(0%) +1 
Query  25   YFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMlreaaeagaearlald 204 
            YFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALD 
Sbjct  155  YFELEVRVPQAEGPPKRVSLVGADDLRKMQEEEARKLQQKRAQMLREAAEAGAEARLALD 214 
 
Query  205  getlgeeeqedeqppWASPSPTSRQDPADPPPLGG  309 
            GETLGEEEQEDEQPPWASPSPTSRQ PA PPPLGG 
Sbjct  215  GETLGEEEQEDEQPPWASPSPTSRQSPASPPPLGG  249 
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Appendix B 
Appendix B includes the following: 
A6.3 Table of spectral count of proteins (shown in Table 6.3) significantly abundant 
between the S[1306+1309]A and S[1306+1309]D pull-down.  
A6.4 Linear graph of proteins represented in Figure 6.4 (in Chapter 6) and Table A6.3. 
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Figure A6.4 Linear bar graph of proteins that were identified in both the S[1306+1309]A and 
S[1306+1309]D pull-downs but showed significant differences in their abundance between the 
pull-downs. Bar graph y-axis represents spectral count.  Log graph in figure 6.4 was used to 
clearly display variations in abundances, that the linear graph could not, between pull-downs, of 
each of the protein identified to be a significant binding partner of both S[1306+1309]A and 
S[1306+1309]D.   
